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Samenvatting
– Summary in Dutch –
Het genoom bevat de blauwdruk voor het functioneren van alle levende wezens. Het
is, samen met omgevingsfactoren, verantwoordelijk voor het gedrag van een orga-
nisme, en bepaalt het fenotype ervan. Fenotype is de verzameling van alle moleculaire,
microscopische en macroscopische eigenschappen van een organisme. Een groot deel
van de geobserveerde verschillen tussen individuen van een soort kan verklaard wor-
den door genetische verschillen tussen deze individuen. Bij mensen bijvoorbeeld ver-
schilt van nature 0.1 procent van de baseparen waaruit het DNA opgebouwd is. Naast
deze natuurlijke genetische variatie zijn soms ook somatische (niet overgee¨rfde) gene-
tische verschillen aanwezig in het genoom. Deze kunnen leiden tot ziektes of kunnen
een bedreiging vormen voor de levensvatbaarheid van een organisme.
Als de genetische variatie op een bepaalde locatie in het genoom gelinkt kan wor-
den aan een eigenschap van een organisme, en als die locatie overlapt met de gekende
locatie van een gen in dit genoom, dan wordt besloten dat het overlappende gen be-
trokken moet zijn bij het bepalen van de bestudeerde eigenschap. Tegengesteld aan
wat dikwijls wordt gedacht gebeurt het heel weinig dat de genetische variabiliteit van
e´e´n enkel gen volledig de geobserveerde variantie van een eigenschap verklaart. Bij-
voorbeeld, oogkleur bij mensen wordt bepaald door de genetische variabiliteit in ten
minste 10 genen, en meer dan 400 genen werden reeds gerelateerd aan lichaamsge-
wicht. Naast het feit dat eigenschappen beı¨nvloed kunnen zijn door veel genen heeft
men ook vastgesteld dat genen niet geı¨soleerd functioneren. Ze interageren sterk met
elkaar, en vormen cascades en netwerken. Het gebruik van specifieke technieken die
in staat zijn om deze interactiemechanismen mee te nemen in een analyse kan de kans
om relevante resultaten te vinden sterk verhogen. In dit werk introduceren we nieuwe
technieken die gebruik maken van gen-interactienetwerken om een aantal problemen
op te lossen die zich stellen bij het koppelen van genetische variabiliteit aan fenotypi-
sche variatie.
Bij een typische studie waarbij variabiliteit van het volledige genoom gelinkt
wordt aan een eigenschap van een organisme maakt men geen gebruik van de vol-
ledige genoomsequentie van de individuen in het organisme. In plaats gebruikt men
een set van probes die op een aantal vaste locaties in het genoom de lokale varia-
biliteit bemonsteren. Aan de hand van zo’n probe kan men vaststellen welke letter
(uit het ACTG alfabet waaruit het DNA is opgebouwd) een bepaald individu heeft op
een bepaalde locatie in het genoom. Als een individu op een locatie een andere letter
heeft dan de overige individuen uit de populatie heeft men een SNP gevonden, een
Single Nucleotide Polymorphism. Deze SNPs kunnen dan gelinkt worden aan een
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fenotypische eigenschap. Wanneer nu de densiteit van de probes die gebruikt worden
om SNPs te identificeren laag is, of wanneer de genetische diversiteit van de bestu-
deerde populatie beperkt is kan het gebeuren dat een SNP representatief is voor een
groot gebied van het genoom. Een gevolg hiervan is dat een SNP dikwijls niet gel-
inkt kan worden aan een individueel gen maar dat veel genen overlappen met de regio
die door de SNP vertegenwoordigd wordt. Het is dan onduidelijk welk gen van deze
groep genen effectief geassocieerd moet worden met de bestudeerde eigenschap. De
taak waarbij uit een lijst van kandidaatgenen dat gen wordt geselecteerd dat het meest
waarschijnlijk betrokken is bij de bestudeerde eigenschap wordt genprioritering ge-
noemd. In dit werk stellen we een nieuwe techniek voor genprioritering voor waarbij
we geninteractienetwerken integreren in de prioriteringsmethode.
Wanneer echter, omwille van een erg lage resolutie van de genetisch data, genprio-
ritering geen optie is zou men bij het linken van genen met fenotype de genetische data
kunnen vervangen door genexpressie data (gemeten als de hoeveelheid afgeschreven
DNA van elk individueel gen). Echter, genexpressie in een weefsel of een cel wordt
niet alleen bepaald door genetische eigenschappen, maar ook door omgevingsvaria-
belen. We hebben daarom een netwerkgebaseerde techniek ontworpen die toelaat om
de invloed van genetische eigenschappen te scheiden van omgevingsvariabelen bij het
bepalen van welke genen betrokken zijn bij een bepaalde eigenschap, en dit gebruik
makende van lage resolutie genetische data.
Een derde uitdaging situeert zich in het domein van tumoranalyse. Tumorontwik-
keling is een ziektegerelateerd fenotype dat veroorzaakt wordt door een complex me-
chanisme waarbij meerdere genetische defecten betrokken zijn. Het identificeren van
de echte oorzaken van tumorontwikkeling is niet triviaal omwille van het probleem
van de mutuele exclusiviteit van genetische defecten: wanneer het voor de ontwikke-
ling van een tumor noodzakelijk is dat een bepaalde cascade van interagerende genen
verstoord is (bijvoorbeeld door een mutatie in een gen in deze cascade), dan zal een
individuele patie¨nt slechts uiterst zelden meer dan e´e´n enkel genetisch defect vertonen
in de genen van de verstoorde cascade. Bijkomende defecte genen zullen immers niet
bijdragen tot extra verstoring van de cascade; het eerste defect zorgde reeds voor de
noodzakelijke wijziging in functioneren. Een gevolg hiervan is dat bij verschillende
patie¨nten waarbij dezelfde cascade verstoord is (en die dus hetzelfde ziektebeeld ver-
tonen) allemaal verschillende genen defect kunnen zijn. Deze mutuele exclusiviteit
van genetische defecten bemoeilijkt het vinden van de echte oorzaken van kanker. Het
is duidelijk dat genetische defecten bestudeerd moeten worden in relatie tot de interac-
tiemechanismen waar ze deel van uitmaken, eerder dan als individuele oorzaken van
tumor ontwikkeling.
Een bijkomende uitdaging in moleculair kankeronderzoek is te vinden in het inte-
greren van verschillende soorten moleculaire data in e´e´n enkele analyse. Tegenwoor-
dig kan een tumorstaal op veel verschillende manieren geanalyseerd worden, en dit
leidt tot de beschikbaarheid van veel soorten tumorgerelateerde data met elk specifieke
eigenschappen. In dit werk maken we gebruik van de eerder vermelde genexpressie-
en mutatiedata, maar ook van copy number- en methylatiedata. Ongeacht of de focus
van het onderzoek ligt op het prioriteren van genen gelinkt aan tumorontwikkeling, op
het aflijnen van groepen van patie¨nten met dezelfde moleculaire eigenschappen of het
rangschikken van volledige cascades overeenkomstig hun betrokkenheid bij kanker, is
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een geı¨ntegreerde aanpak noodzakelijk. Indien elk beschikbaar datatype afzonderlijk
zou worden geanalyseerd kunnen essentie¨le patronen van complementariteit over het
hoofd gezien worden.
De vier hierboven beschreven uitdagingen werden vertaald naar concrete proble-
men in het onderzoeksdomein van de computationie¨le biologie. Hiervoor maakten
we gebruik van verschillende soorten data die beschikbaar waren voor gist, eucalyp-
tusbomen en mensen. Bij elk voorliggend probleem werd gebruik gemaakt van gen-
interactienetwerken en van de assumptie dat wanneer twee genen in een interactienet-
werk in elkaars buurt liggen, ze waarschijnlijk betrokken zijn bij dezelfde biologische
processen. Alle voorgestelde technieken in dit werk maken gebruik van een netwerk-
gebaseerde connectiviteitsmaat die objectief meet hoe goed entiteiten in een netwerk
met elkaar verbonden zijn. Deze connectiviteitsmaat wordt verondersteld representa-
tief te zijn voor similariteit tussen genfuncties enerzijds, of voor hoe relevant een gen
is voor een bepaalde patie¨nt anderzijds.
Gebruik makende van deze benadering werd een nieuwe genprioriteringstech-
niek ontwikkeld die gist SNP- en genexpressiedata gebruikt om zogenaamde expres-
sion Quantitative Trait Loci (eQTL) te identificeren. Genexpressie wordt hier gezien
als een moleculair fenotype. De voorgestelde netwerkgebaseerde connectiviteitsmaat
werd gebruikt om kandidaat genen te linken aan een target gen in een interactienet-
werk. Naast het gebruik van de connectiviteitsmaat werd gebruik gemaakt van het
idee om eerst een lokaal netwerk af te lijnen vooraleer verder te gaan met de analyse.
De performantie van de techniek werd geı¨llustreerd door te vergelijken met naı¨ve en
state-of-the-art alternatieve technieken.
Verder introduceerden we het gebruik van genexpressie die gediffundeerd wordt
door een interactienetwerk als een alternatief voor het identificeren van modules van
genen met gecorreleerde genexpressie. We konden aantonen dat dit een krachtige ma-
nier was om traditionele correlatieanalyse (waarin expressieniveaus van genen gelinkt
worden aan een fenotypische eigenschap) te verbeteren. De kracht van deze benade-
ring werd geı¨llustreerd aan de hand van genexpressiedata, eQTL informatie en een
verzameling complexe hout- en biomassagerelateerde eigenschappen (houtdensiteit,
schorsdikte, ...) van eucalyptusbomen. De voorgestelde aanpak presteerde significant
beter bij het prioriteren van een set van literatuurgebaseerde referentiegenen dan een
conventionele correlatieanalyse.
De tumorgerelateerde uitdagingen, mutuele exclusiviteit en data-integratie, wer-
den simultaan aangepakt. We ontwikkelden een eengemaakte strategie voor tumor-
analyse die gelijktijdig gebruikt kan worden voor het rangschikken van cascades van
interagerende genen, het subtyperen van patie¨nten, het prioriteren van gendefecten die
leiden tot tumorontwikkeling en het aflijnen van subnetwerken die correleren met het
geobserveerde tumorfenotype. Elk datatype dat geconverteerd kan worden naar een
binaire representatie kan meegenomen worden in de analyse, samen met voorkennis
in de vorm van gevalideerde geninteracties. Het basisidee van de voorgestelde bena-
dering is het converteren van alle beschikbare data naar een eengemaakte netwerk-
representatie die niet alleen genen maar ook patie¨nten bevat. De netwerkconnectivi-
teitsmaat die hierboven werd voorgesteld kan dan gebruikt worden om de relevantie
van een gen voor een individuele patie¨nt of een set van patie¨nten te bepalen. We de-
monstreerden de voorgestelde aanpak door gebruik te maken van publiek beschikbare
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borst, ovarium en glioblastoma multiforme kankerdatasets. De bekomen resultaten
werden waar mogelijk gevalideerd door gebruik te maken van naı¨ve en alternatieve
technieken, samen met een uitgebreide literatuurstudie. De voorgestelde techniek
leidt tot biologisch relevante rankschikkingen van cascades, en tot subtyperingen van
patie¨nten die sterk correleerden met de overlevingskans. Verder identificeerden we
voor elk bekomen subtype subnetwerken, die samen met geprioriteerde sets van gen-
defecten sterke overeenkomsten vertoonden met wat in de literatuur gekend is over de
bestudeerde kankertypes.
Summary
The genome of all living things contains the blueprint that manages the organism’s
functioning. It is, together with environmental stimuli, responsible for how an or-
ganism behaves, and determines its phenotype, i.e. the molecular, microscopic and
macroscopic properties of each life form. A substantial part of the observed differ-
ences between individuals of a species can be attributed to genetic variation between
these individuals. For example, the genetic code of humans differs in 0.1 percent of
the base-pairs that make up the DNA. Next to this natural genetic variation, sometimes
somatic (non-inherited) genetic defects are introduced in the DNA that can cause mal-
functions in the organisms, and can even be life-threatening.
For long, researchers have tried to link this genetic variation to observed pheno-
typic variation. If it is found that genetic variation is statistically linked to an observed
trait (a property of an organism), and if the location of the observed variation overlaps
with the known location of a gene in the genome, than it is concluded that that partic-
ular gene is involved in the biological processes that determine the trait. Contrary to
what is often thought, rare are the occasions where the variation of a single gene can
fully explain the observed phenotypic variation. More often than not, traits are gov-
erned by many genes. For example, eye color in humans is known to be influenced by
genetic variation of at least 10 different genes, and over 400 genes are suspected to de-
termine body weight. Additionally, genes do not act in isolation, but rather constitute
pathways and networks of closely interacting genes. Using specific approaches that
take into account these interaction networks when linking genetic variation to traits
can greatly increase the statistical power to discover new findings. Network-based
inference is therefore the main topic of this work. Here, we propose new approaches
that make use of gene interaction networks to tackle a number of challenges often
encountered when linking genetic variation to phenotype.
In a typical genome-wide association study (studies where variation in the en-
tire genome is linked to some phenotypic property), instead of sequencing the entire
genome of the individuals in a population, the genetic variability is sampled using
probes that identify Single Nucleotide Polymorphisms (SNPs) at a fixed number of
locations. These SNPs are then statistically linked to phenotypic variation. When the
density of the probes is low, or when the genetic variability of the population under
study is limited, each SNP can be representative for the genetic variation of a large
genomic region that overlaps with many genes. Consequently, it is not clear which of
the genes represented by a SNP is linked to the trait the SNP was linked to. The pro-
cess of identifying the most likely gene among a list of candidate genes represented
by a SNP is call prioritization, and we propose a method to leverage gene interaction
networks for this purpose.
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When, due to very low genetic resolution, gene prioritization is not an option, one
could revert to linking gene expression data (measured as the amount of transcribed
DNA for each individual gene) directly to traits. Unfortunately, such an analysis is
confounded by environmental factors that will influence the transcription rate of genes
too. We have developed a gene interaction network-based method that allows for the
inclusion of coarse genetic information (representing a large genomic region rather
than a specific location) in the association analysis, in order to identify genes whose
genetic variability most likely influences the traits under study.
A third challenge is situated in the tumour analysis domain. Tumour develop-
ment and proliferation is a disease phenotype that is caused by a complex interplay
of genetic defects. Identifying true drivers of tumour development is statistically non-
trivial because of the frequent mutual exclusivity of driver events: if it is required for a
tumour’s development that the functioning of a particular pathway is disturbed (for ex-
ample by a mutation of the DNA), then an individual patient will almost never exhibit
more than a single genetic alteration in the genes belonging to this pathway. Addi-
tional alterations in genes in the pathway would not give an extra fitness advantage
to the tumour cell, as the pathway was already disturbed by the first driver alteration.
Consequently, different patients in which the same pathway is disturbed can all have
alterations in different genes of this pathway. Mutual exclusivity of driver events ren-
ders the statistical task of identifying true drivers of cancer extremely difficult. It has
become clear that genetic alterations in tumour cells should be analyzed in relation to
the pathways they are found in, rather than as isolated events.
An additional challenge in cancer research is how to integrate different data types
in a single analysis. Indeed often for a patient sample, multiple datasets with each
their specific properties can be acquired. In this thesis, gene expression and muta-
tion data are supplemented with copy number and methylation data. Whether one is
interested in prioritizing genes linked to tumour development, in grouping patients
based on pathways or in ranking pathways that are disturbed, an integrated approach
is necessary. If each data type is analyzed in isolation, one risks missing patterns of
complementarity between the different available data types.
We have translated these four challenges to real world problems in the field of
computational biology, using different combinations of data types that were available
for yeast, eucalyptus trees and humans. To tackle the presented problems, we made
extensively use of the assumption that genes found in the immediate neighborhood
of each other in a gene interaction network have a high likelihood of participating in
the same biological processes. All methods presented make use of a network-based
connectivity measure that either acts as a proxy for gene function similarity, or as a
metric that quantifies how relevant a gene is for a particular sample or patient.
Using this approach, we were able to develop a gene prioritization technique that
was applied to yeast SNP and gene expression data in order to refine so-called ex-
pression Quantitative Trait Loci (eQTL). Here gene expression is considered to be
the molecular phenotype of interest. Next to using a connectivity measure for linking
candidate genes to a target gene, the method is based on the idea of first delineat-
ing a local network before any subsequent analysis takes place. We demonstrated its
superior performance by comparing it to both naive and established techniques.
We introduced the idea of diffused gene expression as an alternative for first iden-
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tifying sets (modules) of genes with similar gene expression and then continuing the
analysis with a module-averaged gene expression signal. This proved to be a powerful
way to increase the statistical power of traditional correlation analysis wherein expres-
sion levels of genes are linked to phenotypic traits. The approach was demonstrated
using a gene interaction network and gene expression, eQTL and high level trait data
(wood density, bark thickness, ...) for eucalyptus trees. We were able to show that the
presented approach greatly outperformed traditional correlation analysis in terms of
prioritizing reference genes compiled from literature.
In order to tackle the problem of data integration in tumour analysis and the sta-
tistical challenges posed by patterns of mutual exclusivity, we developed a unified
framework that can be used for pathway ranking, patient subtyping, driver gene prior-
itization and sub-network delineation. Any data type that can be converted to a binary
representation can be integrated, together with prior knowledge in the form of curated
gene interactions. The framework is based on the conversion of all available data into
a single network representation that not only contains genes, but also patient samples.
The connectivity measure described above is then used to determine the relevance of
each gene in this global network for a single sample or a set of samples. The frame-
work was applied to publicly available breast, ovarian and glioblastoma multiforme
cancer data. Results were validated using both naive and state-of-the-art methods, as
well as by conducting an extensive literature review. We were able to produce biolog-
ically relevant pathway rankings as well as subtypes of patients that correlate highly
with patient survival. We also identified subnetworks and sets of driver genes that
recapitulate to a large extent what is known about the cancer types under study.

1
Introduction
“Ignorance more frequently begets confidence than does knowledge: it is those who
know little, and not those who know much, who so positively assert that this or that
problem will never be solved by science.”
–Charles Darwin (1809 - 1882)
In this chapter, we introduce the reader to some basic concepts that situate the con-
ducted research. The main topic of this work is the use of gene interaction networks to
leverage the simultaneous analysis of different types of data and the prioritization of
genes whose genetic variation can be linked to a phenotype of interest. First, genetic
variability is introduced, followed by a discussion of how properties of an organism
are influenced by many genes rather than by a single gene. We then elaborate on the
fact that genes do not operate in isolation but rather constitute complex interaction net-
works. Given this realization, together with the availability of large amounts of data
pertaining to different data types, a number of challenges arise that are subsequently
discussed. Finally, we summarize the main contributions of the presented work and
outline the structure of this dissertation. At the end of this chapter, we provide an
overview of the publications that were authored during this research period.
1.1 Sources of genetic variability
The genome of all living things, be they e.g. fungi, yeasts, microbes, plants, animals or
humans, contains the blueprint that manages the organism’s functioning. It is, together
with environmental stimuli, responsible for how an organism behaves, and determines
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the phenotype of the organism, i.e., the molecular, microscopic and macroscopic prop-
erties of each life form. The genetic sequence that constitutes the genome consists of
a series of adenine, thymine, cytosine, and guanine bases, abbreviated respectively
as A, T, C, and G. Each A matches with a T, and each C matches with a G to form
a so-called base-pair. Base-pairs are organized in a double helix structure known as
DNA. The genome of an organism may contain several large DNA molecules called
chromosomes. Genes are individual programs, encoded as strings of base-pairs, that
are responsible for one or several specific tasks. Such tasks can range from producing
(part of) a specific sugar-processing enzyme to producing a molecule that acts as a
signal for other genes to become active.
Not all individuals of a species are identical. A large part of this diversity can
be attributed to genomic variability. For instance for human beings, it is known that
on average, two individuals share over 99.9% of there genetic sequences [1, 2]. The
remaining 0.1% is responsible (together with environmental factors) for all the ob-
served natural differences between humans. As the human genome contains over 3
billion base-pairs, this still results in over 3 million single nucleotide polymorphisms
(SNPs). Each SNP represents a position in the genome (a location on a chromosome)
where it was found that some individuals have a particular base (e.g., a C), where
others have another base (e.g., a T). When such a SNP is found within the DNA code
that constitutes a gene, it will sometimes (but not always) alter the functionality of
that gene. Different versions of a gene found in different individuals of a species, or
within a single individual if the organism contains multiple chromosome copies, are
called alleles.
The number of SNPs mentioned above represents only the natural variation be-
tween humans. Next to natural variation explained by inheritance mechanisms, changes
in the genome (e.g., mutations where a C is replaced by an A, or deletions and inser-
tions of individual bases) may occur randomly or under the influence of environmental
factors. These somatic (non-inherited, contrary to germline) changes can sometimes
make organisms function abnormally, causing disease or increased disease suscepti-
bility, deviating phenotype or organism death. For example, somatic mutations are
a very important component of tumour development. A driver mutation is a genetic
defect that makes a gene function differently (or not at all) and creates a growth ad-
vantage for the tumour cell. The opposite of a driver mutation is a passenger mutation
that does not give a growth advantage to the tumour cell.
Note that next to single nucleotide polymorphisms (including mutations, deletions
and insertions), other types of genetic variation exist. In this work, we will also make
use of copy number variation and DNA methylation data. Due to evolutionary pro-
cesses, certain portions of the genome have been duplicated several times, resulting in
multiple copies of some sequences being naturally present in the DNA. Copy number
variation of a sequence is than defined as the deviation of the observed copy number
for that sequence from the copy number observed in the natural population [3]. DNA
methylation is the process of switching genes on or off by binding a methyl group to
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certain locations in the DNA. It is a source of epigenetic variation rather than genetic
variation as the methylation process is regulated by external (non-genetic) factors.
Excessive DNA methylation (hyper-methylation) has been shown to silence certain
tumor suppressor genes [4].
1.2 Traits can be governed by many genes
For long, researchers have tried to link organism-specific properties to genetic vari-
ability. More specific, they try to identify different alleles of one or more genes that
are responsible for observed phenotypic differences. Studies in which variations in the
entire genome are linked to a trait (a characteristic property) of an organism are called
genome-wide association studies (GWAS). As more genetic data become available at
a lower cost, more GWAS studies are carried out.
In mostly popular, non-scientific media, this has given rise to a plethora of news
items wherein it is reported that researchers found the gene for eye color, obesity,
schizophrenia or long life. Even when these reports are based on scientific findings,
they often fail to mention that rather than a single gene, a set of genes was discovered
whose different alleles could be related to a particular trait. Eye color, for instance,
is known to be regulated by over 10 genes, and 50 candidate genes were identified
for being potentially responsible for different iris patterns [5]. Body weight is po-
tentially linked to over 400 genes [6], and over 108 sources of genetic variance (of
which almost all could be directly linked to one or several genes) are associated with
schizophrenia [7]. Most of the variability driving differences in these phenotypes will
be germline, i.e., inherited from ancestors. Cancer on the other hand, can be regarded
as a phenotype that is driven by a great number of mostly somatic (non-inherited) de-
fects [8]. At the time of writing, 534 genes are known to be frequently mutated in
some form of cancer, according to the COSMIC cancer gene census [9]. Complex
traits, governed by many genes are not exclusive to higher animals or humans. In fact,
only very few traits are determined by variation of only a single gene. Such traits
are called Mendelian, named after Gregor Mendel who discovered his famous laws of
inheritance (applicable to Mendelian traits) studying the color of pea flowers growing
in his garden.
All the traits studied in this work are non-Mendelian and can not be described us-
ing single gene models. Analyzing biological processes related to such traits requires
models that simultaneously take many genes into account. Additionally, it has become
apparent that genes do not operate in isolation but instead interact with each other, con-
stituting networks (also called cascades or pathways) of interacting genes. Using spe-
cific approaches that take into account these interaction networks can greatly increase
the statistical power to discover new findings. In fact, without such network-based
approach, most biological processes can not be described at all. Network-based infer-
ence is therefore the main topic of this work. Below we elaborate on these networks
of interacting genes, and how they can be beneficial to different types of analysis.
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1.3 Networks of interacting genes
The realization that genes, and by extension, all entities found in a cell do not act in
isolation, together with the advent of high-throughput data acquisition techniques has
lead to the development of the systems biology research field. In systems biology, the
structure and dynamics of cellular and organismal function, rather than the character-
istics of isolated parts of a cell or organism are analyzed [10]. Networks of interacting
genes and other molecular entities found in a cell are an important element of such
integrated analysis. They contain information on which genes interact, together with a
description of the nature of the interaction relation. Indeed many types of interactions
can be discerned. They can be divided in two broad classes that each can be subdi-
vided in more specialized categories [11]. The gene interaction types relevant for this
work are listed below:
1. Physical interactions: interactions between entities that have a biochemical ba-
sis, corresponding to two (or more) entities reacting (in the chemical sense) with
each other.
• Protein-protein interactions describe direct physical interaction between
proteins. A typical example of this are large complex of many proteins,
whose function is altered by the inclusion or exclusion of particular pro-
teins.
• Transcriptional interactions are involved in regulating (i.e., either promot-
ing or inhibiting) the transcription of genes from the DNA. Examples are
transcription factors that bind to promoter sites of genes to increase the
rate of transcription of that gene.
• Signaling interactions often involve the phosphorylation of a substrate by
a kinase that becomes active as a response to e.g. extra-cellular growth
signals. The phosphorylation alters the substrate in such a way that it can
bind to other proteins to form complexes that in turn can transduce the
signal further into the cell. Eventually such signaling cascades lead to a
cellular response.
2. Functional interactions: these are essentially all non-physical interactions, i.e.,
relations between genes that lack a biochemical basis, or for which the physical
interaction mechanism is unknown.
• Genetic interactions refer to the observation that the effect of genetic vari-
ability of a gene on a quantitative trait is influenced by the genetic vari-
ability of another gene, without knowing the exact underlying molecular
mechanism governing this interaction.
• Co-expression-based interactions are found when the expression levels of
two or more genes are correlated, suggesting the presence of a common
regulatory mechanism.
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Networks may also differ in the way the interaction mechanisms are abstracted.
Ideally, the network could be used to mathematically model the dynamics of mea-
surable quantities like protein concentrations or mRNA levels. This requires a deep
understanding of the molecular interactions between all entities in the network and
quickly becomes extremely computationally demanding [12, 13]. Moreover, the dy-
namic molecular data required to build such models is largely lacking [14, 15]. Such
networks are only used for very focused biological processes containing only a few
genes. A more abstract approximation of gene interactions is found in Boolean net-
works. In these networks, genes are represented as switches that are either on or
off. By applying rule-based reasoning to these networks, inferences about the dy-
namic states of the genes can be made [16, 17]. Despite their higher level of abstrac-
tion, Boolean networks suffer from the same problems as mathematical models. Even
though they can be used to simulate processes with thousands of genes, their training
still demands dynamic data and considerable computational power.
On the most abstract level, gene interactions are simply considered to be quali-
tative relations placing two genes in the same chemical reaction or in the same bio-
logical process without trying to convey any information on the biochemical reality
underlying the interaction. At most, the interaction is annotated with a notion of di-
rection (e.g., a transcription factor has a number of target genes), or is qualified with
the nature of the interaction (e.g., the interaction is a functional interaction, or high
expression levels of gene one are known to inhibit expression of gene two). Such net-
works are unfit to model dynamic processes, but as has extensively been demonstrated
in the past, and as we show in this work, they can be of great value for simultaneously
analyzing large amounts of data. Because of their simplicity, modeling and analyzing
these networks as graphs containing nodes (genes) and edges (interactions) is straight-
forward.
Here we will extensively make use of the assumption that nodes found in the im-
mediate neighborhood of each other (or alternatively, that are easily connected) have a
high likelihood of participating in the same biological processes. The graph represen-
tation of a gene interaction network allows for the application of algorithms that can
quantify this connectivity. Candidate connectivity metrics range from shortest path
calculations using the Dijkstra algorithm [18] to diffusion models where a droplet of
ink, inserted in a node, is allowed to diffuse through the network for a fixed amount of
time after which the ink concentration in all nodes in the network is measured [19].
Multiple initiatives have been started to collect, validate and annotate vast amounts
of gene interactions. As a result, curated gene interactions for many organisms can be
downloaded from public databases like KEGG [20], BioGRID [21], STRING [22] or
ENCODE [23]. In this work we will combine different sources of network information
to obtain a heterogeneous integrated network where several types of gene interactions
are combined (Figure 1.1, [11]).
It is important to realize that the available networks are largely incomplete, and
may additionally be biased towards biological processes that are of particular inter-
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Figure 1.1: Creating an integrated network using different types of homogeneous networks.
Yellow = protein-protein interaction, red = signaling interaction, blue = transcription factor-
target interaction. Reproduced after [11].
est to the research community. In human networks for instance, genes and relations
between genes that relate to disease in general, and to cancer in particular, will be
overrepresented in the network. Additionally, the relations between genes, be they
functional or physical, will not always be present in reality. Most networks provide
a high level overview of gene interactions obtained under many different conditions,
and it is not guaranteed that a gene interaction is actually present under the conditions
that are subject of the analysis at hand. This problem can be overcome by using ad-
ditional data sources that help provide biological context for the network, effectively
weakening unimportant and strengthening relevant relations between genes. In this
work we will typically use gene expression data to provide biological context to the
network. As a final remark, it is important to realize that gene interaction networks
are aggregates of smaller sub-networks or pathways that can be linked to well defined
biological processes. For instance, organisms can have a pathway responsible for cell
division, DNA-repair, photosynthesis, estrogen signaling, ... In fact, the networks that
are used most in this work are derived from KEGG [20], which is a collection of
pathways rather than a database of individual gene interactions.
1.4 Challenges
Often the trait under consideration in a GWAS study is quantitative, indicating that
it can take many continuous values rather than being binary. Quantitative traits are
almost always governed by different genes, otherwise no continuous values could be
obtained (although additive allelic effects or epigenetic effects within the same locus
can play a role too in quantitative traits). Examples are leaf length, body weight, fer-
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Figure 1.2: Illustration of the need for eQTL prioritization when only low resolution genetic
data are available due to insufficient genetic variability in the population or wide spacing of
SNPs.
mentation efficiency, wood density, ... When it is found that the genetic variation at a
locus (a location on a chromosome) correlates with the quantitative trait, it is said that
the locus is a QTL, a Quantitative Trait Locus. In many GWAS studies, the genome
is sampled at fixed locations rather than completely sequenced. A QTL will then be
representative for a large genomic region and might overlap with several genes (Fig-
ure 1.2), especially when the genetic variation in the population under study is limited.
When the trait under study is the expression level of a gene, a QTL found is referred
to as an eQTL, an expression-QTL. Similar to QTL, and eQTL (a locus where ge-
netic variability associates to the expression signal of a particular gene) might overlap
with a large number of genes. It is unlikely that all those overlapping genes interact
directly or indirectly with the gene that associates with the locus. Instead, it is far
more plausible that the genetic variability of only a single gene found in the eQTL is
mechanistically linked to the gene the eQTL associates with. The process of deter-
mining which of the candidate genes overlapping with the eQTL is truly interacting
with the gene of interest is called eQTL prioritization. As it turns out, gene interaction
networks can be of great value in determining this true causal gene.
If one wants to identify genes that influence a trait, but genotype data are not (or
only sparsely) available, statistical methods (of which correlation is the most intuitive
example) linking gene expression to the quantitative traits under study can be used.
The underlying assumption is then that the observed variation in expression of each
gene is caused implicitly by genetic variation between the samples. Unfortunately,
as mentioned above, phenotype is also determined by environmental factors that can
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obfuscate the relation between genes and phenotype. One can try to minimize the
influence of environmental factors by using standardized growth and measurement
protocols, but especially with higher organisms, this can be impossible. Here too, a
network-based analysis can increase to power of the models used to detect gene-trait
associations, especially by allowing for the inclusion of low resolution genetic data
that would otherwise be of little value.
Sometimes genotype data are available, but the trait under study is extremely com-
plex. A typical example of this is tumour development. In principle, this is a binary
trait (the tumour is present or not), but the molecular mechanisms that lead to carcino-
genesis obey a very specific set of rules due to the clonal character of tumour cells.
Clonality here refers to the fact that the genome of a tumour cell contains the same
genetic defects as all the other cells in a tumour. For the sake of completeness, we
should add that tumour cells can be genetically diverse (e.g., due to a failing DNA-
repair system, additional defects can accumulate), but all tumours will contain the
original genetic defects that gave a tumour’s cell-of-origin the fitness advantage that
allowed it to proliferate and survive. If it is required for a tumour’s development that
the functioning of a particular pathway (for example, the apoptosis pathway respon-
sible for programmed cell death) is disturbed, then an individual patient will almost
never exhibit more than one driver mutation in the genes belonging to this pathway
(Figure 1.3). Additional mutations in genes in the pathway would not give an extra
fitness advantage to the tumour cell, as the pathway was already disturbed by the first
driver mutations. Consequently, different patients in which the same pathway is dis-
turbed can all have mutations in different genes of this pathway. This so called mutual
exclusivity of driver mutations renders the tasks of identifying true driver mutations
extremely difficult [8], and it has become clear that mutations in tumour cells should
be analyzed in relation to the pathways they are found in, rather than as isolated events.
Next to identifying individual drivers of cancer, pathway ranking (and by extension,
sub-network delineation) techniques have been developed where for each patient, or
for a group of patients, the impacted pathways are prioritized rather than individual
genes. Patients can then be grouped based on the high-level mechanisms (correspond-
ing to pathways) that initiate or maintain tumour development and proliferation. This
so called subtyping of patients can lead to targeted therapeutic strategies where the
drugs a patient receives are tailored to the biological processes governing the tumour.
An additional challenge in cancer research is how to integrate all of the available
omics data in the analysis. Indeed with the advent of cost-effective high-throughput
techniques, for each patient sample, multiple datasets with each their specific prop-
erties can be acquired. In this thesis, gene expression and mutation data are supple-
mented with copy number and methylation data because the mutual exclusivity prin-
ciple discussed above for mutations extends to these additional data types. Pathway
disturbances are not limited to mutations; methylation or altered copy number too can
change the transcription rate of a gene and consequently alter its activity. Again it
will be very unlikely that a single patient has more than one driver alteration (be it
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Figure 1.3: The principal of mutual exclusivity of driver mutations illustrated for a hypothetical
signaling pathway that activates apoptosis. In a single patient, only one of the genes of the
pathway (g1, g2, g3 and g4) needs to be mutated to disturb the pathway’s functioning. Some
patients may not have any mutation in the pathway; instead a gene in the pathway can for
example have a deviating copy number.
mutation, methylation or an altered copy number) in the same pathway, and multiple
patients exhibiting the same disease phenotype can all have alterations in different
genes in the pathway. Whether one is interested in prioritizing genes linked to tumour
development, grouping patients based on pathways or in ranking pathways that are
disturbed, again a pathway-centric approach is necessary. An approach where each
data type is analyzed separately risks missing patterns of complementarity between
the different available data types. Additionally, the errors associated with each sepa-
rate analysis will accumulate when the different obtained results are merged. Unfortu-
nately, the different data types all have very different properties, and for the values in
each data type, a unique definition of deviation from normality applies, so data from
different data types can not easily be merged or overlaid.
1.5 Outline and research contributions
Each of the four chapters following this introduction address one or several of the
challenges discussed above. The chapters are ordered chronologically, rather than
thematically: chapter two deals with yeast data, chapter three and four focus on hu-
man tumour data, and in chapter five plant data are used. The techniques presented in
the consecutive chapters each build on the work of the previous chapter, and as such,
from a methodological point of view, a coherent story is told. All chapters have in
common that prior knowledge about gene interactions is used as input to the analysis.
Often the networks used will be referred to as prior knowledge networks. Networks
are mathematically modeled as graphs containing nodes (genes) and edges (gene in-
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teractions).
In chapter two, the problem of eQTL prioritization is addressed. First, eQTL were
determined using yeast (Saccharomyces cerevisiae) SNP and gene expression data.
In order to guarantee that any consecutive eQTL prioritization would not be biased
towards the eQTL association technique, we applied three different association tech-
niques: mixed models, elastic net regression and non-parametric regression. For each
of the eQTL associations found, candidate genes overlapping with the eQTL were
identified and subsequently ranked according to how well they were connected (in
a physical gene interaction network) to the gene the eQTL associates with. In or-
der to quantify this degree of connectedness (also called similarity in this thesis), we
calculated several graph-node similarity metrics using random walk-related kernels
operating on graph nodes. The undesirable effects of over-connected genes (hubs)
and unreliable gene interactions are mitigated by, prior to node similarity calculation,
first constructing a local network using a k-shortest path approach. We were able to
demonstrate the effectiveness of the proposed method (named EPSILON: an eQTL
prioritization framework using similarity measures derived from local networks) by
applying it to known locus-gene interactions derived from knock-out experiments. EP-
SILON outperformed both naive reference solutions (random assignment and shortest
path calculation) and state-of-the-art techniques (ITM-probe [24] and eQED [25]).
Chapter three extends the notion of network connectedness or similarity intro-
duced in chapter two to allow for the simultaneous analysis of different cancer-related
data types, while maintaining pathway information in the analysis. The latter is nec-
essary in order to deal with the mutual exclusivity of genetic defects. Different data
sets with different data types are all converted into a single comprehensive network
representation containing not only genes but also individual patient samples. Addi-
tionally, all data are linked through a network of known gene interactions. By again
calculating a measure of connectedness in this so-called global network, the relevance
of a particular gene for a particular patient sample can be assessed. By aggregating
these similarity measures over all genes in a pathway and over all patient samples in
the data, a single score for a pathway under study can be calculated. By evaluating
several hundreds of pathways, a ranking of the most relevant pathways for a set of pa-
tients can be produced. We applied the technique to breast and ovarian cancer datasets
and extensively used cancer literature to corroborate our findings.
The integrated data model developed in chapter three has many different applica-
tions, as is demonstrated in chapter four. By using the network-based similarity be-
tween entities (both genes and patient samples) in the global network, it becomes pos-
sible to identify biologically meaningful tumour subtypes, find lists of potential driver
genes, rank pathways and delineate sub-networks linked to patients belonging to a par-
ticular subtype. This multi-applicability of the developed framework resulted in the
development of MUNDIS, a multi-purpose, network-based data-integration strategy.
We demonstrated the framework’s potential by applying it to ovarian, glioblastoma
and breast tumour datasets containing gene expression, mutation, copy number and
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methylation data. We were able to delineate patient subtypes that correlate highly
with patient survival. MUNDIS outperformed both naive and state-of-the-art subtyp-
ing strategies (iCluster [26, 27]) in terms of patient survival statistics. For each of
the patient subtypes produced by MUNDIS, as well as for the well described Basal
and Luminal A molecular breast cancer subtypes [28], we additionally created lists
of potential drivers of tumour development and proliferation and pathway rankings.
Additionally we also produced sub-networks that provide a more mechanistic insight
in the biological processes underpinning the discovered subtypes. Again an extensive
literature study was performed to asses the biological value of the results produced.
Finally, in chapter five we present yet another application of the measure of con-
nectedness used throughout this work. By diffusing gene expression data though a
network of known gene interactions, we linked genes to complex wood and biomass-
related traits (e.g., wood density, lignin content, tree diameter, ...) in eucalyptus trees.
Together with our research partners we analyzed a unique dataset containing molec-
ular and trait data for a E. grandis x E. urophylla F2 back-cross population. First,
a QTL (linking genetic variability to traits) and eQTL (linking genetic variability to
gene expression) analysis was performed yielding sets of QTL and eQTL that unfor-
tunately had very low genetic resolution due to the limited amount of genetic variation
in the population. A prioritization analysis as that presented in chapter 2 was not ap-
plicable here, since the loci identified overlapped with too many genes (often several
hundred), and no high-quality eucalyptus gene interaction network is available yet.
Instead, a gene interaction derived from A. thaliana was complemented with eQTL
sharing-relations (indicating that two genes are potentially influenced by genetic vari-
ability found at the same locus). By diffusing gene expression through this network,
a network-diffused feature set was obtained. The diffused gene expression data were
subsequently correlated with the high-level traits under study to obtain gene selections
for each trait. Using the enrichment of the resulting gene sets for a list of literature-
based reference genes, we were able to show that the obtained gene sets are highly bi-
ologically relevant. When comparing with gene sets obtained with a naive correlation
analysis using the untransformed gene expression data, we found that our approach
greatly outperformed the naive approach. Additionally, we produced biologically rel-
evant clusters of traits based on the gene selections obtained for each trait. When
mapping the previously identified eQTL associated to the genes selected for each trait
back to the genome, we found that these eQTL tend to cluster, and often overlap with
the location of QTL (that up to this point were not used in the analysis), confirming
the biological validity of our approach. As a final means of validation, gene function
enrichment analysis indicated that many gene sets produced were enriched for biolog-
ical functions related to cell wall biosynthesis and xylan (a major constituent of the
secondary cell wall) metabolism.
To conclude the introduction, we provide a number of different reading tracks
for readers from different scientific backgrounds. The conducted research presented
in this thesis is highly multi-disciplinary, with both a biological and methodological
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component. Even though all chapters are built around a newly developed technique,
and all but chapter three include a objective measures of performance, the rationale for
developing a new technique and additional validation of the results requires biological
insight in the problems to be solved.
• Readers with a technical background can focus on chapter two where the eQTL
prioritization technique is presented, and on the methodological sections 3.2,
4.4 and 5.4 of the remaining chapters.
• Readers with an interest in cancer genomics can forward to chapters three an
four where we demonstrate the use of network-based techniques for a wide
range of applications. In these chapters we placed a large focus on the biological
relevance of the results produced.
• Researchers with a broad interest in bioinformatics should be able to appreciate
the entire work. For the techniques described in all chapters but chapter four, we
also provide reference implementations with demo data, so that the especially
curious reader could try out the presented methods.
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2
EPSILON: an eQTL prioritization
framework using similarity measures
derived from local networks
In this chapter, we address the eQTL prioritization problem using a network-based
approach. The technique developed for the prioritization task will be the foundation
off all the work subsequently conducted in this dissertation. Especially the use of
a measure of connectedness in a gene interaction network as a proxy for functional
similarity and relevance in the broad sense will prove to be of great value for tackling
a great diversity of challenges.
? ? ?
Lieven P.C Verbeke, Lore Cloots, Piet Demeester, Jan Fostier and
Kathleen Marchal.
Published in Bioinformatics 29(10). 2013. p1308-1316
Abstract
When genomic data is associated with gene expression data, the resulting expres-
sion quantitative trait loci (eQTL) will very likely span multiple genes. eQTL pri-
oritization techniques can be used to select the most likely causal gene affecting the
expression of a target gene from a list of candidates. As an input, these techniques use
physical interaction networks that often contain highly connected genes and unreliable
or irrelevant interactions that can interfere with the prioritization process. We present
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EPSILON, an extendable framework for eQTL prioritization that mitigates the effect
of highly connected genes and unreliable interactions by constructing a local network
before a network-based similarity measure is applied to select the true causal gene.
We tested the new method on three eQTL data sets derived from yeast data using
three different association techniques. A physical interaction network was constructed
and each eQTL in each data set was prioritized using the EPSILON approach: first a
local network was constructed using a k-trials shortest path algorithm, followed by the
calculation of a network-based similarity measure. Three similarity measures were
evaluated: random walks, the Laplacian Exponential Diffusion kernel and the Reg-
ularized Commute-Time kernel. The aim was to predict knockout interactions from
a yeast knockout compendium. EPSILON outperformed two reference prioritization
methods, random assignment and shortest path prioritization. Next, we found that
using a local network significantly increased prioritization performance in terms of
predicted knockout pairs when compared to using exactly the same network similarity
measures on the global network, with an average increase in prioritization perfor-
mance of 8 percentage points (p<10-5).
The physical interaction network and the source code (Matlab/C++) of our imple-
mentation can be downloaded from http://bioinformatics.intec.ugent.be/epsilon.
2.1 Introduction
eQTL (expression Quantitative Trait Locus) analysis is the process of associating ge-
netic variation in a population with variable gene expression in order to identify poly-
morphic genetic regions affecting gene expression [1]. Frequently, genetic markers
are used to sample the genetic diversity between individuals of an organism. Due to
linkage disequilibrium and the spacing of the genetic markers on the genome, these
genetic markers represent a region on a chromosome that covers multiple genes rather
than a single gene. The variability in expression of the genes found to be associated
with the eQTL (here referred to as target genes) is most likely caused by a mutation in
a single gene located on the eQTL (the true causal gene). Yet eQTL analysis as such
is not able to distinguish this causal gene from the remainder of the genes located
on the eQTL (the candidate causal genes). Instead, gene prioritization or refinement
methods are needed. A number of prioritization methods that rank candidate genes
according to some criterion have been developed in the past (see Tranchevent et al. [2]
for an extensive overview). Typically, these methods target novel (human) disease-
gene identification. Information about the disease under study, i.e. in the form of a list
of existing disease genes is often needed. Other methods target specific experiments
for which additional data, divided in disease/control groups, are required, and can not
be readily applied to the results of an eQTL analysis where such groups are not nec-
essarily present. Also, some of these techniques do not allow for the incorporation of
a custom gene interaction network as only predefined networks for a limited number
of organisms are available. A smaller number of techniques were developed to tackle
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the more specific eQTL prioritization task. All eQTL prioritization methods have in
common that they use a physical interaction network to define a similarity measure be-
tween a target gene and a set of candidate causal genes. The higher the network-based
similarity between the target and the candidate causal gene, the more likely the can-
didate corresponds to the true causal gene. Tu et al. [3] developed a method based on
random walks in a physical interaction network, an approach later refined by Suthram
et al. [4], who extended the random walk idea with an electric circuit analogy. Vo-
evodski et al. [5] applied the PageRank algorithm to develop a gene affinity measure,
and Stojmirovic´ and Yu [6] used the mathematical modeling of information flow in a
network to rank candidate genes.
According to Stojmirovic´ and Yu [6], it is most important to use directed relations
(e.g. protein-DNA interactions) in the interaction network whenever possible. They
also suggest localizing the network, i.e. excluding distant genes from the network that
connects an origin (the target gene) with a set of destinations (the candidate causal
genes), prior to analysis in order to better reflect the biological context. Otherwise,
results of e.g. gene prioritization will be highly dependent on the node degree of the
genes in the network. A high node degree can point to functionally useless genes
(so-called promiscuous genes). However, genes with a high node degree can also cor-
respond to important hubs [7]. As a result, simply removing genes from the network
with a node degree exceeding an arbitrary threshold, or heuristically downweighting
the importance of relations based on the number of connections, risks removing useful
genes or important relations [8].
To overcome this problem, we propose EPSILON, an eQTL prioritization frame-
work using similarity measures derived from local networks. The main assumption
underlying EPSILON is that the disturbing influence of highly connected genes and
unreliable or irrelevant interactions can be controlled by reducing the global interac-
tion network to a local neighborhood (i.e. a sub-network) connecting the target gene
and all candidate causal genes, prior to calculating a network-based similarity mea-
sure. Once the local network is constructed, a similarity measure between the target
gene and all candidate causal genes can be calculated, and the candidate with the high-
est similarity can be selected as the true causal gene. This approach is not unlike the
diffusion-based methods applied to tumour datasets by Hofree et al. [9] or Leiserson
et al. [10]. We demonstrate the added value of a local approach for eQTL priori-
tization by plugging in established prioritization methods such as path finding and
random walks in the EPSILON framework. Alternatively, we also investigate a graph
node kernel-based similarity measure. We evaluate the performance of all methods
using a gold standard data set derived from a knockout compendium.
2.2 EPSILON framework
An overview of the EPSILON refinement scheme is presented in Figure 2.1. As in-
put, the results of an eQTL association analysis are used. Three different associ-
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ation techniques were tested. It is well-known that the results of eQTL analysis are
highly dependent on the mapping method used, and we wanted to avoid a prioritization
bias towards any method. We used Mixed Models (MM), Non-Parametric Regression
(NPR) and Elastic Net regression (EN) for the association analysis, all of which are
described in the Materials and Methods section. The EPSILON method contains two
steps, which are applied to each association found: (1) construct, from an existing
global interaction network, a local sub-network that connects the candidate causal
genes covered by an eQTL with the target gene and (2) calculate a similarity measure
that expresses the functional similarity between the target gene and a candidate causal
gene. Both steps are elaborated on below.
2.2.1 Extraction of Local networks
To restrict the network around a set of candidate causal genes and a target gene, a
shortest/cheapest path approach is applied. All interactions are assigned a cost (see
below), and an optimal path from each candidate to the target was found using the
Dijkstra algorithm [11]. All genes and interactions that were found on such a shortest
path were included in the sub-network. Furthermore, it was investigated if enlarging
this neighborhood could improve the prioritization results. This was achieved by k
times considering if an alternative shortest path exists, that is different from any pre-
viously found path (see Materials and Methods for a detailed description). All the
alternative paths are merged afterwards to form the local sub-network. Because it is
expected that the value of k will influence the size of the sub-network, EPSILON was
run with different values for k. Our localization method is expected to mediate the in-
fluence of highly connected genes. Even if an unwanted hub were included in the local
network connecting a candidate with the target, it will have at most 2k connections
(in the unlikely case where all k paths enter and leave the hub through different inter-
actions), instead of potentially tens or hundreds of connections. Evidently, the higher
the quality of the underlying network, the higher the quality of the local networks
will be, but by using a shortest/cheapest path based approach, unreliable or irrelevant
(when connecting a specific causal gene with the target gene) connections will only
be followed when there is no more reliable or relevant alternative available. The algo-
rithm will not remove shortcuts (indirect interactions between two genes/proteins that
do not reflect a true physical relation) from the local networks, but only when they are
present as high-confidence interactions.
A naive nearest neighborhood method (take neighbors, and neighbors of neigh-
bors, etc. was tested, but the presence of hubs in the network rendered this approach
useless because the resulting connected sub-networks were almost as large as the
global network. Results for this approach were therefore not considered in further
analysis.
Because the choice of the measure for strength or confidence influences the out-
come of path finding methods, we evaluated three different weight-value schemes.
Standard, and similar to Tu et al. [3] and Suthram et al. [4] we used expression corre-
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lation as edge weights. As a first alternative we used the confidence scores obtained in
the network construction process (see Materials and Methods) and finally, we tested
a simple qualitative weighting scheme of setting edge weights to 1 when an interac-
tion is present and 0 otherwise. Several network-based prioritization methods (e.g.
Suthram et al. [4]) apply, prior to the application of the actual prioritization method,
an extra constraint to the interaction network: based on biological considerations, it
is demanded that a target gene be reached through a directed protein-DNA (transcrip-
tion factor) interaction. We tested if applying this transcription factor based filtering
(TF-filtering) prior to local sub-network construction could improve prioritization per-
formance.
2.2.2 Network similarity measures
Once the local network connecting all candidate causal genes with the target gene is
constructed, the EPSILON framework requires the calculation of a network similarity
measure between the target gene and all candidates to assess their functional related-
ness. In principle, any network-based similarity measure could be integrated. Several
authors (e.g. Tu et al. [3], Suthram et al. [4], Shih and Parthasarathy [12]) propose a
random walk (RW) approach, in which a random walk is initiated a very high number
of times from a candidate causal gene, and it is measured how many times a random
walker is found in the target gene. The probability of choosing a particular direction is
a function of a weight value associated with each interaction. Obviously, the candidate
causal gene that yields the highest number of arrivals in the target gene is chosen to
be the true causal gene.
Next to integrating random walks in EPSILON, we investigated kernels calculated
on graph nodes as an alternative similarity measure. These kernels are an attractive
tool for uncovering relations in large networks [13]. As already demonstrated by Qi
et al. [14], Ko¨hler et al. [15], Nitsch et al. [16] and Lavi et al. [17], kernels operating
on nodes in a biological network can be used as functional gene similarity measures.
In this study, we evaluated two well-known kernels, the Regularized Commute-Time
(RCT) kernel and the Laplacian Exponential Diffusion (LED) kernel. Both are de-
scribed in the Materials and Methods section. The LED and RCT kernels operate
on undirected networks. Kernels operating on directed networks do exist, but their
calculation does not scale well for large graphs [18]. Note that even though we use
undirected kernels, the local sub-network on which the kernels are calculated is con-
structed using path finding techniques operating on a directed global network. The
calculation of the kernels results in a similarity matrix containing the similarity be-
tween all possible pairs of genes in the network. From this matrix, the candidate-target
pair with the highest similarity is easily found.
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2.3 Results
2.3.1 Benchmark data set
To investigate whether reducing the global network to a local network, prior to apply-
ing a network-based similarity measure, can aid in identifying the true causal genes
in a set of eQTL, we applied several refinement strategies to the well-characterized
data set of Brem and Kruglyak [19]. They profiled simultaneously the genotype and
expression phenotype of 112 yeast segregants. eQTL were determined as described
below, and for each eQTL, candidate causal genes were identified (see Materials and
Methods). Prioritization resulted for each eQTL-target combination in a single priori-
tized causal gene.
Each prioritized causal gene-target gene combination was evaluated against the
experimental knockout data set of Hughes et al. [20], as described in Yeang et al.
[21], Ourfali et al. [22] and Suthram et al. [4] (In Figure 2.2, we present a graphi-
cal overview of the evaluation strategy). Here, for each experiment, the knocked-out
gene is considered a true causal gene. Genes that are affected by the knockout are
assumed to be potential targets. Each knockout experiment thus results in a list of
presumably true causal-target gene combinations. For all causal-target knockout com-
binations in such a list, we look for couples of genes that also appear in the result
of an association analysis. This means that we look for those associations for which
one of the candidate causal genes is the same as the causal gene in a knockout pair,
and for which the target gene is identical to that of the same knockout pair. To make
sure that we are evaluating the gene prioritization, and not the quality of the network,
the number of combinations is further reduced by demanding that there exist a path
in the directed interaction network between the causal and the target gene. These so-
called true combinations of causal-target genes derived from the knockout data set,
that also appear in an eQTL-analysis, determine the maximal reference performance.
A performant gene prioritization procedure is assumed to approximate this list of gold
standard knockout pairs. Note that performance here is defined as the amount of over-
lap of the prioritization results with the target list of knockout pairs or alternatively:
performance = number of retrieved knockout pairs. Relative performance is then de-
fined as performance / maximum number of retrievable knockout pairs. Because a
different association technique will result in different associations, and consequently
in a different reference list of knockout pairs, absolute performance depends on the
association technique used.
2.3.2 Association analysis
We applied three commonly used association techniques to the SNP and expression
data (S. cerevisiae) of Brem and Kruglyak [19]: non-parametric regression (NPR),
mixed models (MM) and elastic net regression (EN) (see Materials and Methods).
The genetic variability in the yeast data set is expected to be low, as a limited num-
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Figure 2.2: A schematic overview of the procedure that was used to compile (for each associ-
ation technique) the list of retrievable knockout pairs that was used to evaluate prioritization
performance.
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ber of segregants derived from a cross of only two parental strains were tested. Also,
gene expression was determined under a single experimental condition. Consequently,
it is likely that only a limited number of true eQTL will be detected. Remarkably, the
three association techniques yield very different results, as is illustrated in Figure 2.3.
Only 662 eQTL are detected by all three methods, even when for each method, the
10 000 most reliable associations are selected. In general, the non-parametric regres-
sion results in a very high number of associations, both cis and trans. The mixed
model almost exclusively produces cis associations, which confirms the findings of
Listgarten et al. [23] and Kang et al. [24]. The elastic net produces a much sparser
association map, with less cis than trans associations.
To make the evaluation of the tested gene refinement strategies independent of
the outcome of the association analysis, we tested all described gene prioritization
schemes on the results of each association method separately. For each association
method, the associations that were prioritized were chosen in such a way (using p-
values, see Material and Methods) that the size of the gold standard reference list
was of the same order of magnitude (see Figure 2.1). Since only a small number of
knockout pairs can be found overlapping with the elastic net associations, even with an
elevated p-value cutoff, we also included the unfiltered elastic net results (containing
all eQTL found by the elastic net feature selection technique) in any further analysis.
2.3.3 EPSILON prioritization results
To demonstrate the added value of the EPSILON approach, i.e. extracting a local
sub-network prior to applying a network-based similarity measure, we compared the
results obtained using different similarity measures in combination with both local
networks and the global network. All local networks were based on the k-trials short-
est path network construction method outlined above with k = 5. The global network
corresponded to the original interaction network (and not a local network with a very
high k value). As an established benchmark strategy, we used a shortest path based
method, which comes down to taking the candidate causal gene that lies closest to the
target gene (see Materials and Methods). As a baseline we performed a random as-
signment, i.e. randomly picking a candidate from the list of available candidate causal
genes. All refinement methods except random assignment were tested with and with-
out transcription factor based filtering (TF-Filtering, suggested by Suthram et al. [4]),
meaning that prior to local network construction or to the application of a global sim-
ilarity measure, the global network is modified in such a way that target genes only
contain incoming transcription factor interactions. The full prioritization result matrix
is shown in Table 2.1. In what follows, we highlight the insights that can be drawn
from these results.
Figure 2.4 shows, in relative terms, the difference in prioritization performance
between the use of a local network over a global network. In all cases, over all associ-
ation mapping techniques, pre-filtering steps and prioritization methods, using a local
network is beneficial, with a maximum and minimum gain of 15 and 2 percentage
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Table 2.1: Overview of all prioritization results. Results are show in absolute number of
retrieved knockout pairs, and as relative performance. TF-filter=transcription based filter-
ing. MM=mixed model, EN=elastic net, NPR=non-parametric regression. RW=random walk,
LED=Laplacian Exponential Diffusion kernel, RCT=Regularized Commute-Time kernel.
Absolute values Relative performance
no TF filter TF filter no TF filter TF filter
MM, p < 0.1 max 237 168 1.00 1.00
Random Assignment 43 30.4 0.18 0.18
SP 102 79 0.43 0.47
Global RW 118 85 0.50 0.51
Global LED 126 88 0.53 0.52
Global RCT 129 96 0.54 0.57
Local LED k=5, alpha=0.001 150 105 0.63 0.63
Local RCT k=5, alpha=0.9 141 112 0.59 0.67
Local RW k=5 144 104 0.61 0.62
ITM Probe norm channel df=0.9 130 NA 0.55 NA
EN, p < 0.1 max 72 49 1.00 1.00
Random Assignment 13.9 9.2 0.19 0.19
SP 24 13 0.33 0.27
Global RW 19 13 0.26 0.27
Global LED 18 11 0.25 0.22
Global RCT 22 14 0.31 0.29
Local LED k=5, alpha=0.001 33 21 0.46 0.43
Local RCT k=5, alpha=0.9 26 21 0.36 0.43
Local RW k=5 33 20 0.46 0.41
ITM Probe norm channel df=0.1 23 NA 0.32 NA
EN, all features max 175 116 1.00 1.00
Random Assignment 34 22 0.19 0.19
SP 64 41 0.37 0.35
Global RW 58 37 0.33 0.32
Global LED 48 43 0.27 0.37
Global RCT 64 32 0.37 0.28
Local LED k=5, alpha=0.001 72 46 0.41 0.40
Local RCT k=5, alpha=0.9 67 49 0.38 0.42
Local RW k=5 69 43 0.39 0.37
ITM Probe norm channel df=0.9 66 NA 0.38 NA
NPR, p<0.05 max 797 513 1.00 1.00
Random Assignment 146.2 94 0.18 0.18
SP 399 252 0.50 0.49
Global RW 374 252 0.47 0.49
Global LED 340 264 0.43 0.51
Global RCT 384 231 0.48 0.45
Local LED k=5, alpha=0.001 435 289 0.55 0.56
Local RCT k=5, alpha=0.9 438 295 0.55 0.58
Local RW k=5 425 280 0.53 0.55
ITM Probe norm channel df=0.9 419 NA 0.53 NA
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Figure 2.3: Agreement between association techniques for the 10 000 most reliable associations
per method. NPR=non-parametric regression, MM=mixed model, EN=elastic net.
Figure 2.4: Effect of using local networks vs. using global networks on the relative perfor-
mance. NPR=non-parametric regression, MM=mixed model, ENFULL=elastic net full re-
sult, LED=Laplacian Exponential Diffusion kernel, RCT=Regularized Commute-Time kernel,
RW=Random Walk, TF=using transcription factor based filtering. Relative performance is de-
fined as maximum number of retrieved knockout pairs / maximum number of retrievable knock-
out pairs
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Table 2.2: Relative prioritization performance for the non-parametric regression eQTL. All
results are calculated using expression-correlation based edge weights, without using TF-
filtering. RW=random walk, LED=Laplacian Exponential Diffusion kernel, RCT=Regularized
Commute-Time kernel
Method Relative performance
Random assignment 0.18
Shortest path 0.50
Global RW 0.47
Global LED kernel 0.43
Global RCT kernel 0.48
Local RW k = 5 0.53
Local LED kernel k = 5, α=0.001 0.55
Local RCT kernel k = 5, α=0.9 0.55
points, both for the elastic net associations prioritized with a RCT kernel, but respec-
tively with and without TF-filtering. In general, using a local network yields signifi-
cantly better performance compared to using the global network with an average gain
of 8 percentage points (paired two-tailed t-test, p < 10−5). On average (over all as-
sociation techniques and TF-filtering possibilities), the RCT kernel yields the highest
performance (58%) and the random walks the worst (55%), yet these differences were
not statistically significant (p = 0.13, three way ANOVA). The elastic net associations
were more difficult to prioritize than the associations obtained with mixed models and
non parametric regression, with a maximum performance of respectively 41%, 63%
and 55% (no TF-filter). The average performance (averaged over prioritization meth-
ods and association techniques) is only slightly better when TF-filtering is applied
than when it is not (50% without TF-filtering, 51% with TF-filtering). Moreover, this
difference is not statistically significant (paired two-tailed t-test, p = 0.15).
As a typical example, we present the results for non-parametric regression without
TF-filtering in Table 2.2. The largest overlap with the target list is obtained using
a local LED or RCT kernel (55%). As expected, all methods show a much higher
overlap with the target list compared to random assignment. The shortest path method
performs slightly better (50%) than the global methods, yet it shows a smaller overlap
with the target list than the local methods.
2.3.4 Size of the local neighborhood
We evaluated the added value of using a relaxed local neighborhood. This was achieved
by varying the parameter k in the k-trials shortest path neighborhood construction al-
gorithm between 1 and 20. Local networks generated with different values of k for
a single eQTL-target combination are displayed in Figure 2.5. It can clearly be seen
how, for small values of k, local networks remain sparse. Nodes with a high node de-
gree in the global network sometimes (but not always) become hubs again in the local
EPSILON 31
Figure 2.5: Example local networks generated with the k-trials shortest path method for dif-
ferent values of k. The diameter of the genes is proportional to the node degree in the global
network. Green nodes are target genes, red nodes are candidate causal genes
network for large values of k. Indeed when k → ∞, the local network will resemble
the global network more closely (see Materials and Methods).
Experiments were run for the eQTL obtained with the non-parametric regression
using the random walk similarity measure and the LED and RCT kernels. The results
are displayed in Figure 2.6. A number of observations can be made. First, the low-
est performance is obtained for k = 1, corresponding to a local network constructed
using a single shortest path. Second, although the maximum overall performance is
recorded for the RCT kernel, this kernel seems to be more sensitive to the value of k
as more performance variation can be observed. Third, the RCT kernel behaves as ex-
pected, i.e. performance is suboptimal for very low values of k, reaches a maximum
for intermediate values, and drops when k becomes too large and consequently the
local networks lose their local characteristics. The RW measure and the LED kernel
do not show this performance drop, but the results of the application of global similar-
ity measures (Table 2.2) indicate that both suffer from a performance drop when the
underlying interaction network becomes too large. Finally, a remarkable performance
drop around a k-value of 7 can be observed, for all methods. Closer investigation of
the eQTL data and the local networks constructed indicates that this is due to mis-
prioritization of a single eQTL that is shared by a number of genes. In this case the
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Figure 2.6: Influence of the k parameter on prioritization performance for the three lo-
cal similarity measures. RW=random walk, LED=laplacian exponential diffusion kernel,
RCT=Regularized Commute-Time kernel. eQTL were obtained with non-parametric regression,
edge weights are expression correlation, no TF-filter.
error is caused by the inclusion of a gene that is relatively distant in a directed net-
work, but close in an undirected network. As explained in the Materials and Methods
section, the application of kernels implies an undirected network. It should be noted
that when the neighborhood again becomes larger, the method quickly recovers from
this error.
2.3.5 Edge weight type
The choice of edge weight is non-trivial and an issue for shortest path, random walk
and kernel-based approaches. We tested three scenarios: (1) edge weights are set
proportional to the expression correlation, (2) weight-values are set to the Bayesian
classifier score obtained in the global network construction process (see Materials and
Methods), and (3) values (in the adjacency matrix, see Materials and Methods) are
simply set to one if an interaction is present.
In Figure 2.7, the influence of the choice of weights on the prioritization perfor-
mance is illustrated. Three edge weight types, expression correlation, Bayesian score
and a qualitative approach (with edge weights set to one) and two kernel types, a
random walk and a shortest path method are evaluated using the mixed model associ-
ations. From the figure it is clear that the Bayesian score outperforms the expression
correlation approach, but differences are small in terms of maximum relative perfor-
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Figure 2.7: Influence of the weight type (Expression correlation, Bayesian score and Qual-
itative) on prioritization performance. eQTL data set=Mixed model, p < 0.1, k = 5.
RCT=Regularized Commute-Time kernel, LED=Laplacian Exponential Diffusion kernel.
mance (LED kernel: 62% for Expression correlation, 66% for Bayesian score). Re-
markably, the qualitative approach where edge weights are simply set to 1 still yields
comparable results.
2.3.6 Comparison with other techniques
To put the result of prioritization with EPSILON in perspective, we compared our ap-
proach to two alternative techniques that can be used to perform eQTL prioritization:
ITM Probe [6, 25] and eQED [4] (for the implementation details of both methods,
see Materials and Methods). ITM Probe was tested in normalized channel mode, in
which a random walk is executed that has, at each step, a fixed probability of termi-
nating. In this way, ITM Probe is implicitly generating a localized biological context.
We obtained results that are in general on par with EPSILON (LED kernel, k = 5,
α=0.001, see Table 2.3). For the mixed model associations, EPSILON showed in-
creased performance over ITM Probe, with respectively 63% and 55% overlap with
the target knockout list. Second, we compared EPSILON with eQED. eQED uses an
electric circuit model (operating on a global network) to prioritize candidate causal
genes. Unfortunately, eQED does not support the use of phosphorylation interactions
and a thorough comparison was impossible because the network used by EPSILON
could not be used as input for eQED. We did perform a limited comparison (on the
NPR associations), using a reduced network (see Materials and Methods). We found
an overlap of 65% for EPSILON (LED kernel, k = 5, α=0.001), and 54% for eQED.
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Table 2.3: Relative performance comparison of EPSILON (LED kernel, k = 5, α=0.001) with
ITM Probe (No TF-filter)
EPSILON ITM Probe
Non-parametric regression 0.55 0.53
Elastic net all features 0.41 0.38
Mixed models 0.63 0.55
2.4 Discussion
In this manuscript, we presented EPSILON, a framework for eQTL prioritization that
ranks a number of candidate causal genes, overlapping an eQTL based on their func-
tional similarity with the target gene associated with the eQTL. The method consists
of two steps: (1) local network construction and (2) the application of a network-based
similarity measure. EPSILON is a modular framework that allows for the incorpora-
tion of existing network construction procedures and network similarities. We evalu-
ated a k-trials shortest path network construction method together with random walk
and kernel-based similarity measures using a gold standard data set derived from a
yeast knockout compendium. We were able to show that our approach, the combi-
nation of local networks with network-based similarity measures, outperformed ran-
dom assignment and a shortest path reference method. More interestingly, the global
network analogues of the network similarity measures too were outperformed sig-
nificantly (p < 10−5), clearly showing the added value of using local over global
networks. We assume that constraining the global network to a local neighborhood
around the target gene and all candidate causal genes is effectively reducing the dis-
turbing impact of hubs and promiscuous genes. Highly connected genes (in the global
network) may still be present in the local networks, but the number of interactions
those genes participate in will be significantly reduced. An additional explanation of
the difference between a local and global approach is the inclusion of directional in-
formation in the sub-network construction, even though direction information is not
used for the calculation of the similarity measures. There are indications that the LED
kernel outperforms the random walk similarity measure, but more research is needed
to confirm this.
We observed large differences in prioritization performance when different eQTL
datasets were used (mixed model, non-parametric regression and elastic net). Espe-
cially the elastic net (EN) eQTL seemed to be more difficult to prioritize. Possibly,
the quality of the EN associations was lower than that of the other association tech-
niques. All experiments were run with and without transcription factor based filtering
(TF-filtering). TF-filtering is a technique used by several other authors where it is
demanded that a target gene be reached through transcription factor interactions. We
were not able to detect any significant effect of TF-filtering on the results obtained.
We investigated the sensitivity of the local similarity measures to the value of the pa-
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rameter k, controlling the size of the local sub-network in the network construction
algorithm. All network similarity measures yield a near optimal performance for k-
values of 5, the value we recommend to use as the running time of the local network
construction and the similarity measure calculation increases significantly with higher
values of k. Next, we investigated the influence of different edge weight types on
the prioritization process. Three variants were evaluated: expression correlation, a
Bayesian score and a qualitative weighting scheme where all edges were set to one.
Remarkably, in some cases optimal results were obtained with the qualitative weight-
ing scheme. This indicates that the mere presence of an interaction is more important
than its associated weight. In the absence of reliable edge weights, one can thus revert
to qualitative edge weights, simply expressing the presence or absence of interactions.
Finally, EPSILON was compared to two other methods, ITM Probe and eQED. We
found that EPSILON performed as well or better than ITM Probe. EPSILON clearly
outperformed eQED, be it using a reduced network because eQED could not deal with
the phosphorylation interactions present in the global network.
Importantly, we should note that the intuitive network construction method we
present could be replaced by a more advanced algorithm, yet our approach has the
advantage of simplicity and performance. The network-based similarities too could
be replaced by more specialized variants. For instance, the eQED method of Suthram
et al. [4] could be integrated within the EPSILON framework given that the eQED
model were extended to incorporate other types of interactions.
2.5 Materials and Methods
2.5.1 eQTL analysis
In order to detect associations between SNP and gene expression data, we used the S.
cerevisiae data of Brem and Kruglyak [19]. The SNP data set consists of 2956 indi-
vidual markers for 112 segregants from a laboratory strain and a wild strain. As strong
linkage disequilibrium can be observed, the data set exhibits substantial redundancy.
We reduced the data set to 404 haplotype blocks using estimates of the recombination
probability at each marker. Reducing individual markers to haplotype blocks spanning
multiple SNPs inherited together avoids part of the multiple testing problem associated
with many eQTL detection methods, but will increase the genomic region covered by
the eQTL found.
The gene expression data contained full genome expression values (6130 genes)
for the same 112 segregants. Prior to further analysis, the expression data were re-
normalized. Associations were detected using three methods. As a reference, we
used the non-parametric regression technique (Wilcoxon rank regression) as applied
by Brem et al. [26]. Next, analogous to Suthram et al. [4] the mixed model approach
of Kang et al. [24] was adopted. This method is known to correct for possibly hidden
confounds like population structure or laboratory batches. Finally, we choose elastic
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net regression as a state of the art association technique [27–29]. The elastic net
regression was executed in order to retrieve a maximum of 10 associations per target
gene.
For the mixed model regression, we used the implementation of Kang et al. [24],
that can be found at http://genetics.cs.ucla.edu/ice. For the non-parametric and the
mixed model regression, a matrix of association probabilities was obtained in a straight-
forward way. Probabilities were filtered using p < 0.05 and p < 0.1 for respectively
the non-parametric regression and the mixed models. The thresholds for the p-values
were chosen so that the remaining associations contained a comparable number of
knockout pairs that can be used for evaluation purposes, as explained in the Results
and Discussion section. For the elastic net, probabilities were approximated by apply-
ing a multiple regression to the selected predictors, a strategy suggested by Wu et al.
[28]. Elastic net probabilities were then filtered based on their approximated p-value
(p < 0.1). Because this resulted in a very low number of remaining associations,
we also ran the prioritization method on the full elastic net data set, i.e. without any
p-value filtering.
2.5.2 Generating candidate causal genes
For each eQTL, we enumerated all genes that overlap (within 5kb) the region of the
chromosome spanned by the haplotype block that associates with a certain target gene.
This approach differs slightly from the one adopted by Suthram et al. [4], where a
locus contains all genes that are related to the same closest marker (within a buffer
of 10kb). Our approach will necessarily yield larger loci with a higher number of
candidates.
2.5.3 Network construction
We built a physical interaction network for S. cerevisiae containing protein-protein
interactions (PPI), transcription factor-DNA interactions (TF-DNA) and phosphory-
lation interactions (PI). In the network, a gene name can represent both a translated
protein or a chunk of DNA. Protein interaction data were downloaded from The Bio-
logical General Repository for Interaction Data sets (BioGRID) database [30]. After
removing self-interactions, this PPI data set consisted of 49 381 unique interactions.
TF-DNA interactions, predicted both de novo as from several ChIP-chip experiments
were obtained from Beyer et al. [31]. Their data set consisted of 7817 high confi-
dent TF-DNA interaction predictions. Kinase-substrate interaction data were obtained
from Ptacek et al. [32]. With the use of proteome chip technology, the authors iden-
tified 4 183 in vitro phosphorylation events involving 1325 different proteins in yeast
with a low false positive rate. Only high quality PPI interactions were allowed in the
final interaction network. This was achieved by using a supervised Bayesian classi-
fier that was trained on a set of known interactions derived from literature [33]. As
inputs, the classifier uses features derived from expression data, known and predicted
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domain interactions, network topology and phylogenetic profile similarity. Below, we
elaborate on the network construction process.
2.5.3.1 Protein-protein interactions
Protein interaction data were downloaded from The Biological General Repository for
Interaction Datasets (BioGRID, release 3.0.68, [30]) database. BioGRID is an online
interaction repository with protein and genetic interaction data for major model organ-
isms, as derived from both high throughput studies and conventional focused studies.
Through comprehensive curation efforts, BioGRID includes a virtually complete set
of interactions reported to date in the primary literature for S. cerevisiae [33]. Before
the data were processed, genetic interactions were removed. Next, only undirected in-
teractions were retained. Interactions derived from spoke-expanding complexes were
included in the final dataset, even if the internal wiring of such complexes is uncer-
tain. After removing self-interactions, this PPI dataset consisted of 49,381 unique
interactions.
Prior to include the set of protein interactions in the network, their quality was
assessed through a supervised learning method. Different sources of features can be
probabilistically combined to predict interactions using a Bayesian formalism. We
choose this learning framework since it allows for combining highly dissimilar types
of data in a model that is easy to interpret, and can readily accommodate missing
data. The idea is to predict the quality of each interaction using a number of features
(described below) and a training set. Both are described below.
Training set The prediction quality of a classification scheme depends highly on
the choice of the training set. This training dataset usually consists of positive and
negative examples and is used to discover a predictive relationship between several
features and the positive and negative examples. An ideal training set should be inde-
pendent of the data sources serving as features, sufficiently large for reliable statistics,
and free of systematic bias [34]. Moreover, the choice of training set also depends on
the prediction task at hand: positive and negative examples should reflect the same
entities as the ones one would like to predict. This means, in our case, that a training
set for predicting protein interactions should consist of proteins physically interacting
with each other. The set of positive examples used to train the classifier is based on a
curated, literature-derived dataset, containing only high-confidence interactions [30].
After removing self-interactions, this set consisted of 11,334 unique interactions.
A good set of negative examples is harder to define, since non-interacting pairs
cannot be observed. Negative training sets for predicting protein interactions have
been composed of randomly combined pairs [31, 35] or proteins occurring in different
subcellular components [34–36]. A criticism of randomly chosen negatives is that
they will contain some true interactors. However, the set of interacting pairs in the
full protein pair space is small and thus the contamination rate of randomly chosen
negative datasets will in fact be very low.
Features The set of features provided to the classifier are measurable entities or
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evidences that characterize an interaction or a non-interaction. The classifier then
learns which of the provided features are predictive for the interactions at hand. Such
measurable entities can be direct information (e.g., the interaction was seen in an
experiment) or indirect information (e.g., the expression correlation of two proteins
could indicate that they are members of the same complex). Indirect information can
be used to predict new interactions or extract true positive interactions observed in
high throughput experimental data. Different types of indirect data sources have been
shown to contain valuable information for predicting both functional interactions and
PPI. For the assessment of interactions in our protein dataset, we compiled following
types of features:
Expression correlation (EC)
The expression correlation between two genes is a functional feature that ex-
ploits the observation that biologically relevant protein interactions often have
co-regulated mRNA expression [34]. For the EC feature we used a gene ex-
pression dataset [19, 26], consisting of 269 contrasts. Since the gene expression
data are given in terms of log-ratios, we calculated for each pair of genes the
correlation coefficient. Next, we grouped the correlation scores into 11 corre-
lation bins. Likelihood ratios were then calculated from positive and negative
training sets for each correlation bin (Figure 2.8).
Phylogenetic profile similarity (PP)
Phylogenetic profile similarity is a comparative genomics-based feature that ex-
ploits both the similarities and differences of relationships that exist between
proteins across multiple species. The observation that gene pairs that co-occur
in related species are more likely interact, has been used before as predictor
of functional interactions [37–40]. We downloaded the genomes of 8 bacteria
(Aquifex aeolicus, Bacillus halodurans, Deinococcus radiodurans, Mycobac-
terium leprae, Mycobacterium tuberculosis CDC1551, Mycobacterium tuber-
culosis H37Rv, Synechocystis sp. PCC6803, Thermotoga maritima) and 5 eu-
karya (Arabidopsis thaliana, Caenorhabditis elegans, Candida albicans, Drosophila
melanogaster, Plasmodium falciparum) from NCBI [41] and reconstructed phy-
logenetic profiles with OrthoMCL [42]. Correlation coefficients were calculated
between each pair of profiles where each profile contained at least one ortho-
loguous gene. The correlation coefficients were then used as feature scores and
divided into 5 bins from which the likelihood ratios were calculated (Figure 2.8).
Domain interaction (DI)
For each protein to interact with its appropriate network neighbors, highly spe-
cific recognition events must occur. Interaction specificity results from the bind-
ing of a modular domain to another domain or a smaller peptide motif in the
target protein [43]. We used known domain interactions as a structural feature
to exploit the observation that some pairs of proteins, containing particular pro-
tein domains tend to interact preferentially. To this end we downloaded protein
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Figure 2.8: Log likelihood ratios of different features. The x-axis represents the score values in
the different bins, the y-axis represents the LLRs. (Top-left) LLR for the expression correlation
(EC) feature, (top-right) LLR for the phylogenetic profile correlation (PP) feature, (bottom-
left) LLR for the domain interaction score (DI) feature, and (bottom-right) LLR for the network
topology score (NT) feature.
domain interactions from the DOMINE database [44]. DOMINE is a compre-
hensive collection of known and predicted domain interactions compiled from
15 different sources. Protein domain interactions from this database are cate-
gorized as low-confidence, medium-confidence, high-confidence or known in-
teractions. The domain interaction score (DIS) between a protein pair x and y
can be computed by the number of interacting domains that they contain, taking
into account the reliability of the domain interaction in the database:
DIS(x, y) =
(
∑
di ∈ Dx)(
∑
dj ∈ Dy)R(di, dj)
2
(2.1)
where di and dj are protein domains andDx andDy are the set of Pfam domains
of protein x and y respectively. R(di, dj) is the reliability of the domain inter-
action and is set to 0, 0.25, 0.5, 0.75 and 1 for no interaction, low-confidence,
medium-confidence, high-confidence and known domain interactions respec-
tively. The score values were divided into four bins of increasing score (Fig-
ure 2.8).
Network topology (NT)
Network topology-based features exploit patterns in connectivity of known in-
teraction networks to predict novel interactions or to assess the quality of inter-
actions seen in experimental data. We incorporated the hypergeometric cluster-
ing coefficient (HCC, defined below), of Goldberg et al. [45] which is based
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on the observation that real protein-protein networks have densely connected
neighborhoods (high clustering coefficient), indicating that neighbors of a given
node are more likely to have edges between them than would be expected in a
random graph [46]. Considering a protein-protein interaction network with N
nodes, we define the hypergeometric clustering coefficient for a protein pair x
and y as:
HCC(x, y) = −log
min(|N(x)|,|N(y)|)∑
i=|N(x)∩N(y)|
(|N(x)|
i
)(
N−|N(x)|
|N(y)|−i
)(
N
|N(y)|
) (2.2)
where N(i) represents the neighborhood of a node i. Given fixed neighborhood
sizes N(x) and N(y) of proteins x and y, the hypergeometric clustering co-
efficient increases with elevated overlap between the proteins neighborhoods.
Provided that the neighborhoods are independent, the summation can be inter-
preted as a p-value, reflecting the probability of obtaining a number of mutual
neighbors between proteins x and y at or above the observed number by chance.
The network topology scores were divided into four bins (Figure 2.8).
2.5.3.2 Protein interaction network construction
For every protein pair in the positive and negative training sets, a score was calculated
for each of the four features. After dividing the continuous scores in bins, a likelihood
ratio for each score bin and feature was calculated. The resulting log likelihood ratios
are summarized in Figure 2.8. The features differ in their range of likelihood ratios
they can achieve in each score bin. All features were combined to form an integrated
classifier. We applied a conservative threshold of 3 to select true interactions. This
threshold may imply that some false positives are included in the network, yet the
EPSILON localization procedure should correct for at least part of these unwanted
interactions.
2.5.3.3 Transcription factor-DNA interactions
TF-DNA interactions, predicted both de novo as from several ChIP-chip experiments
were obtained from Beyer et al. [31]. The authors presented a Bayesian framework for
consistently integrating several large-scale measurements about transcriptional net-
works, such as co-expression information, TF binding motifs and information on gene
fusion to determine the set of genes directly regulated by each TF (i.e., TF-DNA inter-
actions) in yeast. Their dataset consisted of 7 817 high confident TF-DNA interaction
predictions. We are aware of the fact that more recent TF-DNA datasets exist, but for
reasons of continuity, we were obliged to use the older dataset.
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2.5.3.4 Phosphorylation interactions
Kinase-substrate interaction data was obtained from Ptacek et al. [32]. With the use
of proteome chip technology, the authors identified 4 183 in vitro phosphorylation
events involving 1 325 different proteins in yeast with a low false positive rate. We are
aware that these data are also present in the BioGRID database, yet no training data
was available for the supervised training method described above. Therefore, they
were removed from the PPI interaction dataset, and processed without filtering. The
phosphorylation dataset may contain in vitro phosphorylation events. We assumed
that setting the interaction strength to the absolute value of the expression correlation
induces sufficient biological context to reduce the impact of such in vitro interactions.
Our final network contains 4 375 genes (connected by 35 569 interactions) that are
also present in the eQTL data sets. Contrary to Suthram et al. [4] who selected only
regulatory proteins contained in 11 MIPS categories, we did not filter the network to
only contain interactions found in regulatory pathways. For all experiments except
one, we used the inverse of the absolute value of the expression correlation between
the two genes involved in the interaction for the edge weights. In a single experiment,
we evaluated the choice of weight value by comparing it to two other variants: (1)
edge weights are set to 1/(score−minimumScore+0.1), using the score obtained
by the Bayesian classifier discussed before and (2) the edges are simply given a value
of one.
2.5.4 Validation data
To evaluate the proposed method, we used the knockout data set of Hughes et al.
[20]. The data were preprocessed by Ourfali et al. [22] and can be downloaded from
http://cs.tau.ac.il/r˜oded/SPINE.html. Each time a variant of the proposed method or
a reference method is evaluated, the knockout data set is filtered to contain only the
knockout pairs that are also found in the network and the eQTL data sets (see Results
and Discussion).
2.5.5 k-trials shortest paths neighborhoods
An intuitive algorithm was constructed that tries k times to find an alternative path
between each candidate causal gene and the target gene using the Dijkstra shortest
path algorithm [11]. In what follows, we will use path cost in stead of path length,
as this allows for easier interpretation of the algorithm. Each time, the cheapest path
is made more expensive by multiplying each edge weight on the path with a constant
factor f (set to 1.2 in this study). The algorithm results in at most k alternative paths
connecting the target with each of the candidates. Often, values of k > 1 will not
result in exactly k alternative paths, as it is possible that no (cheap) alternative paths
exist. For a k value of 5, the average number of alternative paths was between 2 and 3,
for the data sets we used. Once the alternative paths are found, a local neighborhood
is constructed by merging all paths found into a single sub-network. Very large values
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of k will result in larger sub-networks that will be more similar, but not necessarily
identical, to the global network.
The parameter k is an upper bound of the number of paths that will be included
in the local network, and the parameter f controls how different the alternative paths
should be. Values of f very close to 1 will likely yield a single cheapest path or
small variants of the cheapest path (unless paths with equal cost exist, see below),
as the same path is found over and over, even when it is made more expensive. The
parameter f controls how much more costly path k can be in order for it to be picked,
when compared to the first cheapest path found (i.e. fk). The k-trials shortest paths
algorithm can be considered a heuristic variant of the more complicated k-shortest
path problem (see e.g. Hershberger et al. [47]), but the latter will always yield k
paths (at least when k paths exist), even when some of those paths are less relevant.
Also, by making the entire path more expensive, the k-trials algorithm is pushed to
find real alternative paths in stead of variants of an existing path. Paths with equal
costs were not treated in a special way because this is very unlikely to happen when
expression correlation or a Bayesian score is used for edge weights. Furthermore, it
such paths would be found (which is more likely when e.g. all edge weights are set to
1), sufficiently large values of k will alleviate the problem.
2.5.6 Random walks and kernels
The random walk similarity measure is an estimate of the probability that a target
gene is reached when initiating a random walk starting from different candidate causal
genes. For each local network, new random walks were initiated from the target gene
until the sum of the arrival count over all candidate causal genes was equal to 10 000.
Note that using the target gene as the starting point of the random walk is possible
because we used undirected networks as input for the random walk procedure. Once
a candidate is reached, the random walk is aborted, so no walk visits a candidate gene
more than once. The candidate with the highest arrival count is chosen to be the true
causal gene. The approach described above is less accurate and slow for large global
networks. As an alternative to simulating random walks, it is possible to calculate the
final number of visits in each network node based on the (Moore-Penrose) pseudo-
inverse of the weighted Laplacian matrix L = D − A, with D the diagonal degree
matrix (D (i, i) =
∑n
j=1A (i, j), n is the number of genes) and A the adjacency
matrix of the interaction network. For each eQTL, the global matrix A was updated in
such a way that the candidate causal genes in the eQTL had no outgoing connections.
This corresponds to terminating a random walk once a candidate gene is reached.
Next to random walks, we integrated kernel-based similarity measures in the EP-
SILON framework. A kernel calculated on a graph provides a quantitative measure of
similarity between two nodes (i.e. genes) in a graph, that is also a vector inner product
in a possibly very high dimensional feature space. Depending on the type of kernel,
the similarity measure can be interpreted in different physical ways. Fouss et al. [13]
provides a comprehensive overview of different kernel types and their interpretation.
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We decided to use two kernel types that have been used for gene prioritization before
[16], be it in a different context and methodology. The first is the Laplacian Exponen-
tial Diffusion (LED) Kernel that is calculated as follows:
KLED = e
−αL (2.3)
KLED is the kernel matrix that contains the evaluation of the kernel function for
each gene-gene combination. It is calculated on the weighted Laplacian matrix. Note
that the adjacency matrix has been made symmetrical by taking the per element max-
imum of the non-symmetrical adjacency matrix and its transpose. KLED (i, j) con-
tains, at time t = α, the quantity found in node i when a unit quantity starts diffusing
from node j at t = 0 [13].
Analogous to Nitsch et al. [16], the second kernel we use is the Regularized
Commute-Time (RCT) Kernel:
KRCT = (D − αA)−1 (2.4)
Here, KRCT is the kernel matrix, D the degree matrix defined above, and A the
adjacency matrix. KRCT (i, j) corresponds to the probability of visiting node i when
starting from node j where a random walker has α (1− α) probability of disappear-
ing at each step [13]. Both kernels are centered and normalized in feature space by
applying the following transformations:
KN (i, j) =
kij√
kii.kjj
(2.5)
KC = HKH , H = I − 1
n
eeT (2.6)
2.5.7 Comparison with other techniques
We compared EPSILON with ITM Probe [6, 25] and eQED [4], two methods
that can be used to identify the true causal gene in an eQTL. The stand-alone
version of the ITM Probe software (Python, version 1.5.2) was downloaded from
ftp://ftp.ncbi.nlm.nih.gov/pub/qmbpmn/qmbpmn-tools/src and slightly modified (in-
put/output routines only) to accommodate our experimental setup. We ran the model
in normalized channel mode. For each eQTL-target pair, we set the ITM Probe source
gene to the target gene, and the ITM Probe sinks to the candidate causal genes for the
eQTL. The final causal gene corresponds to the sink with the maximum value in the
resulting H matrix. In normalized channel mode, the ITM Probe model is controlled
by a single parameter, the damping factor df . We ran the model with df values rang-
ing from 0.1 to 1.0 and recorded for each association technique the optimal result.
The model was fed with the exact same networks (no TF-filtering) as used to evaluate
EPSILON.
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Next to ITM Probe, we investigated if it was possible to compare EPSILON
with eQED. The software was downloaded from http://www.stanford.edu/ ssuthram/e-
QED/. eQED does not allow for the distinction between directed transcription fac-
tor interactions and directed phosphorylation interactions. This distinction is needed
because eQED always applies TF-filtering, treating all directed interactions as TF-
interactions. Consequently, the interaction network used in this study could not be
used as input for eQED. We tested eQED using a network without phosphorylation
interactions and the NPR eQTLs, and reran EPSILON using the same reduced net-
work.
2.5.8 Parameter tuning and running time
The calculation of the two kernel types, KLED and KRCT , requires the estimation of
a parameter α. An extensive parameter sweep was performed. We found an optimal,
general applicable value of the parameter α to be 0.001 for the LED kernel, and 0.9
for the RCT kernel. We also found that the kernel-based similarity measure is not very
sensitive to this parameter α as performance deteriorates only when α is changed with
an order of magnitude. Testing indicated that near optimal performance can be ob-
tained with a value of 5 for the k parameter in the k trials shortest path neighborhood
construction algorithm (see Figure 2.6), and 1.2-2.0 for the multiplier constant. As the
running time of the algorithm increases considerably with higher values of k, all ex-
periments were executed with the lowest k value that results in optimal performance,
i.e. k=5. For the multiplier, 1.2 was chosen.
Even though the time complexity of calculation of the kernels used will be of or-
der O
(
V 3l
)
with Vl the number of genes in the local network, the running time of
EPSILON in practice (for reasonably small values of k yielding small local networks,
and for a single eQTL-target prioritization task) is determined by the path-finding al-
gorithm. We implemented the Dijkstra path-finding algorithm using a Fibonacci heap,
resulting in a time complexity of O (k (Eg + Vg.log (Vg))) with Vg the number of
genes in the global network, and Eg the number of interactions in the global network.
With k = 5, it takes 40 seconds to prioritize 1000 eQTL-target combinations using a
single core of a 64 bit Intel i3 processor.
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3
Pathway relevance ranking for tumor
samples through network-based data
integration
The notion of network connectedness or similarity introduced in the previous chap-
ter is extended to allow for the simultaneous analysis of different cancer-related data
types, while maintaining the pathway information that is required to tackle tumour
related analysis problems. The network model for pathway ranking developed in this
chapter will be extensively explored in the next chapter where additional tumour anal-
ysis applications of the model will be presented.
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Abstract The study of cancer, a highly heterogeneous disease with different causes
and clinical outcomes, requires a multi-angle approach and the collection of large
multi-omics datasets that, ideally, should be analyzed simultaneously. We present a
new pathway relevance ranking method that is able to prioritize pathways according
to the information contained in any combination of tumor related omics datasets. Key
to the method is the conversion of all available data into a single comprehensive net-
work representation containing not only genes but also individual patient samples.
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Additionally, all data are linked through a network of previously identified molecular
interactions. We demonstrate the performance of the new method by applying it to
breast and ovarian cancer datasets from The Cancer Genome Atlas. By integrating
gene expression, copy number, mutation and methylation data, the method’s potential
to identify key pathways involved in breast cancer development shared by different
molecular subtypes is illustrated. Interestingly, certain pathways were ranked equally
important for different subtypes, even when the underlying (epi)-genetic disturbances
were diverse. Next to prioritizing universally high-scoring pathways, the pathway
ranking method was able to identify subtype-specific pathways. Often the score of a
pathway could not be motivated by a single mutation, copy number or methylation
alteration, but rather by a combination of genetic and epi-genetic disturbances, stress-
ing the need for a network-based data integration approach. The analysis of ovarian
tumors, as a function of survival-based subtypes, demonstrated the method’s ability to
correctly identify key pathways, irrespective of tumor subtype. A differential analy-
sis of survival-based subtypes revealed several pathways with higher importance for
the bad-outcome patient group than for the good-outcome patient group. Many of the
pathways exhibiting higher importance for the bad-outcome patient group could be
related to ovarian tumor proliferation and survival.
3.1 Introduction
Uncovering the molecular mechanisms that give tumor cells their growth advantage
remains a fundamental challenge in cancer research. This task is non-trivial because
cancer is a complex disease: a tumor’s growth advantage often is not caused by ge-
netic alterations of a single type but rather by a combination of defects of different
types. Consequently, the study of tumor development and progression requires the
availability of different types of data. Each data type can capture a different aspect
of the tumor’s deviating (epi-) genetic state and metabolism. Because of the diverse
causes of cancer, the success of applying any tumor analysis method is uncertain if it
operates only on part of the available data.
Furthermore, when one is concerned with revealing the mechanism of action un-
derpinning the tumor’s growth advantage, a network- or pathway-based approach is
crucial. Because of the clonal nature of tumor cells, true oncogenic alterations (con-
trary to e.g. passenger mutations that don’t contribute to the tumors fitness) are sparse.
Patients with the same disease phenotype often will not share any somatic mutations
occurring in the same pathway [1–5]. This so-called mutual exclusivity of somatic
mutations, a concept that can be extended to other data types, renders the statistical
task of identifying true genomic causes of cancer challenging and motivates ’pathway
driven’ analysis [1, 4, 6, 7]. Such an analysis is no longer gene-centric, but exploits
the fact that interacting genes constitute pathways, connecting upstream genetic dis-
turbances (causes) with downstream effects. For tumors to exhibit a similar molecular
or clinical phenotype, it is not required that they share the same disturbances in the
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same individual genes. Instead the same pathways will be impacted by possibly many
combinations of (epi-)genetic alterations. These pathways can be identified by pooling
the information present in different independently evolved tumors.
Tackling tumor analysis problems consequently not only requires multi-omics
datasets and large patient cohorts, but also largely depends on the availability of an
analysis framework that can integrate data of different types in a biologically relevant
way [1, 8–10]. We present a network-based data integration strategy that uses sets of
genes (pathways) as the unit of analysis rather than individual genes. In contrast to
existing tumor analysis methods, addressing either patient subtyping [1, 11], driver
gene prioritization [3–5, 12, 13], pathway impact assessment [6, 7, 14] or interaction
network delineation [1, 5, 15], our method takes as input any combination of data
(e.g., gene expression, mutation, copy number and methylation data). It allows for the
ranking of pathways according to their relevance for a set of patients. To achieve this,
all available data are cast into a unique network model. The model not only contains
genes, but also the individual patients and prior knowledge in the form of a network
of known gene interactions derived from public databases. Including patient samples
as entities in the integrated network allows for quantifying the relevance of groups
of genes for groups of patient samples using an intuitive measure of connectedness in
this network representation. The gene interactions added as prior knowledge introduce
mechanistic relations between individual genes in the network and will help relating
diverse upstream genetic disturbances in the same pathway to the same molecular
(downstream) phenotype, e.g. over or under-expression of another set of genes.
Our contribution consists of a new method for pathway impact assessment. The
method ranks a set of predetermined pathways according to their relevance for a given
set of patient samples, and allows for the integration of any data type that can be cast
into a binary relation between a gene and a sample or patient. It is an intuitive alterna-
tive to other methods incorporating pathway topology in their analysis like Signaling
Impact Analysis [14] operating exclusively on gene expression data, and PARADIGM
[6] operating on gene expression and copy number data. Both methods do not support
the inclusion of mutation data. PARADIGM SHIFT [7], an extension of PARADIGM,
does handle mutation data, but it is targeted specifically at the prediction of the nature
of mutations by analyzing their downstream effects. We applied our method to two
datasets from The Cancer Genome Atlas (TCGA), breast cancer [9] and ovarian cancer
[16]. The method’s ability to rank pathways that are relevant to homogeneous groups
of patients is demonstrated using the simultaneous analysis of mutation, mRNA ex-
pression, copy number and methylation data sets.
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3.2 Materials and methods
3.2.1 Pathway relevance ranking using network-based data inte-
gration
We present an unsupervised analysis method that combines different data types with
prior knowledge resulting in a comprehensive network representation (see below).
Key to the method is the representation of all available data in a single network (re-
ferred to as the global network). This network contains all entities under study (patient
samples, differentially expressed genes, genes containing mutations, ) and their mu-
tual relations derived from either the data themselves or from prior knowledge. Using
this global network representation, a similarity measure that expresses the degree to
which network entities are related to each other can be calculated. Those similarities
are subsequently used to assess the relevance of different pathways for a set of patient
samples. The pathways, or more general, the sets of genes under study, need to be
specified in advance. The proposed method ranks the predefined pathways according
to their relevance for a set of samples. An overview of the method is given in Fig-
ure 3.1 and Figure 3.2. A reference implementation is available for download from
http://bioinformatics.intec.ugent.be/pathwayranking.
3.2.2 Global network construction
The construction of the global network is demonstrated using gene expression, muta-
tion, methylation, and copy number data. Input datasets are required to contain data
for all samples, but can contain different genes. Datasets can be omitted, and any data
that can be converted into a binary form can be added. Indeed all continuous data are
necessarily made binary (see Data section). A ’1’ corresponds to either over- or under-
expression (i.e., differential expression), copy number amplification or loss, mutation
or hyper- or hypo-methylation. Conversely, a ’0’ corresponds to normal expression,
normal copy number, the absence of mutations or a normal methylation pattern. Treat-
ing over-expression of a gene identically to under-expression (and analogously, treat-
ing copy number amplification and loss, and hyper- and hypo-methylation in the same
way) may seem as an oversimplification. In practice, when studying homogeneous
groups of samples (e.g., belonging to an identical subtype), it is less likely that some
samples in this homogeneous group would exhibit over-expression and others under-
expression of the same gene. A ’1’ in a binary dataset merely reflects an abnormal
state of a gene for a particular sample, and we assume that this state of abnormality
will be similar for samples exhibiting the same disease phenotype. Note that because
expression data of tumor samples are analyzed relative to expression data of normal
samples (see Data section), differential expression in this context does not necessarily
correspond to absolute high or absolute low expression.
To construct the global network, first each binary input dataset is represented as
an individual network (Figure 3.1-a). This is achieved by converting each ’1’ in the
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Figure 3.1: Global network construction. (a) Conversion of binary data to a network represen-
tation. All continuous data are mapped to a binary representation with ’1’ corresponding to a
gene with a value deviating from normal for a particular sample. Each ’1’ in the binary datasets
is converted to an undirected link (solid line) between a gene node and a sample node. Char-
acters a-g correspond to gene IDs, S1-S3 represent sample IDs. (b) Construction of the global
network. The network representations of the binary datasets and the prior knowledge network
are merged. Gene nodes originating from the input datasets are connected to the correspond-
ing gene in the prior knowledge interaction network (dashed yellow lines). (c) The resulting
adjacency matrix representation of the undirected global network. NET (grey) = genes from the
prior knowledge interaction network, S (dark blue) = samples, EXP (green) = genes from the
gene expression dataset, CNV (pink) = genes from the copy number dataset, MUT (light blue)
= mutated genes, MET (orange) = methylated genes. (d) The similarity matrix derived from the
adjacency matrix.
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binary data to an undirected link connecting a sample node (labeled S1 − 3 in Fig-
ure 3.1) with a gene node (labeled a − g). For example, if gene a is over-expressed
in sample S1, a link between node S1 and node a is created. As a result, four sepa-
rate networks (one for each input dataset) are created. Next, the individual networks
are merged (Figure 3.1-b). In the merging process, sample nodes are joined (e.g., the
resulting global network only contains one sample node S1) but gene nodes are not.
Gene nodes represent an abnormal state for which the interpretation is different for
each input dataset. A gene can be differentially expressed, mutated, etc. and merging
genes nodes would discard this information. Consequently, the network will contain
multiple gene nodes with the same gene identifier. For example, in Figure 3.1-b, gene
a is present multiple times, once as a differentially expressed gene, and once as a
mutated gene.
Additionally, in order to connect heterogeneous and potentially sparse genetic
aberrations with their downstream effects on gene expression, prior information in
the form of known gene interactions is incorporated. The prior knowledge interac-
tion network will ensure that a pathway is not treated as an isolated group of genes.
Instead, the genes in pathway are analyzed not only relative to each other, but also
relative to other pathways that may or may not overlap with the pathway under study.
New nodes representing genes involved in known gene interactions are created. These
’interaction nodes’ are connected with undirected links whenever an interaction be-
tween these nodes exists (Figure 3.1-a,b). Then, the genes derived from the input
datasets, representing the different abnormal states, are connected to the interaction
node with the same identifier. For example, the two a nodes in Figure 3.1-b, repre-
senting a differentially expressed and mutated state of gene a, are both connected to a
single interaction node a.
Note that the newly constructed global network no longer corresponds to a phys-
ical or functional gene interaction network. Instead, the network representation is a
convenient means for integrating different types of data, including prior knowledge.
This is possible because all links in the network can be identically interpreted, i.e. as a
qualitative ”is relevant to” relation. Because the network is treated as undirected, the
resulting adjacency matrix representation is symmetric. As illustrated in Figure 3.1-c,
several parts of the adjacency matrix remain empty.
3.2.3 Network-based similarity calculation
The adjacency matrix representation of the global network (Figure 3.1-c) is used to
derive the similarity (a quantitative measure of relevance or importance) between sam-
ples and the gene nodes representing the abnormal states of the genes in the different
datasets. The similarities are summarized in the global similarity matrix (Figure 3.1-
d). Similarity measures based on shortest path calculations would be an intuitive
choice, but these measures have been shown to under-perform, especially when data
are qualitative, incomplete or of unknown reliability [17, 18]. Because of their good
performance[18–21], we used kernels calculated on graph nodes. A great multitude
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of kernels on graph nodes exist (see [22] for a comprehensive overview). Preliminary
experiments suggested that the Laplacian Exponential Diffusion (LED) kernel yields
stable results. It is calculated on the weighted Laplacian matrix L as follows [22]:
L = D −A
D(i, i) =
n∑
j=1
A(i, j)
KLED = exp(−αL)
Here n is the number of entities in the global network, D is the diagonal degree
matrix andA(i, j) represents entry j on row i of the global network’s adjacency matrix
A. KLED(i, j) contains, at time t = α, the quantity found in node i when a unit
quantity starts diffusing from node j at t = 0. The exp-operator indicates the matrix
exponential. Calculating KLED results in a similarity matrix with the same size as
the original global adjacency matrix. Before continuing with the analysis, additional
normalization of the similarity matrix is performed by exploiting the kernel properties
of a kernel matrix K with elements kij :
KN (i, j) =
kij√
kiikjj
(3.1)
3.2.4 Pathway relevance ranking
When assessing pathway importance, the goal is to identify which pathways - con-
taining active or inactive genes, mutated genes, genes with altered copy number or
hyper- or hypo-methylated genes - are more relevant for a group of samples than oth-
ers. Pathway relevance will typically correspond to abnormal behavior like activation
or silencing and/or to the presence of genomic alterations. The pathways of interest
should be available as sets of genes. Providing topology information for the pathways
of interest is unnecessary, as the relations between genes are provided by the prior
knowledge interaction network.
The pathway ranking problem can be addressed by focusing on the submatrices
Sexp, Scnv , Smut and Smet derived from the global similarity matrix (Figure 3.1-
d, Figure 3.2). These submatrices represent the similarities between the considered
patient samples and genes measured in respectively the expression, mutation, copy
number and methylation datasets. A high value for a sample-gene similarity indicates
greater importance or relevance of a gene for that sample, and low values suggest that
the gene is not important for the sample. Although each entry in these submatrices
expresses a similarity between a sample and a gene present in one of the aforemen-
tioned datasets, the similarities are calculated using the entire global network. The
similarity metric exploits the fact that the pathways under study are not isolated enti-
ties in the global network (note that the global network is more comprehensive than
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the prior knowledge interaction network). If the pathways were isolated entities, the
average similarity per pathway would correspond to the average number of ’ones’ in
the pathway. Instead, pathways are interconnected through a number of mechanisms:
1. Samples having ’abnormal’ genes in different pathways or in different types of
data will act as bridges between pathways and datasets.
2. Pathways will typically intersect or overlap with each other.
3. The prior knowledge network also contains genes that are not present in the
pathway compendium and that will act as bridges between pathways.
The extra connections allow ’abnormal’ genes from outside the pathway or from
another datatype to contribute to the importance of a pathway for a particular datatype.
As a result, it is possible for a mutated gene to be similar to a sample without actually
being mutated in that particular sample. This can happen when the sample shares
e.g. many differentially expressed genes with several other samples that do exhibit
mutations in that gene.
The calculation of a single aggregate pathway score is illustrated in Figure 3.2.
First, the matrices Sexp, Smut, Scnv and Smet are filtered so that they contain only
genes that are present in the pathway under study. For example, gene c is not present
in pathway P (containing genes a,b and d). Therefore, the third column of Sexp,
corresponding to gene c, is removed. Next, for each filtered submatrix separately, the
average (over all samples and genes) of the remaining similarity values in Sexp, Smut,
Scnv and Smet is calculated, resulting in a single score per input dataset (ScorePexp,
ScorePcnv , Score
P
mut and Score
P
met).
Because a pathway’s score will be influenced by its size, and in order to eliminate
random effects, the scores-per-dataset are converted to p-values that reflect the prob-
ability of observing (at least) the obtained score purely by chance. To achieve this, a
large number of random gene sets are created (in this study, we used 10 000 permuta-
tions, see implementation details below). For each random setRi, a score is calculated
for each input dataset (ScoreRiexp, Score
Ri
cnv , Score
Ri
mut and Score
Ri
met) using the same
approach as used for the pathway under study. The random score distribution obtained
for each dataset then allows for the calculation of the probabilities pPexp, p
P
cnv , p
P
mut
and pPmet. Multiplying these p-values results in a single aggregate pathway score that
can be used to compare pathways.
The aggregate score should not be used as an absolute measure of relevance as it
does not correspond to a true joint-probability. The constituting probabilities calcu-
lated for each input dataset will very likely be correlated. Consequently, the true joint
probability of observing these per-dataset similarity scores will likely be higher than
the value obtained by multiplying the individual p-values. However, we can assume
that the correlation between the scores obtained for each input dataset will be present
for all pathways. Consequently, the aggregated score can still be used to rank path-
ways. It has the additional advantage that it can be broken down into four components
that can be traced back to the input datasets.
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Figure 3.2: Pathway relevance scoring. Given a subset of the global similarity matrix (Sexp,
Scnv , Smut, Smet, see Figure 3.1) and a set of genes (a,b,d) constituting a pathway P, a score
for each input dataset is calculated by first removing genes from Sexp Scnv , Smut, Smet that
do not belong to the pathway and then taking the average of all remaining values in Sexp Scnv ,
Smut, Smet. This process is repeated for n randomly generated gene sets (with the same number
of genes as the pathway P ) yielding n scores for each input dataset. The random pathway scores
are used to calculate a p-value for obtaining the pathway scores purely by chance. The resulting
p-values are multiplied, resulting in a single aggregated pathway score.
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Comparing the scores of pathways containing highly interconnected genes with
scores obtained for random sets of, most likely, unconnected genes may appear counter-
intuitive: the connectivity of the pathways might result in higher scores that could
never be achieved by sets of unconnected genes. However, the p-value of both a path-
way and a random set of genes is calculated using the average similarities obtained
for individual genes. Those similarities in turn are a function of the abnormal states
observed in the different samples (the ’ones’ in the input datasets), and of the way the
gene is connected to other relevant genes in the network. Importantly, a gene’s score
is not determined by how well the gene connects to the other genes that are present in
the gene set under study, be it a pathway or a random gene set. Furthermore, because
all genes in the analysis are present in the prior knowledge network (genes that are not
present in the prior knowledge network were filtered out), all genes have neighbors in
the network. Consequently, it is perfectly possible for a gene of a random gene set to
be very important, either because it contains a lot of abnormal ’ones’, or because it
lies in a network neighborhood containing other important genes that are not required
to be present in the random gene set.
As an alternative to the proposed permutation strategy, one could also permute
the gene labels of the input datasets, and each time measure the score for the path-
way under study. However, for each permutation, the computationally very expensive
calculation of the similarity matrix is required. As illustrated in Supplementary Fig-
ure A.1., the probabilities obtained by the computationally expensive permutation of
the dataset gene labels are highly correlated (ρ > 0.99) with the probabilities obtained
using the proposed method. Consequently the fast random gene set based permutation
strategy was used for all subsequent analysis.
3.2.5 Data binarization
In order to integrate an omics dataset in the global network representation, it needs
to be converted into a list of qualitative gene-sample links or relations. Each entry
in each input dataset is converted into either ’0’ or ’1’, representing respectively the
absence or the presence of a meaningful link between a sample an a gene in the global
network. Although many binarization strategies are possible, the most trivial approach
was adopted: a hard threshold was set to the (absolute) values in a dataset. The dataset-
dependent threshold is chosen in such a way that the fraction of entries in each data
matrix that is set to ’1’ is as a close as possible to a predefined parameter. In order to
find the per-dataset threshold, a naive iterative procedure is used. This procedure is
applied to all but the mutation datasets. The latter are already binary and are included
without further filtering.
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3.2.6 Data
3.2.6.1 Gene expression, mutation, methylation and copy number data
For breast cancer, mRNA, mutation and copy number data were downloaded from
The Cancer Genome Atlas (TCGA, https://tcga-data.nci.nih.gov/tcga) in November
2012 (corresponding to the data from [9]), and methylation data were downloaded
in October 2013. 463 patients had data points for all data types and were retained
in the final analysis. The ovarian cancer datasets were downloaded from TCGA in
April 2014, and contained mRNA, mutation, methylation and copy number data for
447 patients. All breast and ovarian cancer data used in this study are part of the
TCGA open access data tier containing only de-identified and anonymized data. For
breast cancer, we focused on patients with Her2, Basal, Luminal A and Luminal B
tumors. Patients with Normal-like tumors were omitted from the analysis because of
the low number of available samples. All gene identifiers were mapped to Entrez gene
identifiers. Genes that could not be mapped were left out of the analysis.
To reduce the problem size, all datasets were filtered to contain only genes that
are present in the prior knowledge interaction network (see below). For the mRNA
datasets, this resulted in a final selection of 10 100 and 9 463 genes for respectively
breast cancer and ovarian cancer. Expression data were centered on the median of the
available normal samples, and made binary according to the procedure laid out in the
Method section. Rather than corresponding to absolute high or absolute low expres-
sion values, the binary data will reflect whether a gene was differentially expressed,
relative to normal tissue data. No variance scaling was applied as this would increase
the impact of noise for genes with very low and constant normal expression.
The mutation data were preprocessed using MutSig [13]. In order to obtain a
broader selection (with a possibly high number of false positives), we used unadjusted
p-values with a cut-off of 0.05. For breast cancer, the final mutation dataset contained
465 mutated genes with Entrez identifiers. For the ovarian cancer dataset, an identical
procedure was employed resulting in 327 genes.
Copy number data for breast cancer and ovarian cancer were processed in the same
way. Significant copy number regions were identified with GISTIC 2.0 [23] using the
same parameter settings as in the TCGA breast cancer overview [9]. The final dataset
contained 446 and 2 806 genes for respectively breast cancer, and ovarian cancer. The
copy number data were made binary by applying a threshold to the absolute value of
the copy number variation, according to the binarization strategy described above.
The methylation data were downloaded from TCGA and filtered using the proce-
dure and parameters described in the ovarian cancer study of the Cancer Genome Atlas
Network [16]. Summarizing, hyper-and hypo-methylated genes are kept in the data
set only if the following conditions are fulfilled (parameters are for hyper-methylated
genes and correspond to respectively relaxed and strict settings in the filtering proce-
dure, for hypo-methylated genes the procedure is adjusted in a trivial way):
1. In normal tissue, the gene should only slightly be methylated (<0.5, <0.4).
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2. The 90th percentile methylation level of tumor samples should be considerably
higher (0.1, 0.3) than the average normal methylation level.
3. The average gene expression of normal samples should be considerably lower
(2, 3 fold) than the average gene expression of the 10 % highest methylation
levels in tumor samples.
4. There should exist a negative spearman correlation (<-0.2, <-0.3) between the
methylation level and the gene expression level.
Note that probe selection (based on the maximum negative correlation between
Beta values and gene expression) and mapping of probes to genes was performed by
the TCGA consortium. Applying this procedure resulted in 624 hyper-methylated and
270 hypo-methylated genes for breast cancer and 42 hyper-methylated and 173 hypo-
methylated genes for ovarian cancer. All methylation data are transformed from the
[0, 1] range to the [−0.5, 0.5] range by subtracting 0.5. The methylation data were
made binary according to the same binarization strategy used for the other data types.
3.2.6.2 Network data
KEGG pathway data [24] were downloaded on November 11, 2014 using the KEGG
REST-API functionality. 224 pathways (disease pathways were left out of the anal-
ysis) were merged to constitute a single network. Non-gene entities (groups and
complexes) in the KEGG topology were expanded using dummy genes (with unique
identifiers) that were connected to the individual genes constituting the group or
complex. Interacting genes with such groups or complexes are then connected
with the dummy genes rather than with the constituting genes. Because the goal
is to capture and use patterns of regulation, transcription factors and their targets
were explicitly added. Transcription factor target interactions were obtained from
http://encodenets.gersteinlab.org/ which is part of the ENCODE project [25]. Only
interactions based on proximal TFBS data were included in the final network. The
final network contained 12 040 genes and 97 482 interactions.
3.2.7 Parameter tuning and implementation details
The presented procedure is controlled by two parameters: the Laplacian Exponential
Diffusion α parameter, and the desired fraction of entries in each dataset that will
be set to ’1’ in the data binarization process. The diffusion parameter α was set to
0.01 for all experiments (for both breast cancer and ovarian cancer), but comparative
experiments revealed that the obtained pathway rankings are stable for values of α
between 0.0001 and 0.05. The average number of relations between genes and patient
samples was set to 0.1 for all datasets.
The method was implemented in Matlab, and run on a 16-core, 64bit CentOS
6.2 system with 128GB of memory. Source code and sample data is available from
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http://bioinformatics.intec.ugent.be/pathwayranking/. The calculation of the matrix
exponential determines runtime and memory usage which are known to be O(N3)
and O(N2) respectively, with N the number of entities in the global network. To re-
duce runtime and memory requirements, the global adjacency matrix was compressed
by merging the mRNA expression dataset with the prior knowledge network, resulting
in a substantial reduction of problem size. The problem size N was further reduced by
filtering out all genes that were not present in the prior knowledge network. The du-
ration of the pathway ranking procedure is a linear function of the number of random
permutations which is in turn depending on the desired minimum obtainable p-value.
If a minimum p-value of 0.0001 is needed, scores for 10 000 permutations need to be
calculated. Calculating scores for permutations is a problem that is so-called embar-
rassingly parallel (scores for individual permutations are independent of each other)
indicating that the procedure is easily sped up in a multi-core environment. On the
system used, the processing of a typical analysis run (with 10 000 permutations) was
finished in less than 40 minutes.
3.3 Results and Discussion
3.3.1 Pathway importance ranking for breast cancer subtypes
The importance of 224 non-disease KEGG pathways was assessed for each of the
breast cancer subtypes by calculating a relevance score per pathway for each breast
cancer PAM50 subtype (Basal-like, HER2, Luminal A, Luminal B) (Figure 3.3,3.4).
Each relevance score is an aggregate of four components: mRNA expression, copy
number, mutation and methylation. The application to breast cancer tumors serves
as a validation of the newly developed method. The molecular PAM50 breast cancer
subtypes have been extensively characterized [9], and the ranking procedure should
recapitulate to a large extent what is known about these subtypes.
In general, the gene expression score component (or sub-score) is larger than the
other components. This is to be expected, because the sub-scores reflect the probabil-
ity of observing a particular expression, mutation, copy number or methylation pattern
purely by chance. If a pathway is truly relevant for a subtype, we expect
1. that this is reflected by differential expression of a set of genes in that pathway,
and
2. that the expression pattern of genes in that pathway will be consistent for tumor
samples within that subtype (the downstream effect of a genetic aberration on
gene expression will be similar).
Conversely, mutation, copy number and methylation sub-scores are expected to be
lower than the expression sub-score, since
1. oncogenic aberrations are sparse and
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2. pathway-disturbing alterations often are not consistent even when they result in
an identical downstream gene expression pattern (see the Introduction section).
Furthermore, the subtypes are determined using a gene expression-based classifier.
This ensures similar gene expression values for at least the genes that are present in
the classifier. The more consistent genes behave within a single subtype, the higher
the similarities between the samples and the genes of a pathway will be and the less
likely such similarities will be observed purely by chance.
3.3.2 Subtype-independent pathways
The (mitotic) cell cycle pathway is the highest scoring pathway for the Basal-like sub-
type, but it is also ranked high for the HER2 and the Luminal B subtypes. It is absent
in the top 20 for the Luminal A subtype. Closer inspection of the components making
up the aggregate score (Figure 3.3,3.4, Supplementary Figure A.2) indicates that the
score is highly determined by a substantial copy number (predominantly transcription
factor MYC, cyclin CCND1 and the MDM2 oncogene) and mutation (tumor suppres-
sor TP53) component. Mutations of TP53 are absent in Luminal A tumors, explaining
the low score of this pathway for that subtype. The HER2 and the Luminal B sub-
type also exhibit a small methylation component that appears to be determined by the
methylation status of the CCND1 and CCND2 cyclins, CDKN1C (a negative regu-
lator of cell proliferation) and the chromatin binding MCM5 protein (Supplementary
Figure A.2).
The PI3K-Akt signaling pathway, responsible for cell survival and proliferation
through regulation of the AKT protein kinase, scores uniformly high for all subtypes.
Yet, even though the constituting score components are of a similar order of mag-
nitude for all subtypes, the actual genetic disturbances are diverse (Supplementary
Figure A.3). For instance, all subtypes exhibit mutations in this pathway, but for the
Basal-like tumors, this is limited to a single gene (TP53), whereas the HER2 sub-
type is characterized by a combination of mutations in TP53 and the PIK3CA kinase.
The Luminal A and B subtypes are characterized by fewer mutations in TP53, com-
plemented with a combination of mutations in, among others, PIK3CA, the AKT1
kinase, the PTEN phosphatase and KRAS, a kinase and well-known proto-oncogene.
A similar pattern can be observed from the copy number data, where in Basal-like
tumors, a uniform amplification pattern is observed for MYC and PIK3CA, whereas
the other subtypes exhibit a combination of amplified MYC, CCND1, MDM2, IK-
BKB (a serine kinase), MCL1 (involved in apoptosis regulation) and RPS6KB1 (a
protein kinase). Finally, the presence of the Basal-like HER2 Luminal A Luminal
B methylation gradient (Supplementary Figure A.3) is reflected in the presence of a
small methylation component that increases in size according to the same gradient.
Because the Jak-STAT signaling pathway, involved in cytokine and growth fac-
tor signaling, shares many genes with the PI3K-Akt signaling pathway (e.g. MYC,
CCND1, MYC, AKT1, AKT2, PIK3CA, and the PIK3R1 kinase, see Supplementary
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Figure 3.3: The 20 highest ranking pathways for each of the Basal and Luminal A breast cancer
subtypes. The aggregate score assigned to each pathway can be decomposed into 4 probabilis-
tic components. The contribution of each component to the total score is indicated in a different
color bar: mRNA expression (dark blue), copy number (light blue), mutation (green) and methy-
lation (yellow).
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Figure 3.4: The 20 highest ranking pathways for each of the HER2 and Luminal B breast
cancer subtypes. The aggregate score assigned to each pathway can be decomposed into 4
probabilistic components. The contribution of each component to the total score is indicated in
a different color bar: mRNA expression (dark blue), copy number (light blue), mutation (green)
and methylation (yellow).
PATHWAY RANKING 67
Figure A.4), it also scores uniformly high across all subtypes. It scores lower than the
PI3K-Akt signaling pathway because TP53 is not a member of the pathway, nor many
of the additional mutations (KRAS, PTEN) found in the PI3K-Akt signaling pathway.
This results in a smaller mutation component in the aggregate score (Figure 3.1).
The TGF-Beta signaling pathway scores very high for the Basal-like and Lumi-
nal A subtypes, and intermediate (top 10) for the HER2 and Luminal B subtypes. It is
involved in many aspects of development biology, and in the regulation of a wide spec-
trum of cellular functions, including proliferation and apoptosis [26]. Its role in breast
tumor development is ambiguous as TGF-Beta signaling can both suppress and pro-
mote cancer progression [27]. Interestingly, its score is, for all subtypes, determined
by a large methylation component. Indeed no other pathway has (averaged over the
subtypes) so large a methylation sub-score, which is remarkable since only 6 genes
of the pathway are present in the methylation dataset (Supplementary Figure A.5).
A possible explanation lies in the topology and size of this pathway. The TGF-Beta
signaling pathway representation in the KEGG database is relatively small and lin-
ear. This makes it easy to connect upstream methylation events (almost all methylated
genes in the pathway are found at the start of the signaling cascade) with downstream
expression effects, resulting in large similarity scores for those genes. Together with
the TGF-Beta signaling pathway, the presence of the WNT signaling pathway for all
subtypes but Luminal A is notable. For the Luminal B subtype, the Hippo signaling
pathway is found too. These three pathways act as large cross-talking modules [26]
and it has been suggested previously that these pathways play a prominent role in
(triple negative) breast cancer development [15].
The pathways described above were all ranked high for (almost) all subtypes.
Functionally, these pathways take part in biological processes related to cell division,
proliferation and survival. Their role in breast tumor development is well studied [9].
Interestingly, the underlying disturbances leading to the high scores can be divers.
Because disturbances are connected through the a-priori network, the effect on the
pathway score of a set of mutual exclusive mutations or copy number alterations oc-
curring in that pathway can equal (and indeed exceed) the effect of a single consistent
disturbance. This is clearly illustrated by the PI3K-Akt signaling pathway, where sim-
ilar scores are obtained for the Basal-like subtype exhibiting only TP53 mutations and
MYC amplifications, and the other subtypes where TP53 mutations and MYC ampli-
fications are much sparser, but are complemented with other disturbances.
3.3.3 Subtype-specific pathways
Because the analysis was performed separately for each subtype, the method is ex-
pected to identify not only pathways that are active or important for all subtypes, but
also subtype-specific pathways. For a selection of differentially scoring pathways,
Figure 3.5 displays a comparison of scores obtained for the different subtypes.
The scores for the p53 signaling pathway are highly determined by the mutation
status of TP53 (Supplementary Figure A.6) and consequently, the high score for the
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Figure 3.5: Pathway scores compared across breast cancer subtypes for a selection of pathways.
Dark blue = Basal-like, light blue = HER2, green = Luminal A and yellow = Luminal B.
Basal-like subtype and the low score for the Luminal A subtype are to be expected.
P53 signaling is intricately related with a cell’s response to, among others, DNA dam-
age and activated oncogenes. Differential activation of this pathway in combination
with hormone receptor status is an important factor determining breast cancer pro-
gression and outcome [28]. Even though Luminal B tumors too are only infrequently
mutated in TP53, their score is much higher than for Luminal A tumors. A detailed in-
vestigation of the expression data revealed that Luminal B tumors express much more
genes from the p53 signaling pathway than the Luminal A tumors do (Supplementary
Figure A.6), suggesting that the aberrant activity of this pathway is not necessarily
caused by defects in the pathway itself.
The Toll-like receptor signaling pathway, suspected to be involved in the tumor’s
evasion of the immune system [29], scores very high for the Basal-like subtype, inter-
mediate for the Luminal A subtype, and low for the HER2 and Luminal B subtypes.
The differences in scores for the subtypes appear to be caused by differences in the
amplification and mutation status of PIK3CA, where again the lack of PIK3CA mu-
tations in the Basal-like subtype are compensated by additional copy number amplifi-
cation of PIK3CA, copy number amplifications of the MAP3K7 and RIPK1 kinases,
copy number deletions in PIK3R1, and (slight) hypo-methylation of chemokine CCL5
and toll-like receptor TLR9 (Supplementary Figure A.7).
The ErbB signaling pathway couples extra-cellular growth signals to intra-cellular
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signaling pathways that eventually control cell survival, proliferation and motility.
It is involved in tumor development and progression, and many ErbB inhibitors are
currently used therapeutically [30]. Its score is highly determined by the amplifica-
tion state of the ERBB2 receptor tyrosine kinase and the mutation state of PIK3CA
(Supplementary Figure A.8). HER2 tumors exhibit an almost total amplification of
ERBB2 that translates immediately to the overexpression of ERBB2 in this subtype.
Luminal A tumors lack the amplification of ERBB2 but are, like HER2 tumors, fre-
quently mutated in PIK3CA. Luminal B tumors are infrequently mutated in PIK3CA
and exhibit infrequent ERBB2 amplification, whereas in Basal-like tumors PIK3CA
is not mutated, nor is ERBB2 amplified.
The MAPK-signaling pathway is one of the few pathways (together with the
AMPK pathway, see below) that scores highest for the Luminal B subtype. The am-
ple evidence that aberrant MAPK signaling promotes tumor cell proliferation, sur-
vival and metastasis, makes this pathway an interesting inhibitory drug target [31].
MAP3K1, which is known for its critical function in cell fate decisions, is one of the
central genes of the pathway and is crucial in connecting upstream and downstream
genes [32]. Consequently, the observed differences in scores between the subtypes are
expected to depend on its mutation status. Interestingly, although MAP3K1 is more
frequently mutated in Luminal A tumors (Supplementary Figure A.9), the pathway
score is higher for the Luminal B tumors, and the mutation sub-score for Luminal
B tumors is higher than for Luminal A tumors (Figure 3.3,3.3). This can be due to
the fact that, like for the p53 signaling pathway, the Luminal B tumors express more
genes from this pathway and several genes are (slightly) more methylated (Supple-
mentary Figure A.9). The more genes that are differentially expressed or methylated,
the more connections exist (through the global network) between tumor samples and
mutated genes and the higher the similarity scores between the tumor samples and the
mutated genes will be. Conversely, the omnipresent mutations of TP53 in the Basal-
like and HER2 subtypes do not result in a particular higher score for these subtypes,
since the topology of the pathway is such that the connection between TP53 and the
differentially expressed and methylated genes is less straightforward [24].
Like the MAPK signaling pathway, the AMPK signaling pathway, a sensor of cel-
lular energy status [24], scores very high for the Luminal B tumors, intermediate for
Luminal A and HER2 tumors, and low for the Basal-like subtype. Here the path-
way score can be explained (Supplementary Figure A.10) by the inter-subtype differ-
ences in PIK3CA mutations (absent in Basal-like tumors, very frequent in Luminal
A), copy number amplification of CCND1 and RPS6KB1 (unimportant in Basal-like
and Luminal A, frequent in HER2 and Luminal B) and copy number loss of PIK3R1
(Basal-like).
The analysis above indicates that the presented method is able to prioritize subtype-
specific pathway importance with the high score for the ErbB signaling pathway for
the HER2 subtype as a typical example. The results for the p53 and MAPK-signaling
pathway confirm that the integrated approach, where the analysis does not depend on
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a single gene nor a single type of data, is relevant and results in pathway scores that
do not merely reflect mutation or copy number alteration frequencies.
3.3.4 Comparison with alternative approaches
To put the proposed method into perspective, we compared it to a naive frequency-
based approach. Instead of using, for each dataset, per-gene aggregated network-based
similarity scores, we used the frequency of occurrence of ’abnormal’ states (i.e. the
number of times a gene was differentially expressed, mutated, aggregated over all
samples) as the individual gene score. Using the same permutation-based approach
as used for the proposed method, a p-value for each pathway can be obtained for
each dataset, and the p-values can be combined to result in a single frequency-based
score per pathway. This naive approach was applied to the Luminal A breast cancer
subtype, corresponding to the largest group of patients in this study. The frequency-
based pathway ranking was performed on the same (filtered) datasets that were used
to obtain the network-based results. The results are displayed in S2 Table. In gen-
eral, the two approaches agree: even though 224 pathways were evaluated, the 50
highest scoring pathways obtained with the proposed method can almost all be found
among the 50 highest scoring pathways obtained with the frequency-based approach.
However, the ordering of the pathways differs considerably between the two methods.
Several relevant high-scoring pathways (see Result section above) obtained with the
network-based method tend to be ranked lower by the frequency-based method, as
is exemplified by the MAPK signaling pathway. This clinically important pathway
is ranked 14th by the network based method, but ranked only 32th by the frequency
based approach. The pathway exhibits, more than any other pathway, a dispersed pat-
tern of mutual exclusive mutations. The low mutation frequencies for individual genes
result in a low rank when using only frequency as a relevance criterion.
Next, we compared our pathway relevance assessment results with those men-
tioned in the original PARADIGM publication [6]. Re-running PARADIGM with
the same data used in our experimental setup, including mutation and methylation
data, was not possible. We found that the top 15 pathways mentioned in the older
PARADIGM study correspond to, or overlap highly with at least one pathway of
our top-ranked pathways for each subtype (Table 3.1). The only exception to this
is the ’p75(NTR)-mediated signaling pathway’ ranked 6 out of 15 in the original
PARADIGM study. This pathway maps to the neurotrophin signaling pathway in this
study. In addition to the overlapping pathways, our approach also high-scored several
other pathways (e.g. TGF-Beta, WNT and Toll-like receptor signaling). This is to be
expected since firstly, in this study, additional datasets are used as input, and secondly,
breast cancer subtypes are analyzed separately rather than collectively.
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3.3.5 Pathway importance ranking for ovarian cancer
For the ovarian cancer analysis, no molecular subtypes were used. Instead the 447
tumors were stratified based on survival data. We assume that strong differences in
survival have a molecular foundation, although this may not always be the case. Three
groups were identified: a group where patients were not alive 1 000 days after the di-
agnosis (104 patients), a group that survived for at least 2 000 days (47 patients), and
an intermediate group (296 patients). We investigated whether the newly developed
method is able to identify pathways that can help in explaining the different outcome
between these groups of patients. Similar to the breast cancer analysis, the importance
of 224 non-disease KEGG pathways was assessed for each of the survival-based sub-
types. In what follows, we focus on the similarities and differences between the most
extreme survival-based subtypes.
3.3.6 Important pathways common to all subtypes
Figure 3.6 displays the 20 highest scoring pathways for the two most extreme sub-
types. From the figure, it is obvious that in general the patient group with the worst
outcome has higher pathway scores than the group with the best outcome. Only the
MAPK signaling and the cell cycle pathway exhibit similar aggregate scores. The fact
that many different pathways are scored differentially between the subtypes suggests
that the molecular explanation for the difference in survival will most likely not have
a single cause.
In previous studies, as summarized in [16], a number of important deregulated
pathways have been related to ovarian cancer: RB-signaling (cell cycle), RAS/PI3K
signaling (PI3K-Akt signaling), FOXM1 (not present in the KEGG database, but over-
lapping with the cell cycle pathway) and Notch signaling. In this study, the highest
scoring pathways are the MAPK signaling pathway, the cell cycle pathway, the PI3K-
Akt signaling pathway and the WNT signaling pathway. The absence of the Notch
signaling pathway in the top 20 of highest scoring pathways for either subtype is strik-
ing. A closer inspection of the actual data (Supplementary Figure A.11) reveals that
the Notch signaling pathway harbors few (epi-) genetic disturbances, both in terms
of disturbances per gene as well as in terms of the number of disturbed genes. Addi-
tionally, as the KEGG representation of the Notch signaling pathway only contains 24
genes, it is possible that the pathway information is incomplete. However, a close co-
operation between MAPK signaling and Notch signaling has been described in other
tumors [33], and MAPK signaling is top-scored for all subtypes. The presence of
the WNT signaling pathway, implicated previously in ovarian cancer tumorigenesis
[34, 35], is noteworthy. Its high score will likely be determined (Supplementary Fig-
ure A.12) by TP53 mutations and copy number amplification in e.g. MYC, the NDK2
kinase and WNT5B (encoding for a signaling protein).
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Figure 3.6: The 20 highest ranking pathways for the two most extreme ovarian cancer survival-
based subtypes. The contribution of each component to the total score is indicated in a different
color bar: mRNA expression (dark blue), copy number (light blue), mutation (green) and methy-
lation (yellow).
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Figure 3.7: Ratio of bad-outcome pathway scores and the corresponding good-outcome scores.
A ratio of ’1’ indicates that the pathway scores equally high for patients in the bad-outcome
group and patients in the good-outcome group. Values larger than 1 indicate higher pathway
importance / activity for the bad-outcome group. Pathways shown are limited to the top-20
highest scoring pathways in the bad-outcome group.
3.3.7 Differential subtype analysis
More than in the pathways that score uniformly high across subtypes, we are interested
in pathways that score differently for the survival-based patient groups. To achieve
that, we focused on the 20 highest scoring pathways for the bad-outcome group. For
each of these pathways, we calculated the ratio of the score for the bad-outcome group
and the corresponding score in the good-outcome group (Figure 3.7). The assumption
is that the larger a score ratio deviates from one, the more likely a pathway is involved
in a process that determines outcome.
The scores of the pathways in the bad-outcome group are consistently higher
than the corresponding scores in the good-outcome group, with the exceptions of the
MAPK signaling and cell cycle pathways yielding score ratios respectively equal to
0.97 and 0.94. The highest score ratios are found for Jak-STAT signaling, ECM recep-
tor interaction, cAMP signaling, TGF-Beta signaling and estrogen signaling. Supple-
mentary Figures A.14-A.18 illustrate that single (epi-)genetic aberrations cannot be
easily linked to the differential scoring of these 5 pathways, except for slight increases
in MYC, CACNA1D (a Calcium channel) and KRAS amplification, and infrequent
CREBBP (a transcription factor activator) mutations. Still, all five pathways are in-
volved in tumor development and proliferation. Jak-STAT signaling is since long
linked to cell migration and survival in ovarian cancer [36] and often, the expres-
sion of, or the responsiveness to TGF-Beta is lost, leading to cell proliferation [37].
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Furthermore, it is known that the disruption of the extra cellular matrix (ECM inter-
action) can lead to the overproduction of growth factors that promote abnormal pro-
liferation [38]. Estrogen signaling is thought to be involved in the establishment of a
pro-tumorigenic micro-environment, and the long-term use of estrogen-only hormone
replacements is linked to ovarian cancer development [39]. Finally, cAMP signaling
is involved in cell survival in ovarian cancer and the presence of mutant CREBBP
proteins can lead to tumorigenesis [40].
Interestingly, when all pathways are considered instead of only the pathways that
are important for the bad-outcome patient group, the ratio score ranking (Supplemen-
tary Figure A.13) is topped by the Notch signaling pathway event though this pathway
is not high-scored for any patient group. As mentioned above, Notch signaling is in-
volved in embryonic development, proliferation, differentiation and apoptosis, and is
implicated in ovarian (and many other) cancers [16, 41, 42]. Its large score ratio could
be attributed to the differential amplification of DLL3 (Supplementary Figure A.11),
which recently has been reported to be the second most altered gene in the NOTCH3
pathway [43].
3.4 Conclusions
We have presented a new pathway importance ranking strategy that allows for the inte-
gration of any dataset that can be cast in a binary format. The method was evaluated on
two datasets retrieved from TCGA, containing gene expression, mutation, copy num-
ber and methylation data for breast and ovarian tumors. By applying the method to
the well-studied breast cancer TCGA dataset, we demonstrated the method’s potential
to identify key pathways, involved in breast cancer development, that are important
for all molecular subtypes. The method recapitulates to a large extent what is known
about breast cancer pathway activity. Interestingly, sometimes pathways were deemed
equally important for different subtypes, yet the underlying (epi)-genetic disturbances
were diverse. Furthermore, next to prioritizing universally high-scoring pathways, the
pathway ranking method was able to identify subtype-specific pathways. Often the
aggregate score of a pathway could not be motivated by a single mutation, copy num-
ber or methylation alteration, but rather by a combination of genetic and epi-genetic
disturbances. This suggests that the integration of all data through a network of known
gene interactions is an essential step in tumor analysis.
The analysis of ovarian tumors confirmed the method’s ability to correctly identify
key pathways, irrespective of survival-based tumor subtypes. A differential analysis
of survival-based subtypes revealed several pathways with higher importance for the
bad-outcome patient group than for the good-outcome patient group. Many of the
pathways exhibiting higher importance for the bad-outcome patient group could be
related to tumor proliferation and survival.
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A multi-purpose network-based data
integration strategy for tumour analysis
In this chapter, we extend the network-based data-integration idea introduced in the
previous chapter. Using the same model as for the pathway ranking technique, it be-
comes possible to simultaneously identify meaningful clusters of tumour samples, pri-
oritize potential drivers of tumour development and proliferation, rank pathways ac-
cording to their relevance for a homogeneous set of patients and produce sub-networks
that give a more mechanistic insight in the relations between the prioritized genes.
? ? ?
Lieven P.C. Verbeke, Jimmy Van den Eynden, Piet Demeester, Jan
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Abstract The study of cancer, a highly heterogeneous disease with different causes
and clinical outcomes, requires a multi-angle approach and the collection of large
multi-omics datasets. We present MUNDIS, a MUlti-purpose Network-based Data
Integration Strategy that, unlike any other method, provides a unified approach for un-
supervised subtype classification, driver gene prioritization, pathway impact assess-
ment and network delineation. Key to the method is the conversion of all available
data into a single comprehensive network representation containing not only genes
but also individual patients. Additionally, prior knowledge can be incorporated by
adding previously identified molecular interactions to this network representation. We
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demonstrate the performance of MUNDIS by applying it to ovarian, glioblastoma and
breast tumour datasets from The Cancer Genome Atlas. By integrating mRNA, copy
number, mutation and methylation data, MUNDIS was able to identify molecular sub-
types of ovarian and glioblastoma cancer that are highly predictive for patient survival.
Additional in-depth analysis of these subtypes identified by MUNDIS together with
an analysis of predefined PAM50 breast cancer subtypes demonstrates the method’s
ability to provide a mechanistic insight in the underlying biological processes.
4.1 Introduction
Cancer is a heterogeneous disease with different therapeutic strategies and associated
outcomes even within a single cancer type. The molecular mechanisms underlying
clinical subtypes often remain unknown. Sometimes, the subtypes themselves are still
under consideration [1, 2]. Delineating meaningful subtypes and identifying the cor-
responding mechanisms of action, i.e. pathways or networks of interacting genes, thus
remains a fundamental challenge in cancer research. These tumour analysis problems
not only require large patient cohorts and multi-omics datasets, but also largely de-
pend on the availability of an analysis framework that can integrate the different data
types in a biologically relevant way [1, 3–5].
Existing methods address only part of the tumour analysis problem, focusing ei-
ther on patient subtyping [4, 6], driver gene prioritization [7–13], pathway impact as-
sessment [12, 14–16] or interaction network delineation [4, 17, 18], and are typically
limited in the types of data that can be handled (e.g. only somatic mutations without
copy number data). In order to get a comprehensive view of the molecular mechanisms
governing cancer, a number of subsequent analyses are needed [3, 19, 20]. Because of
the heterogeneous genetic causes of cancer [21], the success of applying a specialized
method is uncertain if it operates only on part of the available data. Moreover, con-
secutive partial data analyses unequivocally result in information loss and introduce
an extra level of errors and noise per analysis step. Finally, partial analysis can not
take advantage of the fact that the different aspects of tumour analysis are all closely
related. A newly defined subtype is more relevant if the patient stratification reflects
the underlying drivers and mode of action, and vice versa. As a result, a consecutive
processing chain will result in a less coherent analysis.
To deal with these issues, we present MUNDIS, a multi-purpose network-based
data integration strategy, that is an extension of an earlier developed pathway ranking
technique [16]. MUNDIS allows for an integrative and single-tool analysis applica-
ble to patient subtyping, pathway importance ranking and driver gene prioritization
and subnetwork delineation (in our framework, the latter two are essentially the same
task). All available data are cast into a unique network model that not only contains
genes, but also the individual patients. By exploiting a measure of connectedness in
this network representation, it is not only possible to link genetic disturbances with
their downstream molecular phenotype, but also to link patients with other patients,
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or patients with genes of potential importance for the disease phenotype. Next to con-
taining genes and patients, the MUNDIS network model allows for straightforward
inclusion of prior knowledge in the form of a network of gene interactions as can be
found in public databases [22–25]. In particular for tumour analysis, the inclusion of
such gene interaction networks or pathways is crucial. Somatic mutations are sparse,
to the extent that patients with the same disease phenotype often will not share any
somatic mutations occurring in the same pathway [4, 9–11, 18]. This so-called mutual
exclusivity of somatic mutations, and by extension, the complementarity of somatic
mutations with copy number alterations and methylations found in individual cancer
patients [21], renders the statistical task of identifying true genomic causes of can-
cer challenging and motivates ’pathway driven’ analysis [4, 9, 12, 14]. Successful
patient stratification or driver identification then depends on a search for mutational
consistency between patients in terms of pathways, rather than in terms of individual
mutations.
To benchmark the extent to which our method was able to stratify patients into
meaningful subtypes, we applied MUNDIS to two datasets from The Cancer Genome
Atlas (TCGA): ovarian cancer [26] and glioblastoma multiforme [19]. We aimed at
providing patient groups that correlated highly with patient survival, and this to a
higher degree than both naive and state of the art approaches. The methods’ potential
for unveiling affected pathways, subnetworks and driver genes was evaluated using
the earlier defined subtypes for both tumour types. As a means of validation, we also
used the method to identify driver genes and subnetworks for the the well studied
PAM50 Basal and Luminal A breast cancer subtypes using multi-omics data available
from TCGA [3].
The results confirm that MUNDIS can be used to identify clusters of patients that
are indicative of patient survival for glioblastoma multiforme and ovarian cancer. The
in-depth analysis of the identified (for overian and glioblastoma tumours) and prede-
fined subtypes (for breast cancer tumours) illustrated the ability of the method to ade-
quately prioritize driver genes and pathways, and delineate meaningful sub-networks
of interacting genes.
4.2 Results
4.2.1 Overview of the method
MUNDIS is an unsupervised analysis method that combines different data types with
prior knowledge resulting in a comprehensive network representation (see section 4.4
and [16] for a comprehensive discussion of the network construction process). First,
all available datasets (in this study we use mRNA, methylation, copy number and mu-
tation data) are converted into a binary form (Figure 4.1a). A ’1’ in the binary datasets
corresponds to an abnormal state (compared to normal tissue) of a gene for a par-
ticular patient and corresponds to either over- or under-expression, mutation, hypo-
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or hyper-methylation, and copy number loss or amplification. Next, each ’1’ is con-
verted to a link in a network, connecting a patient node with an ’abnormal’ gene node
(Figure 4.1b). When a gene exhibits deviating values in multiple datasets, the gene
is added once for each dataset in which an aberration occurs. The abnormal gene
nodes are then connected using gene interaction data from public repositories [22, 27]
to form a ’global’ network. After calculating a network-based similarity measure
[28, 29] using the adjacency matrix representation of the global network (Figure 4.1c),
a similarity matrix is obtained that contains similarities between all mutual combina-
tions of entities (patients and genes) (Figure 4.1d). Patients can then be clustered using
the part of the similarity matrix containing inter-patient similarities (see Materials and
methods). Other parts of the similarity matrix allow for finding individual genes with
a potential link to the cancer phenotype (driver gene prioritization) or entire pathways
relevant for groups of patients (pathway importance ranking), and for the construction
of gene interaction network neighborhoods. A reference implementation of MUNDIS
is available for download from http://bioinformatics.intec.ugent.be/mundis.
4.2.2 Unsupervised molecular subtyping of breast, ovarian and
glioblastoma tumours
TCGA data were downloaded and preprocessed (see Materials and methods) for ovar-
ian and glioblastoma tumours. Using an unsupervised parameter tuning strategy that
also determined the number of clusters, ovarian and glioblastoma patients were strati-
fied in patient clusters that correlate highly with patient survival (Figure 4.2 and Fig-
ure 4.3). For ovarian cancer, 447 patients were stratified in a low-, medium- and
high-risk group (log-rank p = 8.1 × 10−7), and 302 glioblastoma patients in a low
and a high risk group (log-rank p = 2.7× 10−7).
For glioblastoma, mutation data were not used due to limited patient overlap with
the other data types and the survival data. We compared the MUNDIS subtypes with
existing glioblastoma multiforme subtypes [19, 30] (Figure 4.3) and found that, in
terms of patient survival, the existing subtypes are situated between the low- and the
high-risk MUNDIS subtypes, except for the G-CIMP subtype. The G-CIMP subtype
is contained entirely in the low-risk group. When MUNDIS is run to produce 4 sub-
types, the G-CIMP subtypes emerges as an additional MUNDIS subtype while retain-
ing a separate low- and high-risk patient group, indicating that the low-risk group does
not depend exclusively on the G-CIMP subtype (Figure B.1). This suggests that the
subtypes found by the integrated MUNDIS approach have a different molecular basis
than the previously identified subtype that were based exclusively on gene expression
data [19, 30].
We compared our stratification with the results of other approaches (Figure 4.4).
First, the added value of data-integration was assessed by applying a naive clustering
algorithm (Materials and methods) to each individual data type (mRNA expression,
copy number data, mutation data and methylation data; all data are continuous). For
all individual data types and across tumour types, we found that the obtained stratifi-
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Figure 4.1: Overview of MUNDIS. (a) All data are converted to a binary representation, with ’1’
(colored squares) corresponding to a gene with a value deviating from normal for a particular
patient (dark blue). Different colors represent different inputs obtained from different datasets:
green = mRNA gene expression, pink = copy number alterations, light blue = mutations, orange
= hypo- or hyper-methylations) (b) Each ’1’ in the binary datasets is converted to a link in an
undirected global network, where additional prior knowledge is added in the form of known
gene interactions (gray nodes and links). Dashed yellow links connect genes with deviating
values in their respective datasets to the genes in the interaction network. (c) The resulting
adjacency matrix representation of the global matrix. (d) The similarity matrix derived from
the adjacency matrix, indicating the parts of the similarity matrix that are relevant for each of
the tumour analysis subtasks.
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Figure 4.2: Kaplan-Meier survival plots for MUNDIS subtyping applied to ovarian cancer.
Figure 4.3: Kaplan-Meier survival plots for MUNDIS subtyping applied to glioblastoma mul-
tiforme (subtype 1 contains only 3 patients and is not shown). Earlier described subtypes [30]
are added.
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cation was less significant (log-rank p > 10−4) than the one obtained using MUNDIS,
confirming the importance of an integrative approach. When all available data types
were integrated by concatenating all data to form a single stacked dataset, applying a
naive clustering approach resulted in a patient stratification that was respectively bet-
ter (log-rank p = 1.5 × 10−6) and worse (log-rank p = 1.4 × 10−2) than the best
result obtained using an individual data type (Figure 4.4), for the glioblastoma and
the ovarian cancer dataset. MUNDIS on the other hand consistently outperforms the
individual and the stacked approaches.
We also compared the MUNDIS results with the results obtained with iCluster,
a subtyping method specifically targeting data-integration [6, 31]. iCluster does not
allow for the inclusion of mutation data nor prior knowledge. Even when parameter-
tuned for maximum correlation (in terms of log-rank p-value) with patient survival,
iCluster obtained a less clear patient stratification than the one obtained using MUNDIS
(log-rank p = 2.0×10−3 and 3.4×10−4 respectively for ovarian cancer and glioblas-
toma).
Figure 4.4: Comparison of MUNDIS with hierarchical clustering of the individual datasets
(CNV=copy number data, EXP=mRNA expression, MUT=mutation data, MET=methylation
data), iCluster and a naive approach where all datasets are stacked (STACK) and then clustered.
The number of patient clusters and optimal parameters for MUNDIS were determined using an
unsupervised tuning procedure.
4.2.3 Pathway ranking
Similar to earlier work [16], we used the MUNDIS framework to rank a set of prede-
fined KEGG pathways [22] according to their importance for a homogeneous set of
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samples. The original pathway ranking strategy was evaluated using the predefined
molecular PAM50 breast cancer subtypes [16]. Here, we use the survival-linked pa-
tient groups identified for glioblastoma and ovarian tumours. Each time, the patient
groups with respectively the worst and the best outcome are first analyzed separately.
For each pathway, a compound score consisting of as many components as there are
datasets in the analysis is calculated using the MUNDIS framework (see Material and
methods). Next, we perform a differential analysis where the pathways are ranked
according to their differential scoring between the good- and the bad-outcome patient
groups. Pathways of metabolic processes and disease related pathways were excluded
from the analysis. Metabolic pathways are unlikely to play a role in cancer (contrary
to signaling pathways), whereas disease pathways in KEGG are often incomplete,
discontinuous and heterogeneous.
4.2.3.1 Glioblastoma multiforme
The results for the glioblastoma pathway ranking are given in Figure 4.5. Several
pathways previously implicated in tumour development are top-ranked for both sub-
types (focal adhesion, adherence junction, cytokine-cytokine interaction and ERBB
signaling) but when the absolute scores are examined, it becomes clear that in gen-
eral, pathways are scored much higher for the bad-outcome group than for the good-
outcome group. As the pathways scores are based on datasets that represent abnormal
states of genes, this means that bad-outcome patients will exhibit much more genes
that are differentially expressed or contain a genetic or epi-genetic disturbance. Espe-
cially the copy number component of the score is more important for the bad-outcome
patient group. Notable differences between the two outcome groups include the high
scores of the HIF-1 and PI3K-Akt signaling pathways for the bad-outcome group
and the absence of the P53-signaling pathway in the good-outcome group. HIF-1
(Hypoxia-inducible factor 1) is crucial for tumour angiogenesis, which may explain
the correlation between its score and patient survival [32].
When for each pathway a differential score is calculated between the good- and the
bad-outcome patient groups (Figure 4.6) to objectify the observed differences (not lim-
ited to the top scoring pathways shown in Figure 4.5), a similar pattern emerges. Most
pathways that are differentially scored are scored higher for the bad-outcome group,
with a notable exception for the dorso-ventral axis formation pathway (involved in
regional specification in embryonic growth), that is ranked very high for the good-
outcome patient group. The score for this pathway contains only an expression com-
ponent, that is based on only a few genes. Therefor, we consider it an artifact (when
only a few genes are present in a pathway, the pathway’s score is easily dominated by
a single important gene) that could possibly be resolved using an alternative sub-score
combination approach. Next to the previously discussed HIF-1 signaling pathway, the
differential scoring of the focal adhesion, P53 signaling, cytokine-cytokine interac-
tion and cell cycle pathways is notable. P53 signaling and cell cycle processed are
long known to be important for tumour development and survival. Focal adhesion
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Figure 4.5: Pathways importance for the previously derived glioblastoma tumour subtypes cor-
responding to bad-outcome and good-outcome patient groups. No mutation data were used.
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and cytokine-cytokine interactions play a role in cell motility, proliferation, differen-
tiation and survival [22] and are thus potentially involved in angiogenesis and tumour
metastasis.
Figure 4.6: Top 20 pathways with the highest differential scoring (log-ratio) between good- and
bad-outcome patient groups for glioblastoma tumours.
4.2.3.2 Ovarian cancer
The ovarian cancer pathway analysis is displayed in Figure 4.7. Remarkably, the
top-ranked pathways for the good-outcome patient group tends to score higher than
those for the bad-outcome patient group. This seems to suggest that the good-outcome
subtype is dominated by genes that are more differentially expressed and exhibit more
genetic and epi-genetic disturbances, but below we give an alternative explanation for
this counter-intuitive result. The Wnt signaling and chemokine interaction pathways
are top-ranked for both subtypes. Wnt signaling participates in cell fate specification
and proliferation, and was implicated previously in ovarian cancer tumorigenesis [33,
34]. Chemokines can induce cell proliferation and help tumours evade apoptosis [35].
Notable differences between the two subtypes are the apoptosis pathway that scores
high for the bad-outcome subtype because of its large mutation component, and the
MAPK signaling pathway scoring very high for the good-outcome patient group.
Interestingly, the results are different from those obtained in previous work [16],
even though the same datasets were used as input for the analysis. In general the
same pathways are top-ranked, but the order of the pathways tends to be less similar
between the subtypes in this study. The differences can be explained by a different
choice of parameters of the algorithm. These parameters control the degree to which
the information in the data is allowed to diffuse through the network, and define the
abnormal states of genes used as input for the analysis. In this work, the parameters
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were obtained in an unsupervised way during the subtyping procedure in order to
obtain a patient classification that is supported by all the available data, whereas in the
previous study the parameters were set to default values. A second factor contributing
to these different results is the fact that the subtypes in the previous study were based
purely on survival whereas here there exist molecular properties that underpin each
subtype.
Figure 4.7: Pathways importance for the previously derived ovarian tumour subtypes corre-
sponding to bad-outcome and good-outcome patient groups.
As noted before, the good-outcome patient group yields in general higher scores
for most pathways than for the bad-outcome patient group (Figure 4.8). This is most
likely explained by the fact that the good-outcome patient group contains many more
samples than the bad-outcome patient group (340 vs. 48). A larger number of samples
will increase the power of the method to detect signals that are significantly different
from random events, and true pathway disturbances will become far more signifi-
92 CHAPTER 4
cant when many samples are available. This problem seems to emerge only when
the number of samples analyzed in the different patient groups differs by an order of
magnitude. For the glioblastoma analysis e.g., the bad- and the good-outcome pa-
tient groups contain respectively 108 and 121 samples, and thus no similar effect of
different sample sizes are expected to occur.
With this in mind, the increased score for the apoptosis pathway for the bad-
outcome subtype is all the more remarkable, even though its combined score contains
only a mutation component. Closer investigation of the binary data used to perform
the analysis (data not shown) indicates that for the bad-outcome subtype, the data bi-
narization algorithm has identified very few ’abnormal’ states of genes in this pathway.
When less than average ’abnormal’ gene states are present in a pathway, it becomes
possible that the component scores used to calculate the per-dataset p-values become
equal to 1, resulting in a zero component score when log-scaling is applied.
Figure 4.8: Top 20 pathways with the highest differential scoring (log-ratio) between good- and
bad-outcome patient groups for ovarian tumours.
4.2.4 Driver genes
Together with stratifying patients and ranking pathways, MUNDIS can be used to
infer genes of importance for a group of patients (see Method section). for validation
purposes, we first demonstrate this using two of the well studied PAM50 breast cancer
subtypes, Basal and Luminal A. Additionally, we performed the same analysis for
the previously found ovarian and glioblastoma survival-related subtypes. Potential
drivers were ranked for each subtype and data type separately. The top 10 highest
ranked genes per data type and subtype are shown in Tables 4.1-4.3.
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4.2.4.1 Breast cancer Luminal A and Basal subtypes
The driver gene prioritization recapitulates to a large degree what is known about the
copy number alterations and mutation patterns in breast cancer [3]. In the copy num-
ber selection, MUNDIS prioritized the MYC transcription factor for both subtypes.
For the Basal subtype, MUNDIS identified a.o. the well known cyclin CCND1 and
MCL1, an anti-apoptotic protein, that was recently put forward as a potential target
for overcoming therapeutic resistance [36]. For the Luminal A subtype, we also found
IKBKB, coding for (part of) an NF-κ-B inhibitor. NF-κ-B is involved in inflammatory
and innate immune responses, and is strongly linked to tumour development [37].
For the Basal subtype, fewer genes with a large number of mutations are found.
In the top 10, we find BRCA1 (involved in DNA repair), tumor suppressor TP53, and
MLL3 (a member of the ASC-2/NCOA6 complex involved in transcription regula-
tion). Luminal A displays frequent mutations of PIK3CA, the MAP3K1 and MAP2K4
kinases, the CDH1 cadherin, T-cell specific transcription factor GATA3, the PTEN
phosphatase, and RUNX1, a transcription factor involved in stem-cell differentiation.
TP53 is less frequently mutated than in the other subtypes. Still, more than 10 % of
the patients have TP53 mutations.
All selected methylated genes were hyper-methylated. The number of methy-
lated genes in general is larger in Basal samples then in Luminal A samples (data not
shown). The TCGA breast cancer study [3] identified strong methylation of genes in
the WNT-signaling pathway, involved in cell differentiation and proliferation. Of that
pathway, for the Luminal A, we find SFRP1, a WNT antagonist whose methylation
condition can be related to patient survival [38]. Additionally, the cyclin CCND2,
a gene with known oncogenic properties [39] scored high for this subtype. For the
Basal subtype, none of the prioritized genes have been previously implicated in breast
cancer.
4.2.4.2 Glioblastoma multiforme
In the copy number dataset, both the good- and the bad-outcome patient group found
for glioblastoma tumours exhibit amplified epidermal growth factor receptor EGFR
(Table 4.2). EGFR amplification is known to be prognostic in glioblastoma cancers
[40, 41] and it is selected more (and thus ranked higher) for the bad-outcome than
for the good-outcome group. The bad-outcome patient group is further characterized
by amplified kinase inhibitors CDKN2A and CDKN2B, and amplified CDK4. The
former act as inhibitors of CDK4 which is a known oncogene [42] that functions as a
stabilizer for TP53. It should be noted that although the good-outcome patient group is
dominated by copy number amplifications of many zinc finger proteins, this does not
necessarily indicate that these proteins are of vital importance for tumour development
and survival. Due to the nature of the data binarization strategy, a fixed proportion of
the gene/sample combinations is marked as an ’abnormal’ state (see Materials and
Methods), which is only an approximation of reality. On the other hand, many zinc
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Table 4.1: Driver gene prioritization using MUNDIS for the Luminal A and Basal breast cancer
patient groups. Top 10 genes per datatype and the fraction of patients for which the gene was
selected (Votes) are shown.
Luminal A Basal
Gene Votes Gene Votes
Copy number CCND1 1.00 ENSA 1.00
MYC 1.00 MCL1 1.00
THRSP 1.00 MYC 1.00
TPD52 1.00 GOLPH3L 1.00
KCTD14 1.00 WNK1 1.00
INTS4 1.00 AIM1 0.99
ORAOV1 1.00 KDM5A 0.99
CLNS1A 1.00 THRSP 0.99
IKBKB 1.00 CHCHD2 0.99
VDAC3 1.00 CCDC77 0.99
Mutation AKT1 1.00 BRCA1 1.00
RUNX1 1.00 HLF 1.00
CDH1 1.00 PPEF1 1.00
DGKG 1.00 RPGR 1.00
GATA3 1.00 TP53 1.00
MAP3K1 1.00 ARHGEF1 1.00
PIK3CA 1.00 MLL3 1.00
PTEN 1.00 UNC5D 1.00
MAP2K4 1.00 HSPA12A 1.00
TP53 1.00 PIK3CA 0.93
Methylation SLC22A3 1.00 DPYS 1.00
SFRP1 1.00 ZNF671 1.00
STXBP6 1.00 TRIM58 1.00
EDNRB 1.00 GALR1 1.00
BNC1 1.00 JAM3 1.00
CDX2 1.00 TRIM15 1.00
CCND2 1.00 SEMA5A 1.00
CYTL1 1.00 MT1E 1.00
ETS1 1.00 SV2A 1.00
AKR1B1 1.00 ADHFE1 1.00
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Table 4.2: Driver gene prioritization using MUNDIS for the GBM good- and bad-outcome
patient groups. Top 10 genes per datatype and the fraction of patients for which the gene was
selected (Votes) are shown. Not mutation data were available.
Good outcome Bad outcome
Gene Votes Gene Votes
Copy number ZNF416 0.89 EGFR 0.98
ZNF134 0.88 ZC3HC1 0.98
CHMP2A 0.88 FAM133B 0.98
ZBTB45 0.88 CDKN2A 0.97
ZNF584 0.88 CDKN2B 0.94
ZNF548 0.87 MTAP 0.93
RPL28 0.85 FNDC3A 0.93
EGFR 0.84 CDK4 0.91
ZNF175 0.84 NEK3 0.91
ZNF432 0.81 SUGT1 0.90
Methylation ERBB2 0.98 KCNK1 1.00
KCNK1 0.98 MTCP1 1.00
POU4F3 0.98 CXCL5 1.00
TSPAN2 0.98 HAPLN3 1.00
HAPLN3 0.98 ERBB2 0.99
RPL7A 0.96 FLNB 0.99
MTCP1 0.95 TBX1 0.99
CXCL5 0.95 TSPAN2 0.99
CCDC109B 0.93 RPL7A 0.98
TBX1 0.89 ONECUT2 0.97
finger proteins are involved in transcription and gene expression regulation [25], and
as such have been identified to play a role in cancer development. The top-10 re-
sults from the methylation dataset contain two genes that are known to be involved
in ovarian cancer: epidermic growth factor ERBB2 and the potassium channel pro-
tein KCNK1. ERBB2 is known to be involved in glioblastoma tumour development
[40] although ERBB2 methylation has not been reported before. KCNK1 has been
previously mentioned to be down-regulated in glioblastoma and ovarian cancers [43].
4.2.4.3 Ovarian cancer
Copy number alterations seem to be less important for the ovarian cancer patient
groups, with lower vote scores (Table 4.3) than those observed for breast and glioblas-
toma tumours. Still, for the good-outcome group we found amplified KRAS, a known
oncogene and FKBP4 involved in immunoregulation. Both genes are members of
the estrogen signaling pathway [22]. The top-ranked copy number aberrations for
the bad-outcome group contain the cell cycle protein kinase CDK7, PSMB1 (part of
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the proteasome multicatalytic proteinase complex) and the TATA-box binding protein
TBP. Interestingly, all are involved in HIV infection [22]. Ovarian cancer, or at least
the subtypes MUNDIS identified, seem to be driven mainly by mutations. Both patient
groups share TP53 and BRCA1 as mutated drivers. Many of the top-ranked mutations
for the good-outcome patient group (tumor suppressor RB1, protein coding RHOA,
tumor suppressor SP100, transcription factor co-activator CREBBP, TP53) have been
implied in viral carcinogenesis [22]. The bad-outcome group contains, next to BRCA1
and TP53 also NF1, a negative regulator of the ras signal transduction pathway. Again
only a few previously reported genes were identified using the methylation data. The
good-outcome group contains heat shock proteins HSPA1L and HSPA2, and the bad-
outcome group contains CALML5. All three genes are involved in estrogen signaling
[22]. HSPA1L and HSPA2 are members of the HSP70 gene family that plays a role in
tumour survival [44].
4.2.5 Networks
The aim of subnetwork delineation is to link upstream pathway perturbations (cor-
responding to the identified drivers) to downstream effects (e.g. expression effects).
Using MUNDIS, it is possible to extract subnetworks for individual patients. By merg-
ing patient specific subnetworks into a consensus subnetwork, the presumed molec-
ular mode of action of a subtype can be determined (see Materials and methods).
Figures 4.9-4.11 show for each of the subtypes studied in this work the connected
components of the obtained subnetworks. To assess the statistical significance of these
subtype-specific networks, we constructed a distribution for the size of the largest con-
nected component (see Materials and methods). The probability of finding by chance
a network with a size of the largest connected component equal or larger than those
displayed in Figures 4.9-4.11 was smaller than 10−4 for all subtypes.
4.2.5.1 Breast cancer subtypes
The subnetworks confirm to a large extent the findings of the previous sections. For
the Basal subtype, a prominent role of mutated TP53 and several overexpressed cell
cycle-related genes (e.g. NEK2 and NUF2, [45]) is found. The Luminal A subnetwork
contains, next to TP53, mutated MAP3K1, MAP2K4, PTEN, PIK3CA and AKT1, all
genes that are well known to be involved in Luminal breast cancers [3]. Figure 4.9
illustrates how the genes selected from the prior knowledge network (blue genes) are
essential for connecting groups of genes: e.g. parts of the Basal and the Luminal
A subnetworks are connected through the EP300 and E2F4 transcription factors, key
players in cell cycle regulation and apoptosis [46, 47].
4.2.5.2 Glioblastoma multiforme
For each of the survival-related molecular subtypes identified earlier, we extracted a
subnetwork containing the most relevant genes using the same methodology as for
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Table 4.3: Driver gene prioritization using MUNDIS for the ovarian good- and bad-outcome
patient groups. Top 10 genes per datatype and the fraction of patients for which the gene was
selected (Votes) are shown.
Good outcome Bad outcome
Gene Votes Gene Votes
Copy number USE1 0.55 PDCD2 0.80
NCBP2 0.48 TBP 0.80
WDR53 0.48 TCP1 0.80
ITPA 0.40 MRPL18 0.80
KRAS 0.40 PSMB1 0.78
C19orf53 0.40 NIP7 0.71
DYNC1LI2 0.38 CDK7 0.67
CSNK2A1 0.36 BTF3 0.66
FKBP4 0.36 DYNC1LI2 0.62
MRPL34 0.36 WIPI2 0.59
Mutation RHOA 1.00 BRCA1 1.00
RB1 1.00 CCR3 1.00
SP100 1.00 CYP11B2 1.00
TP53 1.00 NF1 1.00
IRS4 1.00 PDE6C 1.00
EPHX1 0.95 SPTB 1.00
GLI2 0.95 TP53 1.00
CA1 0.93 ITGA8 1.00
CREBBP 0.93 CDK12 1.00
BRCA1 0.86 PGAP1 0.99
Methylation ACY1 1.00 ACY1 1.00
ALOX12 1.00 ALOX12 1.00
CYP17A1 1.00 CYP17A1 1.00
HAL 1.00 HAL 1.00
HMGCS2 1.00 MEOX1 1.00
HSPA1L 1.00 VHL 1.00
HSPA2 1.00 PSCA 1.00
MEOX1 1.00 PER3 1.00
PTK6 1.00 CALML5 1.00
VHL 1.00 FXYD4 1.00
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Figure 4.9: Consensus networks for the Basal-like, and Luminal A PAM50 breast cancer sub-
types. Gene size is a function of the number of patients a gene was selected for. Gene fill, type
and border color is a function of the dataset(s) the gene was found in to be deviating from nor-
mal behavior (over- or under-expression, mutation, copy number alteration or hyper- or hypo
methylation, see legend). Blue genes are genes that were selected from the prior knowledge
network.
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the breast cancer subtypes. The resulting subnetworks are displayed in Figure 4.10.
Compared to the breast cancer subnetworks, the extracted networks are of similar size.
They show only little overlap with the breast cancer subnetworks, confirming that tu-
mour development and proliferation in these tumour subtypes are governed by differ-
ent mechanisms. There is a limited amount of overlap between the good-outcome and
bad-outcome subnetworks of the same tumour type.
Figure 4.10: Consensus networks for the good- and bad-outcome patient groups identified by
MUNDIS for glioblastoma tumours. Gene size is a function of the number of patients a gene was
selected for. Gene fill, type and border color is a function of the dataset(s) the gene was found
in to be deviating from normal behavior (over- or under-expression, mutation, copy number
alteration or hyper- or hypo methylation, see legend). Blue genes are genes that were selected
from the prior knowledge network.
The glioblastoma subnetworks both are centered around EGFR signaling, which
is well known to be involved in glioblastoma tumour development [40, 41]. Next to
amplified EGFR, both the the networks contain chromatin binding factor CTCF (often
co-localizing with cohesin [48]) and RAD21, a part of the cohesin complex, essential
for error-free DNA repair [49]. The networks differ mainly in the presence of AKT1,
MDM2 and MDM4, which are only found for the bad-outcome patient group.
4.2.5.3 Ovarian cancer
The subnetworks obtained for the good- and bad-outcome ovarian cancer patient groups
both contain CTCF exhibiting copy number loss and mutated TP53 (Figure 4.11).
Both groups exhibit low-frequency mutations in BRCA1. Two main differences can
be found between the patient groups. First, several genes pertaining to the ovarian
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steroidogenesis pathway [22] are present for the bad outcome group: adenylate cy-
clase ADCY8, CYP17A1 coding for an enzyme of the cytochrome P450 superfamily,
protein kinases PRKACA and PRKACB, and STAR, coding for a steroid regulatory
protein. Ovarian steroidogenesis is responsible for the production of progesterone, a
suppressor of ovarian cancer [50]. A second difference is found in the presence in
the good-outcome group of several members of the HLA family of genes, all involved
in antigen processing and presentation [22]. The expression of several of these genes
have been found to correlate with ovarian cancer prognosis [51].
Figure 4.11: Consensus networks for the good- and bad-outcome patient groups identified by
MUNDIS for ovarian tumours. Gene size is a function of the number of patients a gene was
selected for. Gene fill, type and border color is a function of the dataset(s) the gene was found
in to be deviating from normal behavior (over- or under-expression, mutation, copy number
alteration or hyper- or hypo methylation, see legend). Blue genes are genes that were selected
from the prior knowledge network.
4.3 Discussion
We have presented MUNDIS, a data model capable of incorporating different types
of molecular data allowing for an integrated, multi-purpose yet single-tool analysis.
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The central idea behind MUNDIS, a global network representation that includes prior
knowledge and individual patients, allows for many applications that previously would
have required several different tools.
The subtypes produced by the unsupervised application of MUNDIS to ovarian
cancer and glioblastoma multiforme patients correlate highly with patient survival.
Closer investigation of the glioblastoma stratification revealed that the two MUNDIS
subtypes do not coincide with an existing molecular subtype classification [19, 30],
but rather define a general low- and high-risk class of patients. The G-CIMP subtype
is the only previously defined subtype that is fully contained in the MUNDIS low-risk
patient group. When comparing to the results produced by naive approaches and by
iCluster, an existing method for data-integration [31, 52], we were able to demonstrate
the added value of MUNDIS, and data-integration in general.
Application of the pathway ranking application of the MUNDIS framework to the
previously identified glioblastoma subtypes revealed several pathways that are impor-
tant for both the good- and the bad-outcome patient group. Examples are focal ad-
hesion, adherence junction, cytokine-cytokine interaction and ERBB signaling. The
HIF-1 signaling pathway was differentially scored between the two subtypes. The
correlation between its rank and patient survival is likely explained by its crucial role
in tumour angiogenesis [32]. When pathway ranking was applied to the ovarian good-
and bad-outcome subtypes, a less clear image arises. We found the Wnt-signaling and
chemokine interaction pathways to be top-ranked for both subtypes. Additionally, we
observed a striking increase in the general score for the good-outcome patient group.
We argued that this is likely caused by the imbalanced sample size of the good- and
bad-outcome patient groups. The pathway ranking aggregate score should be adjusted
for the sample size in order to obtain truly analysis-independent pathway importance
scores.
As a means of validation, a driver gene prioritization analysis was performed first
on the well studied Basal and Luminal A breast cancer PAM 50 subtypes. Both sub-
types are known to be governed by different genetic and epi-genetic disturbances.
MUNDIS was able to recapitulate to a large extent what is known about genetic and
epi-genetic aberrations in these subtypes. The Basal subtype analysis identified a.o.
mutated TP53 and BRCA1, and amplified MYC as drivers. The Luminal A analysis
put forward mutated AKT1, RUNX1, CDH1, MAP3K1, PIK3CA, PTEN, MAP2K4
and TP53, amplified CCND1 and MYC, and hyper-mythylated SFRP1. Many of these
genetic and epi-genetic aberrations are known to occur in mutual exclusive combina-
tions only [3, 9], confirming the added value of the network-based approach.
The glioblastoma driver analysis confirmed the importance of amplified EFGR for
this tumour type, especially for the bad-outcome patient group. We could further link
the presence of amplified CDKN2A, CDKN2B and CDK4 to poor survival rates. For
both patient groups, methylated KCNK1 and ERBB2 were prioritized. Both genes
have been implicated in cancer, yet methylation of these genes in glioblastoma tu-
mours has not been reported before. Mutations seemed to be more important than copy
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number alterations for the ovarian cancer subtypes. Drivers included mutated TP53
and BRCA1 for both subtypes. Many of the selected genes for the good-outcome
patient group could be related to viral carcinogenesis.
The sub-networks constructed for the subtypes of the different cancer types ana-
lyzed in this work recapitulate to a large extent the findings of the different MUNDIS
applications. By additionally including the most relevant genes from the prior-knowledge
gene interaction network, separate modules of driver genes and differentially ex-
pressed genes could be linked. This was clearly illustrated for the Basal and Luminal
A breast cancer subtypes. The networks constructed for both subtypes include the
EP300 and E2F4 transcription factors as central genes around which the prioritized
drivers and differentially expressed genes cluster. The glioblastoma networks for the
survival-related subtypes are centered around EGFR signaling, but differ in the pres-
ence of AKT1, MDM2 and MDM4 for the bad-outcome patient group. The ovarian
cancer networks all contain CTCF and mutated TP53. The bad-outcome patient group
contains a module of several members of the steroidogenesis pathway whereas the
network for the good-outcome patient group contains a set of genes related to antigen
processing and presentation.
Summarizing, the results in this study indicate that with the global approach of
MUNDIS, it is not only possible to delineate meaningful subtypes, but also to explain
why subtypes were formed, using a unified analysis approach at the level of individual
genes, pathways or networks. In addition, the method is versatile and can easily be
extended to include e.g. miRNA or proteomics data.
4.4 Materials and methods
4.4.1 MUNDIS: A multi-purpose network-based data integration
strategy for tumour analysis
Key to the method is the previously developed [16] representation of all available
data in a single network (referred to as the global network). This network contains
all entities under study (i.e. patients, differentially expressed genes, genes containing
mutations, ...) and their mutual relations derived from either the data themselves or
prior knowledge in the form of a gene interaction network. Using this global network
representation, we calculate a similarity measure that expresses the degree to which
network entities are related to each other. Those similarities are subsequently used to
assess the different sub-problems. An overview of the method is given in Figure 4.1.
4.4.1.1 Global network construction
To construct the global network we use gene expression, mutation, methylation, and
copy number data. Prior information is incorporated as a gene interaction network.
The global network is constructed by translating each of the available datasets to rela-
tions (edges in the network) between entities (nodes in the network) (Figure 4.1). All
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relations are treated qualitatively, i.e. edges in the network are unweighted. To this
end, all datasets are made binary (Figure 1-a, see Data section): ones correspond to ei-
ther over- or under-expression, copy number amplification or loss, mutation or hyper-
or hypo-methylation, and zeroes correspond to normal expression, normal copy num-
ber, the absence of mutations or a normal methylation pattern. Network construction
consists of the following steps:
1. Compile the union (net1-net8 in Figure 4.1) of the genes found in all datasets
and the prior knowledge network, and add known interactions between these
genes. Some genes may not be connected to any other gene at this point.
2. Add an additional node to the network for each gene (row) in the binary expres-
sion, mutation, methylation, and copy number datasets, and add a node for each
patient found in these datasets. Some of the newly added nodes will correspond
to the same gene, yet they represent a different state of that gene, i.e. the gene
is differentially expressed, contains a mutation, or has an altered copy number
or methylation value.
3. Create a link between a patient node and one of the newly added gene nodes if
the entry in the binary dataset for this gene-patient combination is set to one.
4. Link the genes from the binary expression, mutation, methylation, and copy
number datasets to the network nodes.
Note that the newly constructed global network no longer corresponds to a physi-
cal or functional gene interaction network. The global network will be used to measure
the degree of pair-wise connectedness between all entities (both gene nodes and sam-
ple nodes) in the network. Although in principle certain edges in the obtained network
are directed, we will treat the network as undirected. This allows constructing a sym-
metric adjacency matrix representation of the global network in which all (binary)
data sets, except for the already undirected prior knowledge network, are inserted
twice (Figure 4.1-c).
4.4.1.2 Network-based similarity calculation
The adjacency matrix representation (Figure 4.1-c) of the global network is used to
derive a measure of connectedness (a network similarity) between all network enti-
ties, summarized in the global similarity matrix (Figure 4.1-d). Similarity measures
based on shortest path calculations would be an intuitive choice, but these measures
have been shown to underperform especially when data are incomplete or of unknown
reliability [53, 54]. Because of their good performance [54–57], we used kernels
calculated on graph nodes as similarity measure (for details, we refer to the Graph
node kernel section). Every entry in the global similarity matrix reflects the degree of
connectedness between two single entities, e.g. between a single patient and a single
over-expressed gene, or between a gene in the prior knowledge network and a mutated
gene.
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4.4.1.3 Applications of the global similarity matrix
We can now address the different sub-problems raised in the introduction by focusing
on different parts of the global similarity matrix. For subtyping, for instance, we focus
on that part of the global similarity matrix that contains the patient-patient similarities
derived using all information coded in the global network (submatrix SPP in Fig-
ure 4.1-d). Clustering patients based on this submatrix then results in patient groups
that are based on all available molecular information, including the prior knowledge
network. The submatrix thus replaces the distance matrix that otherwise would tradi-
tionally have been obtained from e.g. expression data only.
For pathway importance assessment, driver gene prioritization and subnetwork
delineation, values from the submatrices SPN , SPE , SPMut, SPC and SPMet (Fig-
ure 4.1-d) are used. These values represent the similarities between the considered
patients (e.g. patients of the same subtype) and genes in the prior knowledge network,
or genes measured in respectively the expression, mutation and copy number dataset.
It is important to note that although each entry in these submatrices expresses a simi-
larity between a patient and a gene present in any of the aforementioned datasets, the
similarity itself is calculated taken into account all entities in the global network. By
calculating - for each gene present in either the expression, mutation, copy number
or methylation dataset - an aggregating statistics (mean) over the patients of interest,
we obtain a raw score that expresses the average importance of the given gene (being
either a differentially expressed, mutated, amplified or methylated gene) for the given
patient group.
When assessing pathway importance, we want to identify which pathways - con-
taining active or inactive genes, mutated genes, genes with altered copy number or
hyper- or hypo-methylated genes - are more relevant for a group of patients than
others. The pathways of interest should be available as sets of genes. Rather than
analyzing the individual scores of the genes in the pathway (analogous to driver pri-
oritization), a single score per data type is obtained by averaging the raw scores of all
the genes in the pathway for each data type. These average scores can be converted
to p-values reflecting the probability of observing at least the obtained score by pure
chance. This is achieved using a random score distribution constructed by repeatedly
sampling genes randomly from the submatrices SPE , SPMut, SPC and SPMet and
calculating the corresponding average statistic per data type. The final integrated path-
way score is obtained by simply multiplying the p-values of the different data types.
If one is interested in how a pathway was affected by one of the data types only e.g.
genetic and epigenetic modifications (and not in its activity or suppression), it is of
course possible to multiply only the p-values associated with those data types. We
refer to [16] for a comprehensive overview of the pathway ranking procedure.
The task of driver gene prioritization involves, for a group of patients with simi-
lar phenotype (e.g. those belonging to the same subtype), the selection of the genes
whose genetic or (epi-)genetic alterations have most likely given the tumour cell its
growth advantage over normal tissue. Consequently, we focus here on the similarities
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in the submatrices SPMut, SPC and SPMet containing similarities between patients
and respectively mutated genes, genes with altered copy number and hyper- or hypo
methylated genes. Using these similarity values, for each sample and for each datatype
separately, the top 20 genes that are most similar to the sample node are selected. The
per-sample gene selections are then merged and it is counted how many times each
gene was selected. The (relative) number of times a gene was selected was used as a
voting score metric to produce a final driver ranking per datatype. Because we did not
use an edge weighting scheme, the similarity measure tends to be slightly biased to-
wards larger datasets: the more genes in a dataset, the higher the similarities for these
genes tend to be. Therefore we adopted a stratified approach where per data type, a
separate ranking of genes was produced.
Subnetwork delineation extracts a biological context for a single patient or a group
of patients. Because each row of the submatrices SPE , SPMut, SPC and SPMet in
Figure 4.1-d corresponds to similarities for a single patient, it is possible to select for
each patient the most important genes per data type, in a way similar to the driver
prioritization decribed above. The similarities in submatrix SPN can be used to iden-
tify the most important network genes. A subnetwork per patient then is obtained by
mapping the gene selection for each patient to the original prior knowledge network.
The individual patient subnetworks are subsequently averaged using a simple voting
mechanism where e.g. only genes that were selected in 20% of the networks will be
allowed in the final consensus network. The prior knowledge gene interaction net-
work serves both as a visualization template and a filter: if indeed the selected genes
participate in the same biological processes, they are likely to be connected in the in-
teraction network. Large connected components in a network thus are an indication
that the gene selection was of good quality.
4.4.2 Data
The ovarian cancer and glioblastoma multiforme datasets were downloaded from TCGA
in April 2014, and contained mRNA, mutation (only for ovarian cancer), methy-
lation and copy number data for respectively 447 and 302 patients. We did not
use the glioblastoma mutation data as the limited patient overlap between all data
types would then restrict survival analysis. For breast cancer, mRNA, mutation and
copy number data were downloaded from The Cancer Genome Atlas (https://tcga-
data.nci.nih.gov/tcga) in November 2012, and methylation data were downloaded in
October 2013. 463 patients had data points for all data types and were retained in
the final analysis. These patients belonged to either the Basal, HER2, Luminal A or
Luminal B PAM50 subtype. In this work, only patients belonging to the Basal and
Luminal A subtype will be used, but the other patients are used to performed more
robust preprocessing. Below we elaborate on the preprocessing and filtering of the
mRNA, methylation, mutation and copy number datasets. All gene identifiers were
mapped to Entrez gene identifiers. Genes that could not be mapped were left out of
the analysis.
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4.4.2.1 mRNA expression
For breast cancer, genes were selected based on their within tumour variability and
their differential expression relative to normal samples. For each gene a normal dis-
tribution was fitted using the normal expression samples and z-scores were calculated
for the tumour samples [58]. To capture potential interesting expression variability, we
evaluated the 5- and 95- percentile of the tumour samples. Genes in which the p-value
for these percentiles was below 0.001 and their log-fold change relative to the mean
normal expression was at least 2.5 were selected [59]. The final dataset contained
1,674 genes. For glioblastoma and ovarian cancer, only a small number of matching
normal samples was available so the procedure used for breast cancer could not reli-
ably be applied. Instead, all genes from the mRNA datasets that were also present in
the prior knowledge network (see below) were retained resulting in 4,296 genes for
both cancer types.
4.4.2.2 Mutation data
For breast cancer, per PAM50 subtype, the mutation data was preprocessed and filtered
using MutSig [8]. In order to obtain a broad selection (with a possibly high number of
false positives), we used unadjusted p-values with a cut-off of 0.05. This is different
from the approach of the Cancer Genome Atlas Network [3] where prior to further
analysis, MuSiC [7] was used to obtain 37 Significantly Mutated Genes. As one of the
goals of this work was to evaluate if the presented data representation could be used to
identify subtypes or prioritize driver genes, the broad lists of selected genes obtained
for each subtype were merged. Our final mutation dataset contained 465 mutated
genes with Entrez identifiers. For the ovarian cancer dataset, a similar procedure was
employed (without using any subtype information) resulting in 327 genes.
4.4.2.3 Copy number data
Copy number data for breast cancer, ovarian cancer and glioblastoma multiforme were
processed identically. Significant copy number regions were identified with GIS-
TIC2.0 [60] using the same parameter settings as in TCGA breast cancer overview
[3]. The final dataset contained 446, 2,806 and 2,802 genes for respectively breast
cancer, ovarian cancer and glioblastoma. Data were further filtered by requiring a
minimum positive correlation between the copy number values and the corresponding
expression measurements (see Parameter Tuning and Implementation).
4.4.2.4 Methylation data
The methylation data were downloaded from TCGA and filtered using the procedure
and parameters described in the ovarian cancer study of the Cancer Genome Atlas
Network [26]. Summarizing, hyper-methylated genes are kept in the data set only if
the following conditions are fulfilled (parameters correspond to respectively relaxed
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and strict settings in the filtering procedure). (1) In normal tissue, the gene should
only slightly be methylated (< 0.5, < 0.4). (2) The 90th percentile methylation
level of tumour samples should be considerably higher (0.1, 0.3) than the average
normal methylation level. (3) The average gene expression of normal samples should
be considerably lower (2, 3 fold) than the average gene expression of the 10% highest
methylation levels in tumour samples. (4) There should exist a negative spearman
correlation (< −0.2, < −0.3) between the methylation level and the gene expression
level. For hypo-methylated genes, the parameters are adjusted in a trivial way. Note
that probe selection (based on the maximum negative correlation between Beta values
and gene expression) and mapping of probes to genes was performed by the TCGA
consortium. Applying this procedure resulted in 624 hyper-methylated and 270 hypo-
methylated genes for breast cancer, 42 hyper-methylated and 173 hypo-methylated
genes for ovarian cancer, and 432 hyper-methylated and 494 hypo-methylated genes
for glioblastoma multiforme. Because of the lack of matching normal samples, the
glioblastoma dataset was run with the relaxed parameters only.
4.4.2.5 Network data
KEGG pathway data [22] were downloaded on October 17 2013 using the KEGG
REST-API functionality. 210 non-disease pathways were merged to constitute a sin-
gle network. Because of its size and connectivity, the global metabolic pathway was
left out. Complexes and group entities in the KEGG topology were expanded using
dummy genes (with unique identifiers) that were connected to the individual genes
constituting the group or complex. Interacting genes with such groups or complexes
are thus connected to the dummy genes rather than with the constituting genes. In
general, all non-gene entities were present in the network and were given unique iden-
tifiers ensuring optimal connectivity. Because we want to capture and use patterns of
regulation, we also added explicitly transcription factors and their targets. Transcrip-
tion factor - target interactions were obtained from http://encodenets.gersteinlab.org/
which is part of the ENCODE project [27]. Only interactions based on proximal TFBS
data were included in the final network. The final network contained 6,035 genes and
46,097 interactions. It should be emphasized that the network did not include the
pathways from the KEGG disease database as we did not want the network to be bi-
ased towards cancer related pathways. The final network can be downloaded from
http://bioinformatics.intec.ugent.be/mundis.
4.4.3 Graph node kernel
Similar to previous work [16], we used the Laplacian Exponential Diffusion (LED)
kernel. We refer the reader to [28] for a comprehensive overview of graph node ker-
nels. The LED kernel is calculated as follows:
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L = D −A
D(i, i) =
n∑
j=1
A(i, j)
KLED = exp(−αL)
with n the number of entities in the global network, D the degree matrix and
A(i, j) entry j on row i of the global network’s adjacency matrix A. The exp-operator
indicates the matrix exponential. Calculating KLED results in a similarity matrix with
the same size as the original global adjacency matrix. Additional normalization of the
similarity matrix is performed by exploiting some of the kernel properties of a kernel
matrix K with elements kij :
KN (i, j) =
kij√
kii.kjj
(4.1)
4.4.4 Parameter tuning, data binarization and implementation de-
tails
For the stratification of ovarian and glioblastoma patients, a completely unsupervised
approach was adopted in order to
1. set the thresholds required to make the mRNA, copy number and methylation
data binary
2. determine the kernel parameter
3. determine the number of patient strata
Analogous to the iCluster tuning strategy [31], the parameter tuning strategy is
based on the optimization of the block-like structure of the similarity matrix after re-
arranging the matrix using the obtained clusters (Figure 4.12). For each patient cluster,
three statistics are calculated: the correlation (ρi) between the values (using the entire
rows) in the similarity matrix and the values in the ideal block-like structure, the stan-
dard deviation of the values inside a cluster (σi), and the mean (µi) of the values in
a cluster. The final score is then calculated as max(ρi.µi/σi). The following param-
eters were varied: kernel parameter α[0.0005, 0.001, 0.01], number of clusters [2, 3],
quantile thresholds for absolute values of mRNA expression, copy number and methy-
lation: [0.8, 0.9, 0.95, 0.99]. Prior to binarization, an additional filtering of the copy
number data was performed by calculating the correlation (for each gene) between the
copy number and the mRNA values. Only genes with the 5 % highest correlations
were kept. The parameter combination with the highest score was considered the final
solution.
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Figure 4.12: Structure of the patient-patient similarity matrix. The obtained structure is com-
pared to the ideal block-diagonal structure for a given 3-class patient stratification.
For the breast cancer analysis of the existing PAM50 subtypes, a different ap-
proach was adopted. Paired tumour/normal samples were available that allowed for a
more informed choice of the parameters used. Expression data were made binary by
applying a threshold of 2 to the absolute value of the data centered on the means of
the normal samples. Genes were retained in the copy number dataset if the correlation
between the copy number signal and the mRNA expression signal for that gene was
positive (assuming negative copy number values for deletions) and larger than 0.2, or
if more than 20 samples had a copy number larger than 3 (or smaller than -3). The
copy number dataset was made binary by selecting only copy number values with an
absolute value larger than 1. For the methylation data, whenever we observed a 5-fold
raise (drop) in methylation level for hyper (hypo)-methylated genes when compared
to normal samples, the (gene, patient) entry of the binary matrix was set to 1. As a
result, for the breast cancer analysis, the method only contains a single quantitative
parameter, i.e. the LED kernel parameter. Analogous to the kernel parameter found
by the unsupervised tuning strategy for GBM subtyping, we used a value of 0.01.
MUNDIS was implemented in Matlab, and run on a 16-core, 64bit CentOS 6.2
system with 128GB of memory. Source code and sample data is available from
http://bioinformatics.intec.ugent.be/mundis/. The calculation of the matrix exponen-
tial determines running time and memory usage which are known to be O(n3) and
O(n2) respectively, with n the number of entities in the global network. To reduce
running time and memory requirements, the global adjacency matrix was compressed
by merging the mRNA expression dataset with the prior knowledge network, resulting
in a substantial reduction of problem size. The problem size N was further reduced by
filtering out all genes / entities that could not be related to either a gene in expression
dataset or in the prior knowledge network. On the system used, calculation of the
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global similarity matrix was finished in less than 5 minutes.
4.4.5 Patient subtyping using iCluster and naive methods
In order to optimize executing time, the iCluster 2 algorithm [31] was re-implemented
in Matlab. We validated our implementation by applying it to the example glioblas-
toma data provided with the iCluster publication, using identical parameters as in the
reference R implementation [31]. As a result, we obtained a three class patient strati-
fication with a log-rank p of 1.1× 10−2 (Figure 4.13), which is identical to the figure
mentioned in the iCluster study[31]. iCluster was evaluated on the ovarian cancer and
glioblastoma datasets using mRNA expression, copy number and methylation data.
When comparing MUNDIS with iCluster, rather than using the built-in parameter
tuning strategy of iCluster, we allowed iCluster to use parameters that were optimized
(using a three dimensional parameter sweep in [0.1, 0.7], in steps of 0.1) for minimum
log-rank p.
Figure 4.13: Validation of the iCluster implementation. Three patient classes were distin-
guished using identical parameters as used in the iCluster glioblastoma study [31].
In order to assess the added value of MUNDIS and data integration in general,
a stratification in three classes was performed for each data type separately, for the
ovarian cancer and glioblastoma multiforme datasets. This was achieved by applying
a hierarchical clustering algorithm using an Euclidean distance metric and a minimum
variance linkage (Ward’s) algorithm to the continuous data matrices (as opposed to
the binary data used by MUNDIS) of each data type / cancer type combination. Addi-
tionally, all data available for a single cancer type were concatenated to form a single
stack of data that was subsequently clustered using the same hierarchical approach.
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5
Relating biomass and bioenergy-related
traits in Eucalyptus to genes and
pathways using a integrative
network-based approach
In this final chapter, the idea of diffusing information through a network of previ-
ously described gene interactions is applied to a typical GWAS setting. Low-resolution
eQTL data are merged with gene expression data, using an approach inspired by re-
cent cancer research that is very similar to the work described in the previous chap-
ters. The integrated data model is then used to link genes to a set of highly complex
biomass- and bio-energy-related eucalyptus traits.
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Abstract A better understanding of the molecular basis of biomass and bioenergy-
related traits will provide a major opportunity for a sustainable energy and biomateri-
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als economy. Because of their remarkable adaptability, fast growth and superior wood
properties, eucalypts provide key renewable resources for the production of pulp, pa-
per, biomaterials and bioenergy and are therefore the most widely planted hardwood
forest trees in the world. However, plant growth, density and cell wall properties
all represent complex traits, and the nature of this complexity has not been fully ex-
plored. Systems genetics, integrating different sources of information (e.g. transcripts,
proteins, metabolites, etc.) in populations that vary for traits of interest, has proven
effective for understanding complex traits. Here, we have applied a novel network-
based data integration method for the systems level analysis of genes, processes and
pathways underlying biomass and bioenergy related traits using segregating hybrid
Eucalyptus populations. We show that biologically meaningful sets of genes can be
linked to complex traits. Based on these gene selections, trait clusters and hierarchies
could be delineated. We found that the genes in the sets identified for each trait tend
to cluster in network neighborhoods and are enriched for molecular functions strongly
linked to xylan metabolism and cell wall development. These findings offer novel av-
enues of research for identifying important molecular drivers of variation in complex
biomass and bioprocessing-related traits.
5.1 Introduction
A plant’s amenability to bioprocessing is dependent in part on its aggregate biomass
properties, which are a composite of cellular architecture (e.g. cell type and cell-
cell interactions), as well as secondary cell wall ultrastructure and chemistry. These
determinants of cellular architecture are steered by a network of overlapping devel-
opmental programs that are sequentially activated during xylogenesis [1, 2]. A major
goal of biomass-related biotechnology is to implement rational approaches for strate-
gic intervention, ranging from improving on current properties, to engineering novel
polymers or structures [3, 4]. However, biotechnological interventions have proven
to be challenging, since many modifications either have negligible or a deleterious
effect on normal development [5–7]. Indeed, although traditional approaches like
single gene knockouts in Arabidopsis thaliana have revealed essential components in
the biomass-enhancing network (for example the irregular xylem mutants, reviewed
in [8, 9]), they have not necessarily yielded insight into genes that naturally affect
cell wall chemistry/ultrastructure in more subtle ways without interfering with plant
growth, form and biomass accumulation.
GWAS approaches may reveal putative loci with large effects on biomass and
biomass processability [10], but these would typically explain only a small proportion
of complex trait variation. Arguably, the strongest move towards capturing the maxi-
mum genetic contribution to these traits can be seen in new generation of plant breed-
ing methods, where genomic selection application in trees prioritize 200-300 genomic
loci that together contribute significantly in pushing traits in subsequent generations
[11–13], although here the identity of specific genes or the contribution of specific
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pathways remains unknown. In addition, the efficacy of these methods is still subject
to each trait’s heritability, and the relative relationships of genetic factors (pleiotropy,
additive effects and epistasis), environmental effects, and interactions between these
(G x E). Improvement of these complex traits for any downstream application is there-
fore going to benefit from insight gleaned from reverse engineering of secondary cell
wall formation and biopolymer deposition.
Trees are ideal models for lignocellulosic biomass accumulation, as the majority
of sequestered carbon is channeled and irreversibly synthesized in wood as cellulose,
hemicellulose and lignin. The current and future bioeconomy is going to increasingly
rely on a sustainable supply of woody biomass from fast-growing tree crops suitable
for processing. Today, Eucalyptus is the most planted hardwood genus (approximately
22M Ha worldwide). Eucalyptus inherently has relatively short rotation time, small
genome size, tremendous genetic diversity and established breeding populations, pedi-
grees and clones, and as such is ideally suited for biotechnological improvement [14–
16]. This applies to trait improvement for current applications in fibre and chemical
cellulose (mainly concerning growth, wood and biotic/abiotic stress-related traits), but
in today’s environment it is also important to be prepared for advanced genetic engi-
neering and novel synthetic biology applications that can take advantage of a strong,
relatively homogenous carbon sink.
Despite the importance and multiple studies exploring growth, biomass accumula-
tion in and carbon extraction from trees apart from some known inverse relationship
between polysaccharide and phenolic content of wood the interactions between the
pathways underlying these traits remains underexplored. Here we utilize a segregating
pseudo-backcross population of an E. grandis x E. urophylla pedigree to construct a
systems genetics model by integrating information from the developing xylem tran-
scriptomes of 154 trees with complex growth, biomass accumulation and processing
traits. Since the primary driver of phenotypic variation in this population is genetic
variation, we do this using a novel integration method relating complex and com-
ponent trait variation and quantitative trait locus sharing. This systems view reveals
new relationships between complex traits, identifying genes and pathways impact-
ing lignocellulosic biomass and its utilization, and provides insight into their relative
contribution and roles as major, synergistic or antagonistic drivers of complex traits
impacting industrial importance. These findings offer novel avenues of research for
identifying molecular drivers of variation in complex biomass and processing-related
traits.
In particular, we consider gene expression variation in xylem as partial determi-
nants of this complexity. This is done by integrating information that includes vari-
ation in complex traits and component traits, but also the genetic component of this
variation, using a quantitative trait-locus prioritization approach. In doing so we de-
scribe a new algorithm for network-based data integration (NBDI), which should have
broad application in a wide variety of systems genetics analyses where multi-level
data are available.
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A novel approach for studying gene-trait relations is required because the tradi-
tional GWAS setting, where genetic differences in a large, highly segregated pop-
ulation are linked to quantitative traits, is not applicable here [17, 18]. The traits
under study are highly complex, and the marginal effect of individual genetic poly-
morphisms on these traits is generally too small to surpass a statistical threshold.
Additionally, because of linkage disequilibrium and limited genetic variation in the
population, the genetic resolution of a GWAS approach is too low to allow for linking
polymorphisms to individual genes. An alternative approach, where the expression
of genes is directly linked to a quantitative trait, is suboptimal, because it does not
include genetic information and consequently does not distinguish between environ-
mental and genetic factors influencing a trait. The NBDI method we present here
adopts a network-diffusion idea applied previously in cancer studies [19–22]. First
an eQTL analysis is performed, followed by the identification of pairs of genes that
exhibit overlapping eQTL. Gene expression information is then diffused through a
network containing prior information in the form of known gene interactions and ge-
netic information in the form of eQTL overlap relations. The diffused gene expression
that contains both prior knowledge and genetic information is then finally related to
the traits under study.
5.2 Results
5.2.1 Network-based gene-trait association
Data were collected and combined from 156 Eucalyptus F2 hybrid trees, which con-
sisted of gene expression variation in immature xylem, gene expression (e)QTL in-
formation, and complex trait variation in broad categories of growth, wood density,
cell wall biopolymers and sugar extractability (Table 5.1, see Materials and Methods
for more detail). To identify the molecular mechanisms underlying each of the dif-
ferent traits, we followed an integrative approach that allows maximally exploiting
the available data (Figure 5.1). The genotyping, expression phenotyping and prior
network information are simultaneously used in order to reliably prioritize genes that
can be associated with each of the traits under study. To achieve this, we adapted a
network-based data-integration approach that was successfully applied earlier in the
context of tumor analysis [19, 20, 22]. To this end, prior information (such as known
pathways of interacting genes) or eQTL associations are converted to a sample inde-
pendent gene-gene connectivity network. In this network, nodes are genes and edges
represent two types of information. If derived from prior information, edges are gene-
gene interactions retrieved from a reference database. Additional edges are derived
from eQTL associations: genes connected by an edge have been associated with the
same genomics locus based on their expression profile (they share the same eQTL).
On a per sample basis, gene expression data is subsequently diffused through this
gene-gene connectivity network.
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Figure 5.1: An overview of the network-based diffusion of gene expression. Letters a − f
represent genes, q1−q3 are eQTL and S1−S3 are tree samples. (a) Prior knowledge and eQTL
data are summarized in two network representations. (b) The combination of the two networks
is used to construct a gene connectivity matrix reflecting how well genes are connected to each
other (bright color = high connectivity, dark color = low connectivity). (c) The relevant part of
the connectivity matrix is used to diffuse gene expression data through the network in order to
obtain network-diffused gene expression.
124 CHAPTER 5
This results in a data transformation from the gene expression space to the network-
diffused gene expression space (Figure 5.1). In this network-diffused gene expression
space, each data point (a value for a particular gene-sample combination) now inte-
grates information from the expression of the gene itself as well as from the expression
of other genes that are found in the local neighborhood of the gene in the combined
eQTL and gene-gene connectivity network. The diffused gene expression signal of
a gene can be interpreted as the original gene expression signal that is modulated
by the expression signal of its neighbors in the network. Once the gene expression
is diffused through the network, conventional correlation analysis is used to identify
relevant genes for each trait under study.
Associating NBDI transformed expression values to each of the traits allows for
ranking, per trait, genes of potential relevance to the trait (see Table 5.1). A set of
reference genes compiled from literature (see Materials and Methods) was used to test
to what extent gene sets, predicted to be associated with the traits, were enriched in
these reference genes.
We also performed the same associations, but now using the untransformed ex-
pression profiles instead of the network-diffused gene expression. The raw expression
values of genes were associated with individual traits using classical gene expression
correlation analysis (see Materials and Methods). Figure 5.2 illustrates to what extent
the combined genes selection (the union of all gene sets that were selected for each
individual trait, or alternatively, the set of unique genes that were linked to at least one
trait) for either approach (NBDI or classical correlation analysis) are enriched for the
compiled set of reference genes. Because of the correlation between traits, gene se-
lections obtained for individual traits will overlap to some extent. The combined gene
selection corresponds to the genes that associate with general differences in phenotype
between the testes samples, without focusing on a particular trait. As can be seen, the
NBDI approach greatly outperforms the classical correlation analysis in term of en-
richment probability, regardless of how many genes per trait are selected. Thus, using
the NBDI approach, more reference genes are selected. Together with the fact that
gene selections overlap more between traits, and thus that in general the set of unique
genes linked to at least a single trait is smaller, this results in a stronger enrichment
for reference genes.
Even though selecting fewer unique genes (in the combined gene selection) im-
proves the significance of the hypergeometric enrichment test performed, the scenario
where for each trait each time the same reference (and non-reference) genes are se-
lected should be avoided. This would indicate that the method’s network-based gene
expression transformation associates to an average (or a single) phenotype, and cannot
be used to find distinctive sets of genes that are relevant for different traits. To test this,
we additionally calculated the enrichment probability and several statistics as a func-
tion of the number of unique genes in the combined gene selection (Figure 5.3). In the
extreme case where each time the same genes are selected, the number of unique genes
in the combined gene selection would be identical to the number of genes selected for
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Figure 5.2: Enrichment probability (p-value obtained using a hypergeometric enrichment test)
of the combined selection (the set of genes linked to at least one trait) as a function of the
number of genes selected per individual trait. See text for details.
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each individual trait. On the other hand, if the genes selected for each trait are mutu-
ally exclusive, then the number of unique genes in the combined gene selection would
equal the number of genes selected times the number of traits analyzed. Figure 5.3-top
illustrates the enrichment for reference genes as a function of the size of the combined
gene selection, rather than as a function of the number of selected genes per trait. The
enrichment probability of the NBDI approach continues to outperform the classical
correlation approach, indicating that the increased enrichment significance for NBDI
is not simply explained by the fact the less unique genes are selected. If that were the
case, then the NBDI enrichment probabilities should drop when the combined gene
selection contains more unique genes.
NBDI does tend to produce gene selections that overlap more than correlation
analysis (Figure 5.3, bottom). When 300 genes per trait are selected, 41% unique
genes are selected by NBDI vs. 49% by correlation analysis. Note that because of
the correlation structure of the traits, a substantial amount of overlap between the
gene selections is to be expected. The increased overlap between gene selections is
caused by the diffusion of the gene expression through the network. The expression
of genes that are close in the network will be a function of the expression of the genes
in the immediate network neighborhood of that gene. The longer the gene expression
is allowed to diffuse through the network (as controlled by the diffusion parameter,
see Materials and Methods section), the larger the local neighborhood will be that
is used to calculate the diffused gene expression, and the higher the gene selection
overlap will be. Our selection for the diffusion parameter is a compromise between
mutual exclusivity of gene selections and the desired influence of the network. The
number of genes found by gene expression correlation analysis that are also found by
the NBDI approach increases when more genes are selected. Conversely, the number
of genes that are only linked to a single trait decreases when more genes per trait are
selected.
The claim that NDBI analysis outperforms gene expression correlation analysis is
further supported by Figure 5.4, where the enrichment probability as a function of the
number of selected genes is calculated for each trait individually. In this figure, it can
be seen that the Density trait is the only trait for which classical correlation analysis
scores are on par with the NBDI approach, with p-values (for 300 selected genes per
trait, see Table 5.1) of 6.52 × 10−10 and 5.49 × 10−12 for NBDI and correlation
analysis respectively.
For the Lignin, Total C5 sugar in walls and Total C6 sugar in walls traits, NBDI
outperforms correlation analysis by several orders of magnitude, but even for the
NBDI analysis the enrichments are not significant, with NBDI p-values of 0.28, 0.1
and 0.1 for Lignin, Total C5 sugar in walls and Total C6 sugar in walls respectively
(Figure 5.4, Table 5.1). This does not necessarily indicate that the gene selections
made by NBDI (or by conventional correlation analysis) are meaningless: it is pos-
sible that the reference gene set used is lacking a sufficient number of differentially
expressed lignin reference genes, or alternatively, that the variation of the Lignin trait
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Figure 5.3: Top: Enrichment probability (hypergeometric test) of the combined selection (all
genes selected for all traits) as a function of the total number of genes selected. Bottom: frac-
tion of the number of genes linked to only a single trait, fraction of genes found by classical
correlation analysis that are also found using the NBDI approach and the fraction of unique
genes found by NBDI and correlation analysis as a function of the number of selected genes per
trait.
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Figure 5.4: Enrichment probability (p-value of a hypergeometric enrichment test) of the refer-
ence genes selected for each individual trait as a function of the number of genes selected for
the results obtained using the correlation based (CORR) and network-based (NBDI) methods.
is due to noise or is confounded by factors that cannot directly be related to gene ex-
pression. The gene selections for glucose released, Xylose released, Glucose+Xylose
released, % of max xylose release, % of max glucose released and % of max sugar
released are all several orders of magnitude more significant for the NBDI approach
when compared to gene expression correlation analysis (Table 5.1). When e.g. 300
genes per trait are selected, the number of selected reference genes is 1.7 (for Glu-
cose+Xylose released) to 3.0 (Xylose released) times higher for NBDI than for corre-
lation analysis.
Finally, Figure 5.5 demonstrates, for each trait separately, how the NBDI approach
retains genes that are top-score by classical gene expression correlation analysis in
the top of its ranking. However, simultaneously, the NBDI approach also prioritizes
reference genes that are ranked lower by classical correlation analysis. For all but he
Density trait, NBDI analysis will rank a subset of the top-ranking correlation-based se-
lection substantially higher. This subset will typically contain many reference genes,
resulting in the observed enrichment improvements reported in Figure 5.4. Interest-
ingly, there appears to be a linear relation between the rank of a reference gene in the
130 CHAPTER 5
gene expression correlation analysis and the rank obtained with NBDI analysis. This
can be explained by the fact that, because of the nature of the network-based transfor-
mation, the diffused gene expression still correlates with the original gene expression.
The slope of this linear relation is an indicator of how well NBDI is prioritizing refer-
ence genes. The Density trait is the only trait where the observed slope is steeper than
one (depicted by the diagonal line in Figure 5.5). This is consistent with our earlier
finding that the enrichment for reference genes in the gene selection the Density trait
is comparable to that obtained by gene expression correlation analysis.
Summarizing, the integrative network-based method results in a more biologically
relevant (in terms of the prioritization of reference genes) ranking of trait-associated
genes than a gene-trait association that would have been based on mere expression
data. This is to be expected as we associate a gene to a trait only if its association
is confirmed by its neighbors in the eQTL and/or interaction network. This criterion
imposes a modularity concept to the association as a gene can only be associated to a
trait provided members of the same pathway and/or genes mapping to the same eQTL
as the gene of interest can also be associated to the same trait. Using modules of
co-expressed genes is common practice in gene expression analysis. The added value
of the NBDI approach lies in the use of implicit modules for each individual gene.
Instead of assigning many genes to the same module, here for each gene separately, a
local network neighborhood is used to construct a network-averaged gene signal for
that gene.
We decided to select 300 genes per trait to produce the results discussed in the
remainder of this study. This number yields results that are sparse enough to remain
interpretable, but that demonstrate a highly significant enrichment for reference genes.
In total, 1,529 different genes were selected, of which 102 were found in the reference
set (pNBDI = 1.38 × 10−21). Classical correlation analysis using this number of
selected genes results in 1,892 different genes containing only 93 reference genes
(pCorr = 2.29×10−12). About half of the genes found by classical correlation analysis
(0.53) are also found by the NBDI approach. Table 5.1 gives an overview of the
enrichment for reference genes for each trait separately, when 300 genes per trait were
selected. For all but the Lignin, Total C5 sugar in walls and Total C6 sugar in walls
traits, highly significant enrichments were found.
5.2.2 Identification of trait associated genetic loci
To further validate our results we investigated whether the eQTL, associated to the
genes selected by the NBDI approach for each trait separately, cluster together in
hotspots. If the assumptions holds that the observed variance in phenotype can be ex-
plained by the limited genetic variability introduced in the population, then the eQTL
linked to the genes selected for a trait should at least partially coincide. To test this
for each trait, the eQTL related to the genes selected for that trait were collected and
a density estimator was applied to the list of eQTL positions to identify regions that
are enriched for eQTL. This was achieved using a Gaussian kernel density estima-
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Figure 5.5: Relation between the ranking of genes obtained by the network-based approach
(NBDI) and a classical gene expression correlation analysis (CORR). Blue dots correspond
to genes not present in the reference set, reference genes are marked in red. The blue lines
correspond to the threshold used in the remainder of this study (n = 300). A gene on the
dashed diagonal line is ranked equally by the NBDI and CORR methods. Genes below the
diagonal line received a lower rank when using NBDI than when using CORR. For each trait
individually, only the 2000 top-ranked genes are shown.
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tor (band-with=0.05), where the eQTL density for each chromosome was sampled
in 1024 locations. QTL that were previously identified (See Material and Methods
section) were overlaid with the obtained densities. Ideally, at least some of the QTL
should overlap with the density peaks found, as this would provide additional evidence
that the gene selection is relevant for the trait under study. Note that we expect many
additional peaks to emerge that cannot directly be linked to trait QTL. The traits under
study are complex and most likely governed by epistatic processes. To find trait QTL,
sources of genetic variation were analyzed in isolation (only their marginal effect is
considered); consequently, very few loci could be identified.
The results of this analysis is shown in Figure 5.6. The figure shows how the se-
lected genes for each trait consistently associate to the same set of genomic loci. This
illustrates how the NBDI approach effectively uses the eQTL information to priori-
tize genes: if a gene shares a locus with other genes (the genes exhibit overlapping
eQTL), then the network-diffused gene expression of that gene will be a combination
of the gene expression of the gene itself and the genes it shares an eQTL with. For
all traits, several distinct peaks are found, some of which coincide with the location
of loci known to directly associate with the traits, further confirming that the gene ex-
pression signal is a true molecular reflection of the trait. In many cases the gene-trait
based association identified an additional set of loci that were not recovered by the
marker associations.
Most striking is the presence of 2 distinctive peaks in chromosome 10 for all traits
but the Lignin and Total C6 sugar traits who exhibit only the first of the two peaks.
Trait QTL for DBH(ob), Bark thickness and Density were found previously on chro-
mosome 10 in the immediate neighborhood of these peaks. For DBH(ob), DBH(ub),
Total C5 and Total C6 sugar, two peaks are found on chromosome 6. These peaks
coincide with previously identified trait QTL. For the Density trait, only a single small
peak on chromosome 6 is found, even though many QTL on this chromosome are
present. All traits (except for Lignin, % of max xylose release and Total C6 sugar)
exhibit a strong peak close to the start of chromosome 9 and a peak in chromosome 3
(absent for the Density trait). Especially for Bark thickness, the peak on chromosome
3 coincides with a trait QTL. In general, the number of distinctive peaks is lowest for
the Density and the Lignin traits. This could indicate that the observed variability for
these traits is due to only a limited number of genetic factors. An alternative expla-
nation is that the biological processes underlying these traits are very complex, and
that a few very influential individual factors together with many low-impact sources
of genetic variability are explaining the observed phenotype.
5.2.3 Inter-trait relations
Figure 5.6 already showed how, based on their prioritized loci, some traits share the
same eQTLs. To quantify how traits relate to each other, we determined their simi-
larity in terms of overlap of trait-associated genes. Figure 5.7 displays the pairwise
relations between traits based on their shared number of associated genes. When a
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Figure 5.6: Relative density (calculated using a Gaussian kernel density estimator) of eQTL
associated to the selected genes for each trait. QTL associated to the traits are indicated as
circles. For some traits, no QTL could be identified. Density estimates are normalized.
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hierarchical clustering algorithm is applied using the overlap statistics as a distance
metric, several traits cluster together. We found 3 broad clusters: (1) a group related
to carbon in cell walls containing the Total C5 and C6 sugar in cell wall traits, (2)
a group related to carbon release efficiency containing the xylose, glucose and sugar
release related traits and (3) a cluster containing the growth related DBH and bark
thickness traits. Lignin, density and % of max xylose release are set apart by the clus-
tering algorithm. To test whether the obtained trait relations were independent of the
number of selected genes per trait, we reran the analysis with different numbers of
genes being selected per trait and showed that within a reasonable certain range of
thresholds the trait-trait relations were not affected (data not shown).
We observed numerous antagonistic relationships between gene expression of genes
associated with C release, as compared to density and growth. This is plausible, as
faster growth is linked to lower density and depending on the contributors to overall
density, lower wood density can lead to improved cell wall accessibility. We interro-
gated genes positively associated with sugar release but negatively associated with (on
the one hand) density, and (on the other hand) growth. Based on gene annotation, we
interpret the results as follows: genetic perturbations leading to improvement in sugar
release efficiency from wood are associated with higher expression of secondary cell
wall biosynthetic genes, including especially secondary cell wall middle tier transcrip-
tion factors [23], glucuronoxylan and monolignol biosynthesis. Interestingly, these
were antagonistically associated with Growth, as in the case of transcription factors
(MYB103, SND2) shown to be independently sufficient for increasing cell wall de-
position in Arabidopsis [24], as well as several auxin response factors, which could
indicate a tradeoff between cell differentiation and secondary cell wall deposition.
Expression of glucuronoxylan biosynthetic and acetylation genes was positively asso-
ciated with carbon release efficiency but negatively associated with both density and
growth, while monolignol synthethesis was positively associated with carbon release
efficiency but negatively associated only with growth. In the case of the interplay be-
tween sugar release and density, F5H was positively associated with sugar extractabil-
ity, a relationship proven before in transgenic poplars overexpressing the gene [25],
while it was negatively associated with density.
Figure 5.8 illustrates the relation between traits based on the overlap of selected
genes for each individual trait using an affiliation network representation. Again, 300
genes per trait were selected. In the affiliation graph, two traits are connected if the
gene selections for the two traits overlap for at least 10 percent. A standard force-
directed network layout algorithm was applied to the network to produce Figure 5.8.
The figure confirms the broad trait clusters found by the hierarchical, overlap-based
clustering discussed above.
5.2.4 Trait specific prioritized gene sets
In the above analysis, we focused on inter-trait relations and on the more general prop-
erties of the gene selections produced for each trait. Here, for a selection of traits, we
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Figure 5.7: Grouping of the traits based on the number of overlapping genes in their respective
gene selections (hierarchical clustering, single linkage
Figure 5.8: Inter-trait relations based on the overlap between gene selections (300 genes per
trait) for individual traits (blue circles). Links are drawn between traits whose gene selections
overlap for at least 10%. Link width and color is a function of the number of shared genes
between two traits. Trait size is a function of the number of other traits a trait is linked to.
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investigate the individual genes that were identified by the NBDI approach. The gene
selections for each trait can be mapped back to the network that was used to calculate
the diffused gene expression. A network per trait is obtained by keeping only those
genes in the network that were present in the gene selection for that trait. Connections
between genes (originating from either prior knowledge pathway information or from
eQTL-sharing relationships) are selected if both genes that are connected are present
in the gene selection for the trait. The resulting networks are highly connected, as the
eQTL overlap procedure produces many eQTL-overlap relations. This is in turn is due
to the relative low genetic resolution of the marker dataset that was used to associate
genetic loci with gene expression signals. As many of these eQTL-overlap relations
may be false positives, we decided to further refine the network generation procedure
by using the curated prior-knowledge gene interactions (derived from KEGG [26]) as
a back-bone for the resulting networks (see Materials and Methods).
As an example, networks for the DBH(ob), Bark thickness, Lignin and Glucose
released traits are shown in Figure 5.9, containing respectively 39, 33, 48 and 28
genes from the original 300 selected genes per trait. The reason that so few genes
remain in the per-trait networks is that the prior knowledge network used here only
contains 5,288 genes, severely limiting the number of genes that could be selected by
the NBDI procedure. All networks obtained are very significant (see Methods), with
p-values smaller than 10−23, 10−22, 10−32 and 10−17 for respectively the DBH(ob),
Bark thickness, Lignin and Glucose released traits, illustrating how the underlying
gene interactions and overlapping eQTL relations are integrated in the NBDI analysis.
Additionally, we analyzed the enrichment for particular biological functions of
the gene selections per trait. Figure 5.10 displays, for each trait, how enriched the
gene selection is for gene ontology terms. Only terms from the biological process
class were selected. The p-values in the figure are adjusted for multiple testing using
standard false discovery control. Note that only the top-10 most enriched GO terms
(for each trait) are shown in the figure.
The most striking observation to be made from the figure is the similar enrich-
ment profiles of all but the % of xylose release, Lignin and C5 and C6 sugar in walls
traits. The large block of similar traits is characterized by xylan-related terms and
cell wall biosynthetic processes. Xylan is a major constituent of the dicot secondary
cell wall [8, 18] and as such, xylan related processes are expected to determine wood
properties. DBH and Density traits form a subclass in this block because they lack
enrichment for the serine family and acid biosynthetic process, for photosynthesis and
for cysteine biosynthetic and metabolic processes. Second, genes participating in the
phenylpropanoid process are found for Bark thickness, Xylose release and for the DBH
related traits. Phenylpropanoid related processes are involved in cell wall formation
and lignin biosynthesis [27]. Interestingly, the genes associated with the lignin trait
are not particularly enriched for this term. The lignin trait shows enrichments that are
similar to those of total C5 and total C6 sugar in walls.
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Figure 5.9: Individual trait networks for the Density, Bark thickness, Lignin and Glucose re-
leased traits. Networks were generated by selecting 300 genes per trait and filtered based on
interactions present in KEGG (solid lines). Additional eQTL-based edges were added when
present (dashed lines). Due to the incomplete mapping between the Arabidopsis and the Euca-
lyptus genome, gene symbols may be present multiple times.
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Figure 5.10: Enrichment of GO terms (biological process) of the genes selected for each trait.
For each trait, the top 10 GO terms were selected. Values are log10 p-values obtained using a
hypergeometric enrichment test. Terms are sorted according to the minimum (over all traits)
observed p-value.
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5.3 Conclusion
The variability of most quantitative traits is not explained by the activity of a single
gene, but rather by the activity of a combination of genes (a pathway) that interact
closely with each other. We hypothesized that incorporating gene interaction knowl-
edge in the analysis of traits in relation to gene expression has an added value over
conventional approaches where the gene expression of a gene is treated in total iso-
lation of the expression of other genes. For instance, correlation analysis, linking a
quantitative trait to the gene expression of individual genes, might fail or be incom-
plete if the trait under study is controlled by the expression of multiple genes that in
turn can be influenced by the expression of different genes, etc.. If this is the case, then
any method that captures only the marginal effect of a gene on a trait might render only
a partial view of the genes that are involved in the underlying biological processes.
First we constructed a network containing prior knowledge information derived
from public gene interaction repositories. We then supplemented this network with
additional gene relations derived from an eQTL analysis. If two genes share an eQTL,
they are connected in the network as an implicit co-regulation mechanism is assumed.
Gene expression was then diffused through this network to obtain a transformed gene
expression dataset. The diffused expression value for each gene-sample combination
now integrates the gene expression value of the gene itself with the gene expression
values of the genes found in the network neighborhood of that gene. The diffused
gene expression is then correlated with several complex wood-related traits.
We demonstrated the added value of our approach (NBDI) by comparing it with a
naive gene expression-based correlation approach. We found that NBDI outperformed
the naive approach in terms of reference genes that could be recovered by our method.
When the eQTL associated to the genes selected for each trait were mapped on the
genome, we found that they form clusters rather than being randomly distributed.
Several of these clusters of eQTL coincide with QTL that were obtained for the traits
under study, but that were not used in the analysis. As such, they could serve as an
independent validation of the results.
A deeper analysis of the genes selected for each trait allowed for the grouping
of traits in biologically relevant classes. Additionally, we found that the genes se-
lected for each trait tend to form subnetworks in the gene interaction network used
in the analysis. This confirms the method’s ability to integrate network information
in the analysis, but also is a biological validation of the results obtained, as the genes
involved in the traits under study are expected to be part of pathways that govern
complex biological processes.
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5.4 Materials and methods
5.4.1 Experimental population, transcriptome profiling and com-
plex trait analysis
The previously described [28] F2 backcross population generated from a cross be-
tween an E. grandis x E. urophylla F1 interspecific hybrid parent (GUSAP1, Sappi
Forest Research, South Africa) and an unrelated E. urophylla parent (USAP1), were
planted in 2005 near KwaMbonambi, KwaZulu-Natal (Sappi, South Africa). At three
years old, immature xylem tissue was harvested from 156 individuals for RNA se-
quencing analysis as previously described [29]. Samples were collected from three-
year-old trees over a 7.5 hour period between 09:00 and 16:30 for three days. Total
RNA was isolated (as described in [30]) and used for RNA-Seq expression profiling
(30 million, Illumina PE50, BGI Hong Kong). Gene expression values (fragments per
kilobase of coding sequence per million mapped fragments, FPKM) were calculated
per gene model using TopHat version 1.3 and Cufflinks version 1.0.3 (bias correction
and quartile normalization was enabled for the FPKM calculation) [31, 32].
Diameter (cm) at breast height (DBH) of the main stem was assessed in 2009 as
described previously [33, 34]. Bark thickness was calculated as the difference be-
tween over bark and under bark DBH measurements. A wood disk taken at breast
height (1.35 m) was used to determine wood basic density using the water displace-
ment method (http://www.tappi.org/). Chemical wood properties were assessed using
different analytical methods including pyrolysis molecular beam mass spectrometry
(pyMBMS).
5.4.2 Trait QTL and eQTL mapping
A high-density genetic linkage map consisting of 130 DArT markers was previously
constructed for this population [28]. QTL and eQTL mapping was conducted us-
ing QTL Cartographer [35]. Expression traits were analyzed as parallel tasks on a
computer cluster at the Centre for Bioinformatics and Computational Biology at the
University of Pretoria. A walking speed of 1 cM was used in composite interval
mapping (CIM) with forward regression and backward elimination (p-value = 0.1).
Permutation-based likelihood ratio score thresholds were calculated to globally ap-
proximate α=0.05 experiment-wise [36].
5.4.3 eQTL classification and overlap analysis
eQTL that were located further than half the average size of an eQTL from the lo-
cation of its linked gene, often on a different chromosome, were classified as trans-
eQTL. Only trans-eQTLs, in contrast with cis-eQTL typically representing promoter
polymorphisms (or polymorphisms located close to the gene itself), were used in this
study. A typical example of a trans-eQTL is a polymorphism in a regulator (e.g. a
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Figure 5.11: The eQTL-eQTL overlap score calculation. The score range from 0 (indicating no
overlap) to 1 (indicating identical peak positions and perfect overlap).
transcription factor), influencing the expression of a group of downstream genes act-
ing in the same pathway. These genes will have shared trans-eQTL at the position of
the regulator and are likely co-regulated.
In order to construct the eQTL network, an all versus all eQTL overlap analysis
were performed. Pairs of eQTL were classified as having no overlap (when the two
eQTL regions did not overlap at all), partial overlap (when both eQTL peaks were
not inside the overlapping region) or full overlap (when both eQTL peaks were inside
the overlapping region) (Figure 5.11). A ”hybrid” eQTL overlap score was calculated
for each pair of eQTLs. The overlap score (OS) is called a ”hybrid score” as it uses
a decimorgan (dM) scale for cases where there is partial overlap and a morgan (M)
scale for cases where there is full overlap. This hybrid scale was implemented as a
centimorgan (cM)-based overlap score seemed to place most of the weight on distance
between peaks, a M-based overlap score did not differentiate enough between small
and large overlap and a dM-based overlap score (which seemed to be a good com-
promise) scored cases of full overlap where one QTL is embedded within another for
different sized eQTLs too low. The different overlap scores are calculated as follows
(see also Figure 5.11):
Scoreno overlap = 0
Scorepartial overlap =
Size (dM) of overlapping region+1
Total size (dM) covered by eQTL region+1
Distance (dM) between eQTL peaks+1
Scorefull overlap =
Size (M) of overlapping region+1
Total size (M) covered by eQTL region+1
Distance (M) between eQTL peaks+1
(5.1)
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5.4.4 Reference gene set
To benchmark the performance of the network-based approach in prioritizing genes
of true relevance, we compiled a literature based set of reference genes with known
biological role in secondary cell wall synthesis. These included E. grandis homologs
of known transcription factors involved in secondary cell wall (reviewed in [23]), sec-
ondary cell wall carbohydrate metabolism genes [14] and monolignol biosynthesis
genes [37], which showed preferential and/or high (90th percentile of expression level)
in E. grandis xylem [14, 38]. In total, the reference set contains 542 genes, of which
353 were present in the eQTL-prior knowledge network (only genes present in this
network can be linked to traits by the NBDI procedure).
5.4.5 The NBDI procedure
5.4.5.1 Combined network construction
In a first step, a network incorporating prior knowledge and eQTL information is con-
structed (Figure 5.1-a). For the prior knowledge, we used KEGG Arabidopsis thaliana
pathways (([26], downloaded on March 2014) mapped to E. europhylla gene identi-
fiers. The interaction network contains 5,288 genes and 158,411 gene interactions.
Next to adding gene interactions to the global network, we also want to include the
information captured in a large scale eQTL analysis described above. The available
eQTL data consist of a list of gene-locus associations that is converted to an eQTL-
overlap network first. For 12,988 genes, in total 17,930 eQTL were detected. As each
eQTL refers to a genetic location that represents a considerable region of a chromo-
some, we first calculated the eQTL overlap criterion, assessing to what degree two
eQTL overlap using an overlap score ranging from 0 to 1. By truncating the obtained
overlap scores (overlap≥ 0.2) we were able to identify couples of genes that are likely
influenced by the same genetic variability. These couples were then treated as regular
gene interactions (orange links in Figure 5.1-a), even if the interaction expresses an
is coregulated with relation instead of an is interacting with relation. Finally, the two
networks are merged to constitute the combined network displayed in Figure 5.1-b
(left).
5.4.5.2 Gene connectivity calculation
Once the combined network is constructed, it is possible to calculate a metric that
captures how well a gene node is connected to the other gene nodes in the network.
The assumption is that such a metric will be representative for how similar, or rel-
evant a gene is to another gene. Connectivity measures based on shortest path cal-
culations would be an intuitive choice, but these measures have been shown to un-
derperform, especially when data are qualitative, incomplete or of unknown reliability
[39]. Because of their good performance [40–42], we used kernels calculated on graph
nodes. A great multitude of kernels on graph nodes exist (see [42] for a comprehensive
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overview). Preliminary experiments suggested that the Laplacian Exponential Diffu-
sion (LED) kernel yields stable results. It is calculated on the weighted Laplacian
matrix L as follows [42]:
L = D −A
D(i, i) =
n∑
j=1
A(i, j)
KLED = exp(−αL)
(5.2)
Here n is the number of entities in the global network, D is the diagonal degree
matrix and A(i, j) represents entry j on row i of the global network’s adjacency ma-
trix A. KLED(i, j) contains, at time t = α, the quantity found in node i when a
unit quantity starts diffusing from node j at t = 0. The exp-operator indicates the
matrix exponential. All experiments in this work were carried out using 0.5 as the
α-parameter. Before further analysis, the kernel values are normalized using
KN (i, j) =
kij√
kii.kjj
(5.3)
5.4.5.3 Diffusion of gene expression through the network
First, the available gene expression data are filtered to contain only genes that are
present in the combined network. In total, 15,097 genes were retained. The appro-
priate part of the gene connectivity matrix is extracted, as it can contain genes that
are not present in the gene expression dataset (Figure 5.1-b). Next, the diagonal of
the connectivity matrix is increased by one, ensuring that the original gene expression
signal will be at least partially present in the final diffused data. By multiplying the
gene expression matrix with the filtered gene connectivity matrix (Figure 5.1-c), the
network-diffused gene expression is obtained.
In Figure 5.12, the effect of network-based expression diffusion is illustrated for a
number of genes that are known to participate in the biological processes underlying
the traits under study. Whether the diffused expression of a gene correlates highly with
the original gene expression depends on the network connectivity of the gene and the
expression values of the genes found in the network neighborhood of that gene. The
less a gene is connected to other genes in the combined network, the less the raw gene
expression will be influenced by the expression values of neighboring genes.
5.4.5.4 Linking diffused gene expression to quantitative traits
The network-diffused gene expression signals can be related to quantitative trait val-
ues using techniques that are conventionally used to relate gene expression to a trait.
In this case, we use the (pearson) correlation between a gene’s diffused expression
and the trait values for each sample to select the genes that are relevant to the trait.
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We decided to select, for each trait, the genes with the highest absolute value of the
correlation obtained using the NBDI approach.
5.4.5.5 Constructing trait-specific subnetworks
The construction of trait-specific networks involves three steps. First all genes that are
not present in the prior knowledge network are removed from the network, together
with all eQTL overlap relations. Next, all genes that are not present in the gene selec-
tion for a trait are removed. Finally, eQTL overlap relations that connect the remaining
genes are added.
The size of the largest connected component is considered indicative for the bi-
ological significance of the obtained networks. High quality gene selections are ex-
pected to cluster together in the interaction network used to diffuse the gene expres-
sion, whereas a random gene selection should contain only small clusters of intercon-
nected genes. A background distribution of the size of the largest connected com-
ponent in the obtained subnetworks was constructed by applying the network con-
struction process described above for 10,000 random gene selections. Afterwards, a
Poisson distribution was fitted to model this background distribution and to assess the
probability that an observed size for the largest connected component of a trait-specific
network would be obtained purely by chance.
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6
Conclusion
“Progress is impossible without change, and those who cannot change their minds
cannot change anything.”
–George Bernard Shaw (1856 - 1950)
In this thesis, we demonstrated the use of networks of interacting genes for tack-
ling a range of problems in the field of computational biology. More specifically, we
addressed the four concrete challenges put forward in the Introduction section:
1. (e)QTL prioritization: When genetic variation is linked to a quantitative trait
in a QTL or eQTL analysis, often the genetic resolution of the analysis is too low
to identify the individual gene whose genetic diversity is causing the observed
phenotypic variation. Instead, loci linked to phenotype are representative for a
large region on a chromosome and consequently, this region can overlap with
many genes. The process of ranking these candidate genes according to the
likelihood that the genetic variability of gene is responsible for the observed
phenotypic variation is called QTL (and if the phenotype is gene expression,
eQTL) prioritization.
2. Separating environmental and genetic factors in correlation analysis: If the
resolution of the available genetic is even lower, or the genetic variation in the
dataset at hand is limited, (e)QTL prioritization techniques might not be appli-
cable. In order to identify genes involved in complex traits, one could revert to
correlating (in the broad sense) gene expression directly to complex trait data.
Unfortunately, since phenotypic variation is influenced by environmental fac-
tors too, such a direct approach can not guarantee that the identified genes are
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mechanistically involved in the trait under study because genes and traits might
co-vary under different environmental conditions.
3. Analyzing traits in clonal systems that exhibit mutual exclusivity patterns:
if a complex phenotype (e.g., tumour development) is caused by the malfunc-
tioning of a pathway of interacting genes, then the genetic or epigenetic alter-
ation of a single gene present in the pathway is sufficient to create the observed
phenotype. Because of the clonality of the system (each cell is essentially iden-
tical to its ancestors), it is extremely unlikely that a sample (e.g., a tumour cell)
has more than a single altered gene. The necessary condition to create the phe-
notype (e.g., the (epi)genetic disturbance that gave a tumour cell a fitness ad-
vantage) was already present after the alteration of the first gene. Additional
alterations will not create additional fitness advantages. Consequently, these
secondary alterations will not, by means of selection mechanisms, disseminate
in the population. This mechanism (the mutual exclusivity of driver genes) will
lead to samples that exhibit the same phenotype, but that are diverse in the dis-
turbances that lead to the phenotype. It greatly complicates the statistical task
of identifying the genes linked to the phenotype.
4. Analyzing a phenotype using different types of data: with the advent of cost-
effective high-throughput techniques, data can be acquired faster and cheaper
than ever. Samples are simultaneously analyzed using different analysis plat-
forms that each produce datasets of a different data type. These different types
of omics data (e.g., mutation, copy number variation or gene expression data)
are mostly analyzed separately, as each data type require a specialized set of
tools and techniques. Such parallel analysis risks missing out on patterns of
complementarity between the different available data types. Since the mutual
exclusivity of genetic disturbances in clonal systems is not limited to mutation
data, integrative analysis in combination with a network-based approach ap-
pears to be a requirement for obtaining a mechanistic understanding of these
phenotypes.
Each challenge was translated to a real-world problem in computational biology.
Depending on the challenge, we developed methods that operate on different types
and combinations of yeast, plant and human data. The common denominator of all
these techniques is the use of a network of known gene interactions as the backbone
of the analysis. More specifically, we used an objective measure of connectivity in
these networks as a proxy for functional similarity between genes, or to quantify the
relevance of a gene for a sample or a set of samples. Below, we list the main research
contributions of this work, and summarize how we addressed each of the challenges.
We conclude by suggesting logical tracks for future research.
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6.1 Major research contributions
Here we list the main contributions of the presented work:
• We have presented an eQTL prioritization technique with superior performance
when compared to naive and established techniques. Especially the idea of
first delineating a local network before any subsequent analysis takes place is
innovative.
• We developed a unified framework, with proven performance, for tumour analy-
sis that can be used for pathway ranking, patient subtyping, driver prioritization
and sub-network delineation. Any data type that can be converted to a binary
representation can be integrated, together with prior knowledge in the form of
curated gene interactions.
• We introduced the idea of diffused gene expression as an alternative to using
gene expression modules as a powerful way to increase the statistical power of
subsequent correlation analysis. We additionally presented an alternative way
to incorporate eQTL data in the analysis.
• All methods presented make use of a network-based connectivity measure that
either acts as a proxy for gene function similarity, or as a metric that quantifies
how relevant a gene is for a particular sample or patient.
6.2 Summary
To address the eQTL prioritization challenge, in chapter 2 we presented EPSILON
(eQTL Prioritization using SImilarity measures derived from LOcal Networks), a
framework for eQTL prioritization that prioritizes a number of candidate genes over-
lapping with an eQTL, based on their functional similarity with the target gene asso-
ciated with the eQTL. First we performed three types of eQTL mapping, linking yeast
SNP data to gene expression data [1] using respectively non-parametric regression,
mixed models and elastic net regression. After compiling a curated network of gene
interactions from multiple sources [2–5], we constructed for each combination of an
eQTL and a target-gene a local network (using an intuitive k-shortest path method)
that connects the candidate genes in the eQTL with the target gene. Next, a con-
nectivity metric was calculated to quantify how well each of the candidate genes is
connected to the target gene. This was done using several kernels calculated on graph
nodes. The candidate genes in the eQTL were than ranked according to how well
they connect to the target gene. The quality of the produced rankings was evaluated
using an independent knockout compendium. We compared our approach with naive
approaches (random assignment and shortest path) and established techniques (ITM
Probe [6] and eQED [7]). We could conclude that:
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• Both naive and established approaches were outperformed by our method. The
network connectivity metrics used proved highly useful for quantifying how
well genes connect to each other in the network. The success of the method
suggests the validity of the most fundamental assumption in this work, i.e. net-
work connectivity is representative for functional similarity.
• The construction of a local network was essential to the correct prioritization of
candidate genes, suggesting that the negative influence of over-connected genes
and unreliable connections can be effectively mitigated. Additionally, in the
construction of the local networks, directional information was used, possibly
restricting the local networks to more biologically-relevant neighborhoods.
• The prioritization results obtained for the different eQTL association techniques
are highly variable, suggesting a strong dependence of the prioritization results
on the quality of the eQTL association.
• The prioritization quality is only marginally depending on the network edge
weight-scheme applied, and in the absence of reliable edge weights, one can
revert to a qualitative weighting scheme that simply indicates the presence / ab-
sence of an interaction between genes rather than trying to quantify how strong
or reliable an interaction is. This realization was important, as objective, sen-
sible edge weights are hard to obtain. Unweighted networks were used in all
consecutive research.
The second challenge, separating genetic from environmental factors in cor-
relation analysis, was tackled in chapter 5 where we prioritized genes according to
their relevance for a number of complex, wood- and biomass-related traits of euca-
lyptus trees. Datasets containing gene expression, eQTL, QTL and trait data were
integrated using a network diffusion method. First, a network of A. thaliana gene
interactions [8] was mapped to the Eucalyptus species. Then, the available low res-
olution eQTL data were converted to an eQTL network representation by calculating
an overlap criterion for all combinations of eQTL. In the eQTL network, two genes
are connected if they are associated to eQTL that significantly overlap. The eQTL
network was merged with the gene interaction network, and again a network connec-
tivity metric was calculated. This time, the network connectivity was used to diffuse
the gene expression data through the network. The resulting diffused gene expression
was subsequently correlated with the traits under study to identify the most relevant
genes for each trait. We validated the results obtained using the QTL data and a
literature-based compendium of references genes that are known to be involved in the
traits under study. To put the method into perspective, we compared our approach to
correlation analysis of non-diffused gene expression data. Our major findings include:
• Our approach greatly outperformed the gene expression-based approach. The
resulting gene sets obtained using our method were much more enriched for
reference genes than those using the naive approach.
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• When the traits under study are grouped based on the overlap between the gene
sets selected for these trait, three biologically relevant clusters emerge: (1) a
group related to carbon in cell walls, (2) a group related to carbon release effi-
ciency and (3) a cluster containing the growth related traits.
• The selected genes tend to form subnetworks in the gene interaction network
used in the analysis. This indicated that the proposed method is effectively
incorporating network information in the analysis.
• The eQTL associated to the genes prioritized for each trait tend to cluster to-
gether, and to some extent, overlap with QTL (directly linking loci to traits)
that were not used in the analysis and as such can be used as an independent
validation of the results.
• Functional analysis of the gene sets identified for each trait indicated that the
selected genes are involved a.o., in (secondary) cell wall biosythesis and xylan
metabolism.
The statistical challenges posed by patterns of mutual exclusivity of genes re-
lated to phenotype in clonal systems and the simultaneous analysis of many types
of data were addressed in chapters 3 and 4. Here, the phenotype of interest is tu-
mour development and proliferation in breast, ovarian and glioblastoma multiforme
cancers, and we used a combination of data types (mutation, gene expression, copy
number variation and methylation) together with a prior knowledge network consist-
ing of curated gene interactions, to perform a number of tumour-related analysis tasks.
The resulting analysis framework is called MUNDIS: a MUlti-purpose Network-based
Data-Integration Strategy. In chapter 3, the mutual exclusivity problem is tackled
using a pathway-oriented analysis, rather than a gene-centric approach, whereas in
chapter 4, we extend the method developed in chapter 3 to accommodate additional
types of analysis like patient subtyping, driver gene prioritization and sub-network
delineation. Each time, all the available data (cancer data were obtained from TCGA
[9–11], network data from KEGG [8]) were integrated using a single network repre-
sentation that not only contains genes but also individual samples (or patients) and
the prior knowledge network. This was achieved by first making all continuous data
binary, and then representing each dataset as a network connecting abnormal states of
genes (gene mutation, differentially expression, abnormal copy number and hypo- or
hyper-methylation) to the samples (patients) they were found to be abnormal in. After
merging these networks with a network containing prior knowledge in the form of
curated gene interactions, again a network connectivity measure was calculated to as-
sess functional gene similarity and the relevance of genes for a particular sample. We
showed how the all-vs.-all matrix containing the connectivity metric for all couples
of entities in the global network can be used to perform the different tumour analysis
tasks at hand. Whenever possible, we compared our results with those obtained using
established methods. As is often the case in tumour research, the quality of the results
156 CHAPTER 6
can not easily be assessed. Instead, a literature study has to be carried out to establish
the validity of predictions and rankings. Summarizing, we found that:
• When applying the pathway ranking technique developed in this work to the
well studied PAM50 breast tumour subtypes, we were able to recapitulate to a
large extent what is known, at the molecular level, about the different subtypes.
A set of commonly disturbed pathways could be identified, as well as several
subtype-specific pathways. Often the aggregate score of a pathway could not
be motivated by a single mutation, copy number or methylation alteration, but
rather by a combination of genetic and epigenetic disturbances.
• After analyzing two survival-based subtypes of ovarian cancer, a large number
of differentially ranked pathways could be immediately linked to tumor prolif-
eration and tumour survival.
• The results of the pathway ranking approach were compared to the published
results of PARADIGM [12], an alternative technique. Next to top-ranking all
the pathways found by PARADIGM, we additionally identified several rele-
vant pathways (TGF-Beta, Toll-like receptor and WNT signaling) that were not
found by PARADIGM.
• When a differential pathway analysis is performed, it is important that the sam-
ple group sizes are the same order of magnitude: we found that larger groups of
samples tend to yield higher pathway scores.
• Ovarian cancer and glioblastoma patient subtypes identified using MUNDIS
correlate highly with patient survival. The subtypes found do not coincide with
earlier described, gene expression-based subtypes, indicating that MUNDIS
is capturing additional molecular information by incorporating additional data
types in the analysis.
• When comparing the subtypes found using MUNDIS with those obtained using
naive or established methods (iCluster [13]) the added value of data-integration
in general, and MUNDIS in particular could be demonstrated.
• Driver gene prioritization for the breast cancer Luminal A and Basal PAM50
subtypes largely recapitulates what is known about genetic and epigenetic aber-
rations in these subtypes. Many of these genetic and epigenetic aberrations are
known to occur in mutual exclusive combinations only [10, 14], confirming the
added value of the network-based approach.
• Driver gene analysis for the glioblastoma subtypes identified earlier confirmed
the overall importance of amplified EGFR for both bad-and good-outcome pa-
tient groups. Poor survival for glioblastoma could be linked to amplified CDKN2A,
CDKN2B and CDK4.
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• The subnetworks delineated for the breast cancer subtypes and the previously
identified glioblastoma and ovarian cancer subtypes summarize the earlier find-
ings. Interestingly, additional (non-disturbed or non-differentially expressed)
genes were included in the subnetworks. These genes were derived from the
prior knowledge network used as the backbone of the MUNDIS analysis, and
help linking driver genes to differentially expressed genes.
6.3 Future directions
Here we provide a number of logical next steps that can be taken towards improvement
and valorization of the ideas presented in this work. New applications of the concepts
introduced here have presented themselves along the way, and were not pursued due
to a lack of resources or necessary data.
6.3.1 The similarity metric used throughout this work might be
replaced by alternative measures of network connectivity
The kernels calculated on graph nodes used here are attractive because of their inter-
pretability, compact mathematical formulation, straightforward implementation and
demonstrated performance, but other researchers have used alternative approaches (of-
ten also based on random walks or diffusion processes, see e.g. [15]) that appear to
work equally well, albeit for different applications. Note that the kernel properties
of the connectivity measures used here are only remotely exploited. As such, alter-
native connectivity measures can be easily plugged in any of the methods presented
in this work. One of the drawbacks of the graph node kernels is their restriction to
undirected networks, and although the added value of directionality for MUNDIS-like
applications remains to be demonstrated, directional options should be explored.
6.3.2 The gene interaction networks used are only crude approxi-
mations of reality
As already mentioned in the Introduction chapter, the gene interaction networks used
are very likely incomplete, biased towards biological processes that are of particu-
lar interest to the scientific community (e.g., cancer) and too abstract to map directly
on the biological and molecular processes they are meant to capture. Next to being
incomplete, they also can be over-complete, in the sense that networks can contain
information on gene interactions that is valid under many, very different conditions
whereas the data that are being mapped onto the network are limited to a single condi-
tion. Additionally, they lack logic, and can not be used to model dynamic processes.
A more mechanistic network model, in combination with an appropriate connectiv-
ity measure might increase the performance of all applications demonstrated in this
work. Another way to improve on the network models used is to use condition depen-
dent (e.g. tissue- or process-specific) networks. This way, many spurious interactions
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can be removed upfront from the network. Of course this requires a specific research
setting where the process under study is already well known.
6.3.3 Numerous algorithmic improvements and implementation
optimizations can be made
Many of the algorithms in this work were presented as proof-of-concepts, and should
be considered reference implementations of the main ideas introduced in each chapter.
They leave room for many potential improvements. A drawback of all the algorithms
presented here is the presence of parameters that need to be tuned. Because reference
data that could be used for calibrating the developed model were not available, we
have based the optimal values of parameters on sensible estimates or preliminary test-
ing. In chapter 4, we successfully applied an unsupervised parameter tuning strategy
to optimize the classification of patients into distinct subtypes but the optimization
criterion is heuristic at best. A scenario were parameters are tuned using additional
(public) data sets might be desirable.
Next to objectifying the choice of parameters, the implementations of the pre-
sented algorithms can be optimized (in terms of memory usage and execution speed).
Especially when dealing with large networks and many input datasets, the execution of
the algorithms requires high-memory servers with many computation cores. Single-
machine systems might not be able to deal with additional data types and/or datasets
containing many more samples. A distributed implementation of the algorithms can
transfer calculation to a dedicated high performance computing environment. Such a
distributed implementation will likely rely on frameworks like MPI [16] and ScaLA-
PACK [17].
6.3.4 The data binarization strategy used in chapters 3 and 4 is
suboptimal
Another major improvement that is related to parameter selection would be the imple-
mentation of an unsupervised data binarization strategy for the tumour analysis tech-
niques presented in chapters 3 and 4. The current binarization strategy is naive and
we found that results depend highly on the thresholds used. Alternative approaches
could be the use (and extension to other data types) of established algorithms for the
detection of differential expression like limma (linear models for micro-array data,
[18]) or the use of Gaussian mixture models in combination with a model selection
criterion. Furthermore, data binarization is only a crude approximation of the under-
lying biological reality: for example, assigning both under- and over-expressed genes
to the same ’differentially expressed’ class is evidently not correct. We have argued
that for homogeneous sets of samples exhibiting the same phenotype, this is unlikely
to happen, but when e.g. patient subtypes are to be delineated (and consequently the
samples are assumed to be diverse), this can cause patients to be incorrectly clustered
together.
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A solution to this problem can be the extension of the data binarization scheme
to a data discretization strategy. Each value in an input dataset would then no longer
be labeled normal (corresponding to a ’0’ in the binary data) or abnormal (a ’1’ in
the binary data), but could receive a value from the set {-1,0,1} where a ’-1’ could
e.g. indicate under-expression and a ’1’ could indicate over-expression. The trans-
lation of these discrete data to a network model requires adding extra gene nodes,
effectively representing under- and over-expressed genes rather than differentially ex-
pressed genes.
Alternatively, the method could be adapted to allow for the use of weighted edges.
Edge weights could be based on correlation, mutual information, or relative expres-
sion, copy number or methylation values, each time rescaled and transformed in po-
tentially many ways and combinations. Unfortunately, the optimal choice of the edge
scoring function could be very much problem-dependent and heuristic, and could in-
troduce extra, dataset- and application-dependent parameters.
6.3.5 The tumour analysis framework can be applied to tackle ad-
ditional problems
We presented a framework for tumour analysis that is based on the integration of all
data into a single network representation. After such a network is constructed, we
calculated how well all entities (genes and patient samples) are connected to each
other. The connectivity measures constitute a similarity matrix. Different parts of this
similarity matrix are then used to address different tumour analysis problems. Several
regions of the matrix remain unexploited, but could offer alternative, network-guided
solutions to existing challenges:
• If a global network model were constructed using SNP data (instead of muta-
tion data) and gene expression data, than we expect that the part of the similarity
matrix that contains the network connectivity between the individual SNPs and
the genes in the gene expression dataset will contain an indication of how well
each SNP relates to each gene in the gene expression dataset. Consequently,
this part of the similarity matrix could be used as way to perform eQTL associ-
ation analysis. The added value over existing eQTL mapping methods would be
that using this approach, the network would be an integral part of the analysis.
Before such a method can be applied, the prior knowledge network that links all
data together needs to be extended in order to link SNPs to individual genes.
• The parts of the similarity matrix that represent the network connectivity be-
tween the genes in the input datasets can be used to cluster the genes of each
dataset separately. For example, the genes of a gene expression dataset can be
grouped according to how well they connect to each other in the global network,
yielding biologically relevant modules of differentially expressed genes that are
not only based on similar patterns of gene expression, but also on how genes
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connect to each other in the network. Additionally, genes pertaining to all in-
put datasets can be simultaneously clustered using those parts of the similarity
matrix that express how well a gene from one dataset connects to genes present
in all other datasets. This way, an over-expressed gene might for example be
clustered together with genes exhibiting copy number alterations.
6.3.6 In order to be useful in a real-world context, the tumour
analysis framework should allow for single patient analysis
In their current form, the algorithms developed in chapters 3 and 4 analyze groups of
cancer patients. In the case of a homogeneous patient set, they result in features of
interest that are shared by all patients under study. In the case of a heterogeneous pa-
tient group, homogeneous subgroups of patients are obtained. If a new patient sample
would become available, and one is interested in either driving features or the subtype
the new sample belongs to, a number of options are available:
• One possibility is that the data from this single patient is added to the avail-
able data, and the entire analysis is rerun, in order to identify patients with a
similar molecular profile (in the broad sense). Afterward, the new patient data
are re-analyzed together with the data of the group of patients the new patient
was assigned to (this group is now considered to be homogeneous), and the
drivers and pathways that were found to be relevant for the group of patients are
extrapolated to the new patient
• Alternatively, one could first collect a reference dataset containing a large num-
ber of samples relevant to the subject under study, and perform an analysis as
presented in chapters 3 and 4. Afterward, new patients can be linked to the
reference dataset with nearest neighbor approaches that use for instance gene
expression data and mutation of the new patient, filtered for drivers that were
found relevant for different groups of reference patients. This way, the method
is used to identify network-based features that can be used to focus subsequent
analysis. This approach is similar to [19] who built a gene-expression-based
classifier using features derived from a network-based analysis.
• A third option is to run the analysis for a single patient. Here, the network
is used to link patterns of disturbance and differential expression, but it is not
possible to benefit from information derived from patients with a similar phe-
notype. In a way, this resembles the analysis presented in chapter 5 (NBDI),
where each tree is analyzed in isolation rather than in relation to each other.
6.3.7 Mutual exclusivity is only implicitly present in the tumour
analysis framework
At no point did we explicitly demand from driver gene selections that their (epi)genetic
alterations be mutual exclusive in a local network neighborhood. Integrating such
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a criterion in the analysis is expected to reduce the number of false positives when
prioritizing drivers. Unfortunately, integrating mutual exclusivity in the analysis is
not straightforward. A number of approaches can be imagined:
• Mutual exclusivity can be integrated in a pre-processing step by modifying the
binary input data in such way that genetic alterations in the same patient sam-
ple are penalized when they occur in the immediate network neighborhood of
each other. Calculation of a connectivity measure, prior to the global network
construction, between all genes in the interaction network used as the back-
bone for the analysis can help in assessing if genes belong to the same network
neighborhood.
• Alternatively, mutual exclusivity could be incorporated in a post-processing
step. First, drivers are prioritized using the MUNDIS framework. In a next
step, the prioritized genes can be used as input to tools like MEMO [14] that are
specifically designed to take into account mutual exclusivity.
6.3.8 In its current form, the tumour analysis framework is un-
able to integrate alterations in non-coding DNA
Currently, full-genome tumour sequences are becoming available, opening up a new
range of analysis opportunities. The realization that (epi)genetic defects in parts of
the DNA that do not code for proteins (e.g., promoter regions of genes, enhancer
and silencer sites, long non-coding RNA and micro-RNA) can contribute to tumour
development [20] together with the availability of whole tumour genomes has urged
researchers to develop new techniques (e.g., FunSeq2 [21], or extensions to the On-
codrive analysis suite [22]) for exploring non-coding DNA. The first results of such
analysis have only recently been published [23, 24], leaving much room for additional
exploration.
The main difficulty of incorporating non-coding mutations in the MUNDIS frame-
work is the requirement that all entities in the network (except for patient sample
nodes) should eventually link to a gene interaction network. In the case of mutations
in promoters of genes, this problem can be circumvented by adding the promoter mu-
tations as an additional dataset to the analysis, or equivalently, adding an additional
type of abnormal gene nodes, corresponding to genes with a mutated promoter region,
to the global network. For enhancer sites, this approach will not work, since there is no
one-to-one mapping between enhancers and individual genes: an enhancer site might
regulate transcription of several target genes. To allow for the inclusion of enhancer
(and silencer) mutation data, the gene interaction network needs to be extended with
enhancer sites as additional entities, together with extra connections linking enhancers
to the genes they regulate. The inclusion of mutation data related to long non-coding
RNAs and micro-RNAs requires updating the gene interaction network with extra en-
tities and interactions that link the new entities to the existing network. The success
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of this approach will depend largely on the public availability and reliability of this
additional network information.
6.3.9 We should provide a user-friendly toolbox that helps lever-
aging the power of networks and networks-based connectiv-
ity measures in computational biology
In order to bring the developed techniques to potential users, the technical details of
the procedures should be shielded from the non-technical user. Ideally, a stand-alone
implementation of the algorithms (ideally with a graphical user interface) that does not
require proprietary, licensed software is provided. Unfortunately, the presented meth-
ods are computationally demanding, and can not be run (even for small datasets) on
personal computers. A solution is the use of a webservice-based architecture, where a
user uploads data (using a local or web-based application) to a dedicated computation
resource. All calculations are then executed on the computation node. Once the calcu-
lations are finished, the results are returned to the user for further analysis. Software
clients for such applications can be integrated in commonly used analysis tools like
R [25] or Cytoscape [26], rendering the process of uploading data and downloading
results transparent to the user.
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Table A.1: Comparison of the proposed, network-based method (SIM) to a nave frequency-
based approach (FRQ). Pathway IDs correspond to KEGG identifiers.
Score Rank
ID Name SIM FRQ SIM FRQ
4151 PI3K-Akt signaling pathway 8.59 8.31 1 1
4630 Jak-STAT signaling pathway 8.31 5.41 2 5
4152 AMPK signaling pathway 8.22 7.57 3 2
4350 TGF-beta signaling pathway 7.39 5.38 4 6
4012 ErbB signaling pathway 7.26 5.04 5 12
4550 Signaling pathways regulating pluripotency of stem cells 7.12 5.20 6 10
4921 Oxytocin signaling pathway 7.08 5.36 7 7
4510 Focal adhesion 7.05 7.00 8 3
4915 Estrogen signaling pathway 6.80 4.13 9 30
4917 Prolactin signaling pathway 6.68 4.14 10 29
4062 Chemokine signaling pathway 6.48 4.38 11 21
4024 cAMP signaling pathway 6.38 4.13 12 31
4014 Ras signaling pathway 6.30 4.10 13 33
4010 MAPK signaling pathway 6.09 3.87 14 38
4022 cGMP-PKG signaling pathway 5.96 4.43 15 20
4722 Neurotrophin signaling pathway 5.95 5.07 16 11
4930 Type II diabetes mellitus 5.87 4.92 17 13
4932 Non-alcoholic fatty liver disease (NAFLD) 5.83 4.85 18 15
4060 Cytokine-cytokine receptor interaction 5.77 5.64 19 4
4725 Cholinergic synapse 5.76 3.15 20 58
4919 Thyroid hormone signaling pathway 5.73 4.36 21 22
4015 Rap1 signaling pathway 5.73 4.31 22 24
4620 Toll-like receptor signaling pathway 5.56 4.01 23 35
4310 Wnt signaling pathway 5.53 3.22 24 55
4110 Cell cycle 5.42 3.32 25 54
4662 B cell receptor signaling pathway 5.34 4.46 26 19
4066 HIF-1 signaling pathway 5.32 3.94 27 37
830 Retinol metabolism 5.30 5.36 28 9
4150 mTOR signaling pathway 5.10 4.60 29 18
4611 Platelet activation 5.03 3.55 30 46
4920 Adipocytokine signaling pathway 5.01 4.65 31 17
3320 PPAR signaling pathway 4.95 4.77 32 16
4666 Fc gamma R-mediated phagocytosis 4.92 4.21 33 27
982 Drug metabolism - cytochrome P450 4.81 4.90 34 14
4390 Hippo signaling pathway 4.78 4.11 35 32
4610 Complement and coagulation cascades 4.70 5.36 36 8
4910 Insulin signaling pathway 4.67 3.67 37 42
350 Tyrosine metabolism 4.61 4.27 38 26
4660 T cell receptor signaling pathway 4.60 3.47 39 50
4261 Adrenergic signaling in cardiomyocytes 4.58 3.48 40 49
4916 Melanogenesis 4.57 2.73 41 70
4068 FoxO signaling pathway 4.54 3.62 42 44
4668 TNF signaling pathway 4.52 3.83 43 40
140 Steroid hormone biosynthesis 4.51 4.17 44 28
983 Drug metabolism - other enzymes 4.49 3.87 45 39
4380 Osteoclast differentiation 4.44 3.62 46 45
4512 ECM-receptor interaction 4.35 4.33 47 23
4750 Inflammatory mediator regulation of TRP channels 4.29 3.15 48 59
40 Pentose and glucuronate interconversions 4.26 3.96 49 36
4210 Apoptosis 4.24 4.27 50 25
4914 Progesterone-mediated oocyte maturation 4.22 3.09 51 60
4960 Aldosterone-regulated sodium reabsorption 4.15 3.47 52 51
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Table A.1 – Continued from previous page
Score Rank
ID Name SIM FRQ SIM FRQ
980 Metabolism of xenobiotics by cytochrome P450 4.06 4.05 53 34
4912 GnRH signaling pathway 4.05 2.79 54 69
4670 Leukocyte transendothelial migration 3.95 3.52 55 47
4020 Calcium signaling pathway 3.86 3.00 56 62
4973 Carbohydrate digestion and absorption 3.83 3.35 57 52
860 Porphyrin and chlorophyll metabolism 3.81 3.49 58 48
4713 Circadian entrainment 3.72 1.54 59 106
4810 Regulation of actin cytoskeleton 3.72 3.18 60 57
360 Phenylalanine metabolism 3.71 3.62 61 43
561 Glycerolipid metabolism 3.67 3.20 62 56
4370 VEGF signaling pathway 3.64 2.91 63 64
4664 Fc epsilon RI signaling pathway 3.58 3.33 64 53
4970 Salivary secretion 3.55 2.44 65 76
4080 Neuroactive ligand-receptor interaction 3.53 3.82 66 41
4070 Phosphatidylinositol signaling system 3.52 2.64 67 73
4728 Dopaminergic synapse 3.34 1.32 68 120
590 Arachidonic acid metabolism 3.30 2.60 69 75
480 Glutathione metabolism 3.25 2.71 70 71
562 Inositol phosphate metabolism 3.15 2.90 71 65
500 Starch and sucrose metabolism 3.13 2.82 72 68
4971 Gastric acid secretion 3.13 1.98 73 87
4520 Adherens junction 3.07 2.84 74 66
4622 RIG-I-like receptor signaling pathway 3.02 2.83 75 67
4913 Ovarian steroidogenesis 3.01 2.12 76 85
4612 Antigen processing and presentation 3.00 3.01 77 61
4726 Serotonergic synapse 2.91 1.82 78 94
601 Glycosphingolipid biosynthesis - lacto and neolacto series 2.87 2.92 79 63
565 Ether lipid metabolism 2.83 2.27 80 80
4270 Vascular smooth muscle contraction 2.75 1.77 81 99
4115 p53 signaling pathway 2.67 2.70 82 72
4650 Natural killer cell mediated cytotoxicity 2.65 2.63 83 74
4724 Glutamatergic synapse 2.48 1.42 84 113
330 Arginine and proline metabolism 2.47 2.37 85 78
564 Glycerophospholipid metabolism 2.47 2.12 86 84
4540 Gap junction 2.42 1.34 87 118
4975 Fat digestion and absorption 2.39 2.29 88 79
4360 Axon guidance 2.34 2.11 89 86
232 Caffeine metabolism 2.32 2.41 90 77
4978 Mineral absorption 2.31 2.25 91 81
4320 Dorso-ventral axis formation 2.31 1.87 92 93
430 Taurine and hypotaurine metabolism 2.29 2.20 93 82
4623 Cytosolic DNA-sensing pathway 2.28 2.14 94 83
4730 Long-term depression 2.23 1.52 95 108
4723 Retrograde endocannabinoid signaling 2.17 1.11 96 124
380 Tryptophan metabolism 2.05 1.80 97 97
600 Sphingolipid metabolism 2.02 1.81 98 96
4727 GABAergic synapse 2.01 1.43 99 111
4972 Pancreatic secretion 1.96 1.43 100 112
4114 Oocyte meiosis 1.95 1.41 101 115
620 Pyruvate metabolism 1.95 1.89 102 89
71 Fatty acid degradation 1.91 1.55 103 105
4621 NOD-like receptor signaling pathway 1.91 1.87 104 92
4144 Endocytosis 1.90 1.42 105 114
4720 Long-term potentiation 1.88 0.82 106 134
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Score Rank
ID Name SIM FRQ SIM FRQ
270 Cysteine and methionine metabolism 1.88 1.87 107 90
310 Lysine degradation 1.85 1.87 108 91
4514 Cell adhesion molecules (CAMs) 1.85 1.94 109 88
4530 Tight junction 1.82 1.63 110 102
4340 Hedgehog signaling pathway 1.81 1.52 111 107
130 Ubiquinone and other terpenoid-quinone biosynthesis 1.80 1.82 112 95
4742 Taste transduction 1.77 1.58 113 103
4064 NF-kappa B signaling pathway 1.76 1.77 114 98
260 Glycine, serine and threonine metabolism 1.72 1.74 115 100
512 Mucin type O-Glycan biosynthesis 1.70 1.70 116 101
250 Alanine, aspartate and glutamate metabolism 1.64 1.55 117 104
10 Glycolysis / Gluconeogenesis 1.59 1.31 118 121
4961 Endocrine and other factor-regulated calcium reabsorption 1.57 1.01 119 131
340 Histidine metabolism 1.56 1.27 120 122
4330 Notch signaling pathway 1.55 1.45 121 110
760 Nicotinate and nicotinamide metabolism 1.51 1.33 122 119
400 Phenylalanine, tyrosine and tryptophan biosynthesis 1.51 1.39 123 117
3460 Fanconi anemia pathway 1.44 1.48 124 109
591 Linoleic acid metabolism 1.42 0.80 125 136
51 Fructose and mannose metabolism 1.37 1.41 126 116
592 alpha-Linolenic acid metabolism 1.36 1.08 127 125
410 beta-Alanine metabolism 1.31 1.05 128 127
4918 Thyroid hormone synthesis 1.27 0.80 129 135
4672 Intestinal immune network for IgA production 1.15 1.06 130 126
900 Terpenoid backbone biosynthesis 1.07 1.13 131 123
4962 Vasopressin-regulated water reabsorption 1.05 0.70 132 143
61 Fatty acid biosynthesis 1.04 0.97 133 132
230 Purine metabolism 1.04 0.66 134 148
603 Glycosphingolipid biosynthesis - globo series 1.03 1.04 135 129
604 Glycosphingolipid biosynthesis - ganglio series 1.01 1.05 136 128
510 N-Glycan biosynthesis 0.99 1.02 137 130
4911 Insulin secretion 0.98 0.51 138 159
4976 Bile secretion 0.89 0.61 139 155
280 Valine, leucine and isoleucine degradation 0.86 0.74 140 140
4140 Regulation of autophagy 0.83 0.85 141 133
670 One carbon pool by folate 0.82 0.77 142 138
4744 Phototransduction 0.81 0.64 143 153
240 Pyrimidine metabolism 0.78 0.67 144 146
100 Steroid biosynthesis 0.78 0.78 145 137
770 Pantothenate and CoA biosynthesis 0.73 0.72 146 141
531 Glycosaminoglycan degradation 0.73 0.71 147 142
520 Amino sugar and nucleotide sugar metabolism 0.69 0.75 148 139
4940 Type I diabetes mellitus 0.66 0.65 149 150
4145 Phagosome 0.65 0.65 150 149
20 Citrate cycle (TCA cycle) 0.64 0.68 151 144
3013 RNA transport 0.63 0.64 152 152
4977 Vitamin digestion and absorption 0.63 0.65 153 151
190 Oxidative phosphorylation 0.63 0.67 154 147
3015 mRNA surveillance pathway 0.61 0.67 155 145
650 Butanoate metabolism 0.55 0.51 156 160
4964 Proximal tubule bicarbonate reclamation 0.53 0.63 157 154
970 Aminoacyl-tRNA biosynthesis 0.52 0.55 158 157
750 Vitamin B6 metabolism 0.52 0.48 159 163
30 Pentose phosphate pathway 0.49 0.56 160 156
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Table A.1 – Continued from previous page
Score Rank
ID Name SIM FRQ SIM FRQ
120 Primary bile acid biosynthesis 0.49 0.49 161 162
630 Glyoxylate and dicarboxylate metabolism 0.49 0.49 162 161
52 Galactose metabolism 0.48 0.47 163 164
72 Synthesis and degradation of ketone bodies 0.46 0.46 164 165
3018 RNA degradation 0.44 0.54 165 158
790 Folate biosynthesis 0.40 0.42 166 166
300 Lysine biosynthesis 0.35 0.21 167 171
740 Riboflavin metabolism 0.33 0.30 168 169
640 Propanoate metabolism 0.33 0.33 169 167
4950 Maturity onset diabetes of the young 0.33 0.28 170 170
450 Selenocompound metabolism 0.29 0.32 171 168
62 Fatty acid elongation 0.21 0.19 172 173
4740 Olfactory transduction 0.19 0.20 173 172
730 Thiamine metabolism 0.16 0.12 174 175
4721 Synaptic vesicle cycle 0.10 0.13 175 174
4710 Circadian rhythm 0.09 0.08 176 178
532 Glycosaminoglycan biosynthesis 0.08 0.11 177 176
4260 Cardiac muscle contraction 0.08 0.09 178 177
910 Nitrogen metabolism 0.07 0.08 179 180
4141 Protein processing in endoplasmic reticulum 0.07 0.05 180 182
3008 Ribosome biogenesis in eukaryotes 0.07 0.04 181 185
920 Sulfur metabolism 0.06 0.06 182 181
4146 Peroxisome 0.05 0.08 183 179
471 D-Glutamine and D-glutamate metabolism 0.04 0.04 184 183
780 Biotin metabolism 0.03 0.04 185 184
785 Lipoic acid metabolism 0.02 0.02 186 186
4122 Sulfur relay system 0.00 0.01 187 187
563 Glycosylphosphatidylinositol(GPI)-anchor biosynthesis 0.00 0.01 188 188
4130 SNARE interactions in vesicular transport 0.00 0.00 189 189
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Figure A.1: Comparison of scores obtained by two permutation strategies. Scores for shuffled
pathways (10000 permutations, X-axis) are plotted against the scores obtained after shuffling
the gene labels of the input datasets (100 permutations, Y-axis). The correlation is ¿ 0.99.
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Figure A.11: Notch signaling pathway summary for ovarian cancer. mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the Notch signal-
ing KEGG pathway (hsa4330). Red = high value/presence, blue = low value. Methylation data
are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-
Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01, ***=p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
SUPPLEMENTARY INFORMATION FOR THE PATHWAY RANKING PAPER 181
Figure A.12: WNT signaling pathway summary for ovarian cancer. mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the WNT signal-
ing KEGG pathway (hsa4310). Red = high value/presence, blue = low value. Methylation data
are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-
Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01, ***=p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
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Figure A.13: Ratio of bad-outcome pathway scores and the corresponding good-outcome scores
for 100 pathways. A ratio of 1 indicates that the pathway scores equally high for patients in
the bad-outcome group and patients in the good-outcome group. Values larger than 1 indicate
higher pathway importance / activity for the bad-outcome group.
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Figure A.14: Fig. Jak-STAT signaling pathway summary for ovarian cancer. mRNA gene ex-
pression, mutation pattern, copy number status and methylation pattern for the genes of the
Jak-STAT signaling KEGG pathway (hsa4630). Red = high value/presence, blue = low value.
Methylation data are rescaled to the interval [0,1]. Genes are sorted according to the signifi-
cance of a Kruskal-Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01,
***=p<0.001). No FDR correction was applied. Maximum 30 genes per data type are shown.
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Figure A.15: ECM-receptor interaction pathway summary for ovarian cancer. mRNA gene
expression, mutation pattern, copy number status and methylation pattern for the genes of the
ECM-receptor interaction KEGG pathway (hsa4512). Red = high value/presence, blue = low
value. Methylation data are rescaled to the interval [0,1]. Genes are sorted according to
the significance of a Kruskal-Wallis test, with the subtype as categorical factor (* = p<0.05,
**=p<0.01, ***=p<0.001). No FDR correction was applied. Maximum 30 genes per data
type are shown.
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Figure A.16: cAMP signaling pathway summary for ovarian cancer. mRNA gene expression,
mutation pattern, copy number status and methylation pattern for the genes of the cAMP signal-
ing KEGG pathway (hsa4024). Red = high value/presence, blue = low value. Methylation data
are rescaled to the interval [0,1]. Genes are sorted according to the significance of a Kruskal-
Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01, ***=p<0.001).
No FDR correction was applied. Maximum 30 genes per data type are shown.
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Figure A.17: TGF-Beta signaling pathway summary for ovarian cancer. mRNA gene ex-
pression, mutation pattern, copy number status and methylation pattern for the genes of the
TGF-Beta signaling KEGG pathway (hsa4350). Red = high value/presence, blue = low value.
Methylation data are rescaled to the interval [0,1]. Genes are sorted according to the signifi-
cance of a Kruskal-Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01,
***=p<0.001). No FDR correction was applied. Maximum 30 genes per data type are shown.
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Figure A.18: Estrogen signaling pathway summary for ovarian cancer. mRNA gene expres-
sion, mutation pattern, copy number status and methylation pattern for the genes of the Es-
trogen signaling KEGG pathway (hsa4915). Red = high value/presence, blue = low value.
Methylation data are rescaled to the interval [0,1]. Genes are sorted according to the signifi-
cance of a Kruskal-Wallis test, with the subtype as categorical factor (* = p<0.05, **=p<0.01,
***=p<0.001). No FDR correction was applied. Maximum 30 genes per data type are shown.
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Figure B.1: Stratification of glioblastoma multiforme patients using a combination of MUNDIS
and existing subtypes.
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Figure B.2: MUNDIS applied to glioblastoma multiforme, requesting four patient classes. The
third MUNDIS subtype contains only three patients and is not shown. Additionally, existing
subtypes are added illustrating the correspondence between MUNDIS subtype 1 and the G-
CIMP subtype.

